text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
NATCHEZ, Miss. (KTVE/KARD) — On Tuesday, April 12, 2022, at approximately 2:11 AM, Natchez Police were issued a BOLO alert for a silver Lexus that was involved in a alleged kidnapping. According to witnesses, a female was allegedly forced into the vehicle by a male suspect after whispering to them to call police.
As officers searched for the vehicle, they spotted the car and initiated a traffic stop. According to authorities, the female passenger/victim mouthed “help me” to officers as they approached the vehicle.
The victim was immediately removed from the vehicle and officers made contact with the driver/suspect and he was identified as 22-year-old Cartrell Frye. Frye was placed under arrest and transported to the Natchez Police Department where he was interviewed about the kidnapping allegations.
Frye was then charged with Kidnapping. | https://www.cbs42.com/news/mississippi-man-arrested-for-kidnapping-victim-mouthed-help-me-to-officers-in-vehicle/ | 2022-04-14T03:25:41 | 1 | https://www.cbs42.com/news/mississippi-man-arrested-for-kidnapping-victim-mouthed-help-me-to-officers-in-vehicle/ |
FORT WAYNE, Ind. (WANE) – Brian Esposito is new to Fort Wayne – but that doesn’t mean he’s new to baseball in the Hoosier state.
The TinCaps new manager spent the last four years as the manager of the Indianapolis Indians, the Triple-A affiliate of the Pittsburgh Pirates.
The 43-year old Esposito made it to the majors as a catchers with the Astros and Cardinals, and is looking to turn what is a talented TinCaps roster into group that can eventually impact the Padres on the MLB level. | https://www.wane.com/sports/tincaps/esposito-looking-to-put-his-stamp-on-tincaps-squad/ | 2022-04-14T03:25:41 | 0 | https://www.wane.com/sports/tincaps/esposito-looking-to-put-his-stamp-on-tincaps-squad/ |
SALADO, Texas (KXAN) — “That’s all I have left, just sighs,” Naomi Benavidez said Wednesday.
Bulldozers crunched through snapped trees and crumbled homes in Central Texas Wednesday, showing the impact of a bad storm. But it’s stories from people like Benavidez that show how a vicious tornado changes lives forever.
“She was picking up … holding onto her babies as much as she could,” Benavidez said.
According to Benavidez, her sister, her sister’s husband and their two kids are now in the hospital after a tornado tore through Salado Tuesday, about 50 miles north-northeast of Austin.
“The little girl — she had to hold onto her by her hair. They ended up getting lifted up from the trailer and just thrown into the trees,” Benavides said. “She was about three-months pregnant; she lost her baby today.”
Benavides and other relatives are walking through the area, collecting what’s still worth saving.
“I want to say this is probably the laundry room door,” Benavidez said as she picked up a door knob from the rubble.
Bell County Judge David Blackburn said the tornado tracked for eight miles, hurting 23 people. Twelve people ended up in the hospital. One was in critical condition as of Wednesday afternoon.
According to Bell County, the Cedar Valley tornado is a confirmed “high-end EF-3 tornado,” reaching a maximum wind speed around 165 mph.
Sixty-three structures were damaged.
“We believe we have accounted for all individuals that were in the path,” Blackburn said.
Still, people are without power and water. One of the main priorities is getting that restored and making sure no one is buried under rubble, according to Blackburn.
“It is not, in any sense, a minor miracle. As you look at the devastation .. created [Tuesday] night, it’s hard to imagine that that didn’t occur,” Blackburn said.
Now, carried by their faith, Benavidez hopes for another miracle as she waits for their family to recover.
“This is going to be a slow process for everyone,” Benavidez said. | https://www.cbs42.com/news/pregnant-texas-woman-loses-baby-after-family-ripped-from-home-by-tornado/ | 2022-04-14T03:25:47 | 1 | https://www.cbs42.com/news/pregnant-texas-woman-loses-baby-after-family-ripped-from-home-by-tornado/ |
Posted: Apr 13, 2022 / 11:17 PM EDT Updated: Apr 13, 2022 / 11:17 PM EDT SHARE Close Modal Suggest a Correction Your name(required) Your email(required) Report a typo or grammatical error(required) Submit Δ Suggest a Correction | https://fox59.com/hoosier-lottery/daily-3-daily-4-evening-drawing-april-13-2022/ | 2022-04-14T03:30:23 | 1 | https://fox59.com/hoosier-lottery/daily-3-daily-4-evening-drawing-april-13-2022/ |
A cold front will sweep the state and deliver a notable chilly by sunrise. Grab that winter coat as chilly days are to return.
STORMY WENDESDAY EVENING
Early morning showers lingered long enough to stunt larger storms from developing for most of central Indiana Wednesday but just a small window of dry time allowed more unstable air to surge north. The instability was just enough for developing storm to feed on and accelerated from Bedford, east to Seymour from 6pm through 9pm. The arcing line of storms would down power lines in Bedford with winds estimated by radar over 60mph. Late Wednesday reports were sparse downstate with speculation that some damage south of Greensburg was a tornado. NWS meteorologists will investigate Thursday but ultimately, most of the state faired very well considering there was a real potential for a wide-spread severe outbreak.
Several photos of the incoming storms are consistent with a shelf or roll cloud, not a funnel.
The majority of the severe storms and tornado reports were concentrated south.
COLDER MORNING
Early Wednesday morning the low temperature was the warmest of 2022, look out! It will be sharply colder by sunrise. Skies will clear overnight but out the door early Thursday morning temperatures will have fallen into the mid/upper 30s.
A cooler spell is returning and temperatures are slide even further with lows early Easter morning below freezing! This looks to be the coolers Easter since 2018’s 46° high temperature. | https://fox59.com/weather/storm-threat-is-over-and-so-is-the-warm-up-temps-tumble-overnight/ | 2022-04-14T03:30:29 | 1 | https://fox59.com/weather/storm-threat-is-over-and-so-is-the-warm-up-temps-tumble-overnight/ |
Peoria woman charged with aggravated DUI in deaths of pedestrians; vodka found at the scene
PEKIN — A Peoria woman faces up to 28 years in prison after being charged this week in connection with a fatal crash that killed two pedestrians in East Peoria.
Stephanie Melgoza, 23, was charged Tuesday in Tazewell County Circuit Court with felony counts of aggravated DUI, aggravated reckless driving and unlawful possession of marijuana in the deaths of Andrea Rosewicz, 43, of Avon, Ohio, and Paul Prowant, 55, of Seattle.
Both died at the scene after they were struck in the 3300 block of North Main Street around 10:15 p.m. Sunday.
According to a probable cause statement filed in court, an East Peoria police officer arrived on the scene to find Melgoza's Dodge Dart with heavy front-end damage. The officer reported she had slurred speech and red, watery eyes. There was a strong odor of alcohol as well, he reported.
She admitted, the statement said, to driving about 40 mph in a 30-mph zone and striking a person. Officers found a baggie of cannabis, a hitter pipe and an open bottle of Tito's vodka in the Dart.
She failed a field sobriety test and was arrested at the scene. She allegedly admitted to drinking three vodka drinks before driving her car.
Melgoza is free on bond after posting $15,000, or 10% of a $150,000 bond. She is scheduled to next appear in court on May 24.
The most serious count is the aggravated DUI, which carries a prison term of at least three years and a maximum of 14 years. Because two people were killed, Melgoza could be sentenced to consecutive sentences if convicted.
She must serve at least 85% of any sentence imposed. There is a chance she could get probation, but she must show “extraordinary circumstances” as to why a judge should not send her to prison.
That’s different from most crimes, as the burden is on Melgoza to show why she should get probation.
More:Identities released of two pedestrians killed in East Peoria traffic accident | https://www.pjstar.com/story/news/crime/2022/04/13/peoria-woman-was-drinking-before-hitting-pedestrians-according-to-documents/7312312001/ | 2022-04-14T03:30:53 | 0 | https://www.pjstar.com/story/news/crime/2022/04/13/peoria-woman-was-drinking-before-hitting-pedestrians-according-to-documents/7312312001/ |
INDIANAPOLIS — The Centers for Disease Control and Prevention extended the travel mask mandate on Wednesday, meaning it will continue for at least the next 15 days — through May 3 — while the agency evaluates the situation.
Despite this, travel is soaring throughout the country, and in the Circle City.
"At this point where we are, in our lives and the world, travel is necessary to keep our sanity," said Caitlin O'Brien.
O'Brien flew to Indianapolis to visit family on Wednesday. It was her first time on an airplane since 2019, and the first-ever for her son, Chase.
This is not O'Brien's only planned trip. She has two planned over the summer, despite the pandemic-era travel headaches and rising fares. And she's not the only one.
"You gotta get away. You stay around town, or something like that, it's not the same as getting away. I'd rather take the trip," said Hoosier Jeff Williams while he waited to pick up his girlfriend at the Indianapolis International Airport.
The CDC still has international travel restrictions in place, including a requirement for anyone entering the country to produce a negative COVID test taken within 24 hours of travel.
Experts say a lot of people feel that traveling is worth the extra hurdles.
Delta Airlines announced that March 2022 was the first profitable month since the pandemic started, calling the gains a rebound.
The trend is also visible in Central Indiana. Michael Grueninger, president of Greuninger Travel Group, said his local clients are excited to get out after two years of being pent up at home.
"I think that two years of being at home — nice bonding with the family. But the kids are ready to get out, the parents are ready to get out, and people are still traveling," he said.
Greuninger said that airfares are increasing, COVID travel restrictions are still difficult to navigate, and airlines are still plagued by staffing issues that can slow down the whole travel experience.
But that's not slowing people down. In fact, Expedia reports that 68% of people they polled are planning to go all-out for their next trip.
"A lot of people, even if you did travel over the last few years, it was domestically. Now a lot of families and travelers and guests are going overseas," said Greuninger.
Over the last two years, Grueninger has seen travelers learn to adapt to ever-changing rules and fluid situations.
"People are a lot more flexible now than they ever have been," he said.
Grueninger added that travel insurance and travel advisors are more popular these days, due to their usefulness in navigating today's travel troubles. He recommends that travelers have a backup plan and be ready to roll with the punches because sometimes the unplanned moments can be the most magical.
"Those are the memories you're going to bring back of a small little restaurant, the museum you went to, the people that you met on the street."
For O'Brien, the idea of showing the world to her son is worth every headache.
"We're just thirsty for human interaction, and human contact, and experiencing things. Chase is a COVID baby. I want him to go out and see the world, and if that means we have to spend a little more, so be it. Even if we cry about it later," she said. | https://www.wrtv.com/news/coronavirus/despite-cdcs-renewal-of-public-transit-mask-mandate-local-travel-experiencing-a-boom | 2022-04-14T03:35:30 | 1 | https://www.wrtv.com/news/coronavirus/despite-cdcs-renewal-of-public-transit-mask-mandate-local-travel-experiencing-a-boom |
TELL CITY, Ind. (AP) — A $1.6 million federal grant will pay for the construction of a new southern Indiana pier on the Ohio River to be used for unloading of pig iron for a foundry.
U.S. Transportation Secretary Pete Buttigieg went to Tell City to discuss the grant and tour the Ohio River port.
The project will pay for building a 40-foot-diameter pier for a crane that will be used for direct barge-to-truck unloading of pig iron when the river is high.
The pig iron is a necessary raw material for Waupaca Foundry and other manufacturers. Federal officials say the pier will help increase port productivity by up to 60% and help maintain 1,000 jobs.
TOP STORIES: IUPUI commencement ceremony subject of uproar as some students won't be able to walk | Gainbridge concertgoers say they were denied access to rescheduled Elton John show; told tickets invalid | Meteor likely cause of mysterious explosion-like noise that rattled parts of Indiana, AMS says | Carvana building demolished to clear way for construction of new I-465 interchange | Apple to pay $14.8M to iCloud subscribers over breached contract | https://www.wrtv.com/news/local-news/buttigieg-goes-to-ohio-river-port-to-discuss-grant-for-pier | 2022-04-14T03:35:36 | 1 | https://www.wrtv.com/news/local-news/buttigieg-goes-to-ohio-river-port-to-discuss-grant-for-pier |
Canadian Prime Minister Justin Trudeau has weighed in on growing calls to declare Russia’s actions in Ukraine as genocide, saying it is “absolutely right” that the term is being used given rampant allegations of war crimes and other human rights violations.
Trudeau made the comments during a news conference on Wednesday, a day after U.S. President Joe Biden told reporters that Russia’s conduct in Ukraine appeared to his eyes to be a genocide.
While both North American leaders noted that it will be up to lawyers to determine whether Russia’s actions meet the international standard for genocide, they were nonetheless united in welcoming the use of the term.
“It’s absolutely right that more and more people be talking and using the word ‘genocide’ in terms of what Russia is doing,” Trudeau said.
The prime minister went on to list a series of war crimes and human rights violations allegedly perpetrated by Russian forces under the direction of President Vladimir Putin, including deliberate attacks on civilians and the use of sexual violence. Trudeau said they’re attacking “Ukrainian identity and culture.”
Canada has dispatched police investigators to help the International Criminal Court collect evidence to ultimately hold Putin and other Russian leaders to account. | https://www.wrtv.com/news/national/russia-ukraine-conflict/canadas-justin-trudeau-says-using-term-genocide-for-russias-ukraine-invasion-absolutely-right | 2022-04-14T03:35:42 | 1 | https://www.wrtv.com/news/national/russia-ukraine-conflict/canadas-justin-trudeau-says-using-term-genocide-for-russias-ukraine-invasion-absolutely-right |
RICHMOND, Va. (WRIC) — It is time once again for a local Richmond art museum to open a new special exhibit.
The Virginia Museum of Fine Arts is opening its upcoming Whistler to Cassatt: American Painters in France exhibit to the public for three months starting April 16. The exhibit will feature American painters who left the US to train under prominent French artists in France, who then returned to the US and shaped the course of American art.
The exhibit will include more than 100 paintings on display, featuring art by James Abbott McNeill Whistler, Mary Cassatt, and John Singer Sargent, Childe Hassam, Theodore Robinson, Henry Ossawa Tanner, Elizabeth Nourse, Cecilia Beaux, and many others.
Museum curator Susan Rawles spoke on the impact the artwork had on the US art and culture scene.
“I think for many people now, pictures like this, paintings like this appear pretty on the surface and they become almost mainstream in our thought processes, that we forget the revolutionary ideas that inform the development of impressionism in the United States,” she said.
The exhibit opens to the public this Saturday, but VMFA members can preview it early Thursday, April 14, and Friday, April 15. | https://www.wric.com/community/whistler-to-cassatt-vmfa-exhibit-features-artwork-by-american-painters-in-france/ | 2022-04-14T03:35:42 | 1 | https://www.wric.com/community/whistler-to-cassatt-vmfa-exhibit-features-artwork-by-american-painters-in-france/ |
(UNITED NATIONS) — A U.N. task force is warning in a new report that Russia’s war against Ukraine threatens to devastate the economies of many developing countries that are now facing even higher food and energy costs and increasingly difficult financial conditions.
U.N. Secretary-General Antonio Guterres launched the report Wednesday stressing that the war is “supercharging” a crisis in food, energy and finance in poorer countries that were already struggling to deal with the COVID-19 pandemic, climate change and a lack of access to adequate funding for their economic recovery.
Rebeca Grynspan, secretary-general of the U.N. agency promoting trade and development who coordinated the task force, said 107 countries have “severe exposure” to at least one dimension of the food, energy and finance crisis and 69 countries are severely exposed to all three and face “very difficult financial conditions with no fiscal space, and with no external financing to cushion the blow.”
The report urges countries to ensure a steady flow of food and energy through open markets, and it calls on international financial institutions to do everything possible to ensure more liquidity immediately. | https://www.wrtv.com/news/national/russia-ukraine-conflict/un-warns-107-countries-have-severe-exposure-to-consequences-of-ukraine-war | 2022-04-14T03:35:48 | 1 | https://www.wrtv.com/news/national/russia-ukraine-conflict/un-warns-107-countries-have-severe-exposure-to-consequences-of-ukraine-war |
Update 11:24 p.m.: All lanes have been reopened
Update 10:45 p.m.: One lane has been reopened.
CHESTERFIELD COUNTY, Va. (WRIC) — All northbound lanes of a section of I-95 north in Chesterfield were shut down by police after a multi-vehicle car crash Wednesday night, according to the Virginia Department of Transportation.
VDOT said that a multi-vehicle car crash shut down the interstate near mile marker 63, near Route 288. The traffic impediment was announced by VDOT just after 10:30 p.m.
The crash involved a Mini Cooper and a motorcycle, and, according to Virginia State Police, the driver of the motorcycle was taken to VCU Medical Center for treatment of their non-life-threatening injuries.
Traffic was diverted off of I-95, using Route 288.
VDOT said for drivers to use alternate routes, and expect delays in the area.
This is a breaking news story, stay with 8News for updates. | https://www.wric.com/news/local-news/chesterfield-county/multi-vehicle-car-crash-shuts-down-section-of-i-95-north-in-chesterfield/ | 2022-04-14T03:35:48 | 0 | https://www.wric.com/news/local-news/chesterfield-county/multi-vehicle-car-crash-shuts-down-section-of-i-95-north-in-chesterfield/ |
(KYIV, Ukraine) — Ukrainian President Volodymyr Zelenskyy said he’s “sincerely thankful” to the U.S. for the new round of $800 million in military assistance.
In his daily late-night address to the nation, Zelenskyy also said he was thankful for Wednesday’s visit by the presidents of Poland, Estonia, Lithuania and Latvia.
He said those leaders “have helped us from the first day, those who did not hesitate to give us weapons, those who did not doubt whether to impose sanctions.”
In his telephone conversation with U.S. President Joe Biden, Zelenskyy said they discussed the new weapons shipment, even tougher sanctions against Russia and efforts to bring to justice those Russian soldiers who committed war crimes in Ukraine.
Zelenskyy also said work was continuing to clear tens of thousands of unexploded shells, mines, and tripwires that were left behind in northern Ukraine by the retreating Russians.
He urged those returning to their homes in those towns to be wary of any unfamiliar object and report it to the police. | https://www.wrtv.com/news/national/russia-ukraine-conflict/zelenskyy-sincerely-thankful-to-us-for-additional-800m-in-ukraine-assistance | 2022-04-14T03:35:54 | 0 | https://www.wrtv.com/news/national/russia-ukraine-conflict/zelenskyy-sincerely-thankful-to-us-for-additional-800m-in-ukraine-assistance |
(KTLA) – A 50-year-old Los Angeles man who appeared in “Game of Thrones” was arrested last week after detectives said he was engaging in “online sexually explicit communication” with a minor victim who lived in another state. Now, investigators are looking for other possible victims.
Joseph Gatt of Los Angeles was arrested on Wednesday, April 6, after authorities served a search warrant at his home in Beverly Grove.
LAPD’s Internet Crimes Against Children Task Force began investigating Gatt after they received a tip that he was engaged in sexually explicit communication with the minor victim.
Gatt also had an outstanding felony warrant for a similar crime involving communication with a minor, police said.
Investigators are now looking for any additional victims who may not have been contacted.
Gatt, who was born and raised in London, played Thenn Warg in “Game of Thrones,” according to his IMDB page. Other acting credits include the live-action “Dumbo,” “Star Trek Into the Darkness” and “Thor.”
Anyone with information about this case or any other alleged victims is encouraged to contact detective Denos Amarantos at 562-624-4027. You can also submit an anonymous tip at lacrimestoppers.org.
If you have knowledge or suspicion about someone making inappropriate contact with a minor, or if you know of child sexual abuse material online, you are urged to contact local law enforcement or the National Center for Missing and Exploited Children at 800-843-5678. | https://www.wric.com/news/u-s-world/game-of-thrones-actor-arrested-on-suspicion-of-sex-crimes-against-child-lapd/ | 2022-04-14T03:35:54 | 1 | https://www.wric.com/news/u-s-world/game-of-thrones-actor-arrested-on-suspicion-of-sex-crimes-against-child-lapd/ |
The Supreme Court has been back in the headlines recently, and it's not just because of the historic nomination of Ketanji Brown Jackson.
There was also a much more controversial story, surrounding Justice Clarence Thomas and his wife, Ginni, and the story reveals something somewhat shocking about the nation's highest court.
Between November 2020 and the insurrection on Jan. 6, Ginni Thomas repeatedly texted then-White House Chief of Staff Mark Meadows, urging him to overturn the election results.
This raised major red flags because one year later, her husband on the Supreme Court voted to block the release of White House records on the insurrection, which would likely include the texts with his wife.
While many critics cried foul at the conflict of interest, legal experts pointed out, technically, the Supreme Court has no code of ethics. In fact, it's the only court in the nation that doesn't have one.
Chief Justice John Roberts explained that he lets justices decide for themselves if they have conflicts of interest. There's no external check on this.
The scandal comes at a time when public trust in the Supreme Court is at an all-time low. In a Pew Research study, only 16% of adults say that the justices do a good or excellent job of keeping their own politics out of their rulings.
This case has renewed calls from legal experts and prominent Democrats for major reforms of the Supreme Court, one of which would be establishing a code of conduct.
The case with Justice Thomas is far from the only prominent potential conflict of interest among the court. The nonprofit Fix The Court documented potential conflicts of interest with every sitting justice and many former Justices.
For example, the organization Americans for Prosperity spent more than $1 million to help confirm Justice Amy Coney Barrett, who did not recuse herself from the case Americans for Prosperity v. Bonta. She ended up ruling in favor of the organization that aided her confirmation.
In another instance, although the court ended up not hearing the case, Justice Sotomayor failed to recuse herself from Nicassio v. Viacom, where Penguin Random House was on the side of the respondents. Sotomayor had earned over $3 million from her book contracts with Penguin Random House.
Some Congressional Democrats have called for Chief Justice Roberts to create a code of ethics by later this month. April 28 to be exact. Other Democrats are moving a step further, proposing legislation that would require a judicial ethics code. The bill so far has no Republican support.
Republican leaders have been particularly vocal against another proposed reform: Expanding the number of justices on the court. The proposal is actually an old one, as FDR once tried to expand the court in 1937. Critics accused him of court packing, to add more liberals to the court who would support the New Deal. The idea of court expansion only recently gained more popularity among some lawmakers and some legal experts, particularly on the left.
But it's worth noting, court packing is not a one-party issue. Republican governors in Georgia and Arizona, both vocal against Supreme Court expansion, have recently expanded their states' supreme courts in order to create Republican majorities.
A third Supreme Court reform that gets a lot of attention is the idea of term limits. This has surprising bipartisan support among legal experts and the general public. Supporters say this would help the court adapt to the current ideological makeup of the country, but opponents argue this might actually make the Court more politicized and not less, nominations would become a regular election issue and justices might decide opinions to shape their post-judicial political careers.
The Supreme Court nominations do seem to have become recently politicized. Liberal Justice Ruth Bader Ginsburg was approved with a 96-3 split in the Senate, and Conservative Justice Antonin Scalia was approved 98-0.
There seems to be little consensus on what reforms are best or even possible. The Biden administration created a bipartisan team of legal experts to form the Commission on the Supreme Court.
"And I will ask them to over, 180 days come back to me with recommendations as to how to reform the court system, because it's getting out of whack," President Biden said.
Although the report did suggest establishing a code of conduct, even the commission could not definitively decide on a number of suggestions, like court-packing or term limits. As the Justice Thomas scandal has renewed momentum for reforms, the thorny debate over what those reforms will actually look like presses on.
Newsy is the nation’s only free 24/7 national news network. You can find Newsy using your TV’s digital antenna or stream for free. See all the ways you can watch Newsy here. | https://www.wrtv.com/news/national/the-supreme-court-has-a-lot-of-problems-can-they-be-fixed | 2022-04-14T03:36:00 | 1 | https://www.wrtv.com/news/national/the-supreme-court-has-a-lot-of-problems-can-they-be-fixed |
NEW MEXICO (KRQE) – Crews are working to contain the Nogal Canyon Fire in the Lincoln National Forest, on April 12. According to officials, the fire started around 1:25 p.m. It remains 0% contained.
Multiple resources with the Forestry Division, Lincoln County, United States Forest Service, local fire departments are working to contain the fire. According to NM fire 10 structures have been lost, including homes, and many remain threatened.
Evacuations are in place for all of Nogal Canyon up to NM Highway 37. An evacuation center is set up at Carrizozo School, 800 D Ave in Carrizozo. Livestock can be taken to the Capitan Fairgrounds in Capitan.
- Start Date: April 12, 1:25 p.m.
- Location: The Nogal Canyon fire is located 8 miles east of Capitan in Lincoln County.
- Containment: 0%
- Size: 400 acres
- Structures Threatened: Homes, outbuildings
- Structures: 10 structures lost or damaged
- Evacuations: All of Nogal Canyon is under immediate evacuation notice
- Cause: Downed Power lines
- Total Personnel: Lincoln County and US Forest Service firefighting resources
- Area Vegetation: Grass, Pinon Juniper, and Ponderosa Pine
- Ownership(s): Private and USFS | https://www.wric.com/news/u-s-world/nogal-canyon-fire-0-contained-400-acres-burned/ | 2022-04-14T03:36:01 | 0 | https://www.wric.com/news/u-s-world/nogal-canyon-fire-0-contained-400-acres-burned/ |
JACKSON COUNTY — A Scottsburg man died Wednesday when his vehicle went into oncoming traffic, hit the side of a dump truck, then crashed head-on with another vehicle.
Ronnie Brickley Jr., 43, was pronounced dead at the scene and another person suffered minor injuries when her car was hit by debris as a result of the crash, according to Indiana State Police.
State troopers responded about 3 p.m. for a report of a four-vehicle crash on U.S. 31 south of Seymour.
Investigators determined Brickley was driving a Toyota Tacoma north on U.S. 31 south of County Road 275 North when for an unknown the pickup truck crossed the center line into the path of a dump truck heading south.
Brickley then struck the side of that truck and went toward a second dump truck, which he hit head-on. The force of the collision threw debris toward a fourth vehicle, a Kia Sportage, causing minor damage and injuries to its 62-year-old driver, ISP said.
The other two drivers involved in the crash were uninjured,
U.S. 31 was closed for about four hours after the crash.
Alcohol and drugs aren't believed to be factors in the crash, but police say toxicology results are still pending.
An investigation is ongoing. | https://www.wrtv.com/news/public-safety/man-dies-after-hitting-truck-crashing-head-on-with-oncoming-car-in-jackson-co-crash | 2022-04-14T03:36:07 | 1 | https://www.wrtv.com/news/public-safety/man-dies-after-hitting-truck-crashing-head-on-with-oncoming-car-in-jackson-co-crash |
INDIANAPOLIS — Three Indianapolis Indians pitchers combined to throw a no-hitter Wednesday night against the St. Paul Saints.
Chase De Jong started the game and threw seven innings of nearly perfect baseball. He struck out nine and walked two batters.
Austin Brice pitched the eighth inning and Yerry De Los Santos closed out the game by striking out two Saints batters.
The Indians won the game 5-0 and moved to 6-2 on the season.
TOP STORIES: IUPUI commencement ceremony subject of uproar as some students won't be able to walk | Gainbridge concertgoers say they were denied access to rescheduled Elton John show; told tickets invalid | Meteor likely cause of mysterious explosion-like noise that rattled parts of Indiana, AMS says | Carvana building demolished to clear way for construction of new I-465 interchange | Apple to pay $14.8M to iCloud subscribers over breached contract | https://www.wrtv.com/sports/three-indy-indians-pitchers-combine-for-no-hitter | 2022-04-14T03:36:13 | 0 | https://www.wrtv.com/sports/three-indy-indians-pitchers-combine-for-no-hitter |
Harvard scientists discover 1st interstellar meteor to collide with Earth, US military confirms
One meteor traveled quite a long way from home to visit Earth.
Related video above: Top astronomy events for April 2022
Researchers discovered the first known interstellar meteor to ever hit Earth, according to a recently released United States Space Command document. An interstellar meteor is a space rock that originates from outside our solar system — a rare occurrence.
This one is known as CNEOS 2014-01-08, and it crash-landed along the northeast coast of Papua New Guinea on Jan. 8, 2014.
The finding came as a surprise to Amir Siraj, who identified the object as an interstellar meteor in a 2019 study he coauthored while an undergraduate at Harvard University.
Siraj was investigating ʻOumuamua, the first known interstellar object in our solar system that was found in 2017, with Abraham Loeb, professor of science at Harvard University.
Siraj decided to go through NASA's Center for Near Earth Object Studies database to find other interstellar objects and found what he believed to be an interstellar meteor within days.
A need for speed
The meteor's high velocity is what initially caught Siraj's eye.
The meteor was moving at a high speed of about 28 miles per second (45 kilometers per second) relative to Earth, which is moving at around 18.6 miles per second around the sun. Because researchers measured how fast the meteor was moving while on a moving planet, the 45 kilometers per second was not actually how fast it was going.
The heliocentric speed is defined as the meteor's speed relative to the sun, which is a more accurate way to determine an object's orbit. It's calculated based on the angle at which a meteor hits the Earth. The planet moves in one direction around the sun, so the meteor could have hit Earth head-on, meaning opposite the direction the planet is moving, or from behind, in the same direction the Earth is moving.
Since the meteor hit the Earth from behind, Siraj's calculations said the meteor was actually traveling at about 37.3 miles per second relative to the sun.
He then mapped out the trajectory of the meteor and found it was in an unbound orbit, unlike the closed orbit of other meteors. This means that rather than circling around the sun like other meteors, it came from outside the solar system.
"Presumably, it was produced by another star, got kicked out of that star's planetary system and just so happened to make its way to our solar system and collide with Earth," Siraj said.
Difficulty getting published
Loeb and Siraj have been unable to get their findings published in a journal because their data came from NASA's CNEOS database, which doesn't divulge information such as how accurate the readings are.
After years of trying to obtain the additional information needed, they received official confirmation that it was, in fact, an interstellar meteor, from John Shaw, deputy commander of the U.S. Space Command. The command is a part of the U.S. Department of Defense and is responsible for military operations in outer space.
"Dr. Joel Mozer, the Chief Scientist of Space Operations Command, the United States Space Force service component of U.S. Space Command, reviewed analysis of additional data available to the Department of Defense related to this finding. Dr. Mozer confirmed that the velocity estimate reported to NASA is sufficiently accurate to indicate an interstellar trajectory," wrote Shaw in the letter.
Siraj had moved onto other research and almost forgotten about his discovery, so the document came as a shock.
"I thought that we would never learn the true nature of this meteor, that it was just blocked somewhere in the government after our many tries, and so actually seeing that letter from the Department of Defense with my eyes was a really incredible moment," Siraj said.
A second chance
Since receiving the confirmation, Siraj said his team is working to resubmit their findings for publication in a scientific journal.
Siraj would also like to put a team together to try and retrieve part of the meteor that landed in the Pacific Ocean but admitted it would be an unlikely possibility due to the sheer size of the project.
If researchers were able to get their hands on the "holy grail of interstellar objects," Siraj said it would be scientifically groundbreaking in helping scientists discover more about the world beyond our solar system.
NASA and U.S. Space Command did not initially respond for comment. | https://www.koat.com/article/harvard-scientists-1st-interstellar-meteor-collide-earth-us-military/39718159 | 2022-04-14T03:38:27 | 1 | https://www.koat.com/article/harvard-scientists-1st-interstellar-meteor-collide-earth-us-military/39718159 |
Los Angeles police were asking for the public's help Wednesday in search of people who may have been victimized by an actor arrested on suspicion of engaging in "online sexually explicit communication with a minor.''
Joseph Gatt, 50, of Los Angeles, was arrested at his home April 6 by detectives from the Internet Crimes Against Children Task Force, according to the Los Angeles Police Department.
Gatt's acting credits include "NCIS: New Orleans,'' "Game of Thrones," "Thor" and "Star Trek Into Darkness," according to IMDb, which listed his age as 47.
Detectives served a search warrant at Gatt's home in the area of 3rd Street and La Jolla "after they received information that Gatt had been engaged in online sexually explicit communication with a minor across state lines,'' according to an LAPD statement.
Gatt was arrested on a felony warrant for "contact with a minor for sexual offense,'' police said. Details of his alleged crime were not released.
The Los Angeles Regional Internet Crimes Against Children Task Force includes more than 100 federal and local affiliate agencies that detect and investigate child predators that use the Internet as a means to contact children or deal in child sexual abuse material.
Entertainment News
Anyone who may have been victimized by Gatt was urged to call Detective Denos Amarantos at 562-624-4027. During non-business hours or on weekends, calls should be directed to 877-LAPD-247. Anyone wishing to remain anonymous should call Crime Stoppers at 800-222-TIPS or use the website www.lacrimestoppers.org. | https://www.nbcnewyork.com/entertainment/entertainment-news/la-actor-ncis-got-arrest-sexually-explicit-communication-with-minor/3645124/ | 2022-04-14T03:38:27 | 1 | https://www.nbcnewyork.com/entertainment/entertainment-news/la-actor-ncis-got-arrest-sexually-explicit-communication-with-minor/3645124/ |
Skip to content
Continuing Coverage
Brooklyn Subway Shooting Suspect Arrested; Called Police Tip Line on Himself, Sources Say
Main Navigation
Search
Search for:
Local
Weather
Investigations
Baquero
Video
TV Listings
Our Voices
Newsletters
Live TV
Share
Close
Trending
COVID-19
BA.2
CRIME STOPPERS
Frank R. James
Brooklyn Subway Shooting
Latest Updates
Eric Adams
Gilbert Gottfried
Gilgo Beach
Russia-Ukraine
Lifestyle
NBCLX
Expand
Local | https://www.nbcnewyork.com/news/local/latest-forecast-from-storm-team-4-4001/3644918/ | 2022-04-14T03:38:33 | 0 | https://www.nbcnewyork.com/news/local/latest-forecast-from-storm-team-4-4001/3644918/ |
Smoke, bangs, blood and panic: Riders describe being inside the NYC subway when shooting began
Hourari Benkada didn't pay much attention to the man he sat next to on a New York subway car Tuesday morning. Benkada, headphones on, put his head down and only got a glimpse of the person.
But after the train started moving to the next stop, the man set off a "smoke bomb," Benkada said.
That sent Benkada and others rushing in confusion toward the car's other end. And Benkada believes that the man he sat next to was the one who would shoot him and nine other people in that car, under cover of thick and choking smoke, as the train headed to the 36th Street subway station in Brooklyn's Sunset Park.
It was "the worst pain in my entire life," the 27-year-old Benkada, who was shot in the back of the knee, said in one of several interviews he gave CNN on Tuesday and Wednesday while recovering post-surgery in a hospital bed.
Police said a gunman set off two smoke grenades and fired a handgun 33 times on the crowded train, leaving 29 people injured, including 10 who were shot. A suspect was arrested Wednesday.
Benkada and others on the train described a harrowing scene: Smoke, a mad rush away from its source — and then what sounded like fireworks, followed by a panicked realization that people were hurt and bleeding.
As passenger Claire Tunkel recalled: "When I heard people saying, 'I'm hurt; there's so much blood' ... that's when my mind changed to, 'This is not fireworks.'"
Man had duffel bag
Benkada, a housekeeping manager at The New Yorker hotel, said the person he sat next to had a duffel bag, was wearing a mask and appeared to be wearing a Metropolitan Transportation Authority vest.
When the smoke started, "all you see (is) smoke — black smoke ... going off, and then people bum-rushing to the back," Benkada said.
"This pregnant woman was in front of me. I was trying to help her. I didn't know there were shots at first. I just thought it was a black smoke bomb.
"She said, 'I'm pregnant with a baby.' I hugged her. And then the bum-rush continued. I got pushed, and that's when I got shot in the back of my knee."
The noise, he too said, at first sounded "like fireworks going off."
The shooting started about 20 seconds after the train took off, and felt like it lasted for 1 to nearly 2 minutes, Benkada said.
As people flocked to the end farthest from the smoke source, someone broke down a door at that end, hoping to cross to the next car, but that car had its own door that didn't open, Benkada and others said.
Benkada heard other people in pain, but couldn't see them or the suspect because of the smoke, he said.
Adding to the riders' terror, the train didn't seem like it was heading to the next station as fast as it could. It stopped at least once between stations, riders said.
"The conductor said that there was a delay, because there was train traffic ahead of us," rider Yav Montano, who said perhaps 40 to 50 people were in the car, told CNN.
"Thank goodness the train moved within a minute. I don't know what could have happened if we were stuck there for longer."
People were crying out for help and falling down, witness says
Tunkel, 46, said that before the chaos started, she thought she'd seen the person police have described as a suspect in the shooting.
"He said there was urine in the seat (next to him), don't sit there." However, she said, "with masks and hats and things like that," she can't be sure that was the suspect.
She said her first indication something was wrong was hearing "something drop on the floor," and smoke "just started coming out."
Tunkel ran with others to the car's other end, but the train filled with smoke. "And that's when ... what I thought was fireworks, at the beginning, started going off," she said.
She said she heard people crying out for help and others who said they were bleeding.
"You couldn't see anything, but you could feel it," and some people rushing to that end were falling down, she said. "You could feel the bodies."
'Clothes ... were covered in blood'
Montano, who was trying to get to work in Williamsburg, said he also thought the noise was "like fireworks on the floor."
But just in case, he said, he move behind a wooden plank on the other side of a chair, by some doors — "I moved myself out of the way."
Eventually, he said, he saw some people "whose clothes ... were covered in blood."
"There were some people -- it didn't even seem like their blood, because the person whose pants had ... blood on it was OK and walking and helping the other people," Montano said.
On his phone, he recorded a few seconds of video showing people holding their hands to their mouths in the smoky car "after the popping and shooting," he said.
"The whole car was engulfed in smoke. Like, I had a mask on in the train; I couldn't even use my mask anymore because it was black with smoke," Montano said.
Riders rushed from train
The train eventually arrived at the 36th Street subway station In a video taken from the platform, people rush off the train after it arrived.
Smoke pours out of the car where the shooting took place, and people can be heard screaming. Someone helps an injured and bleeding person off the train, and another man is seen hobbling off the train shortly afterward.
Images taken by others at the scene show the subway platform streaked with blood and people sitting and lying on the train platform following the incident.
Now off the train, Tunkel said she saw a man with a gunshot wound. She said she took off her jacket and tied it around his leg.
Tunkel, who went to a hospital for smoke inhalation, said several victims were lying on the floor of the subway platform after the train arrived at the station.
She said Wednesday she was "doing alright" physically.
"I have two small children that ... go to school nearby, and they had a lockdown yesterday. So explaining this to them was definitely probably the hardest part of all of this. ... I'm just taking it moment to moment."
Benkada said that when he got off the train, he "looked at all the blood and (said) 'this ain't right.'"
He went up some stairs, and told a man in a booth that "I needed a lot of napkins -- I'm bleeding." Eventually, two firefighters helped him.
Doctors told him the bullet grazed his kneecap. He is expected to walk on his own after several weeks on crutches.
At the hospital Wednesday, Benkada still was coping with pain and seemed to have made up his mind about one part of his future.
"I don't think I can ever ride the train again," he said. | https://www.koat.com/article/nyc-subway-survivors-share-experience/39717141 | 2022-04-14T03:38:37 | 0 | https://www.koat.com/article/nyc-subway-survivors-share-experience/39717141 |
The man charged with terrorizing a New York City subway station Tuesday was in Philadelphia the day before, where he had both an apartment and a storage facility, according to a criminal complaint.
Frank R. James, 62, was arrested Wednesday morning, hours after he had been officially named as a suspect in the shooting that left 10 people with bullet wounds after the attack in the Sunset Park section of Brooklyn. James previously lived in Milwaukee, Wisconsin, but last month arrived in Philadelphia, officials and court documents said.
A tip to the NYPD's Crime Stoppers line brought police to the suspect, sources told NBC News. He was arrested on a East Village street Wednesday.
Authorities zeroed in on James after finding a key to a U-Haul truck in belongings left on the subway after the shooting, New York police said in a press conference Tuesday. They found that truck in Brooklyn Tuesday evening, and quickly traced it to James.
That truck may have been rented in Philadelphia. Video shows a Philadelphia address and the words "Allegheny West" on the side of the van. Later Wednesday, neighbors and law enforcement officials told NBC10 Philadelphia that the FBI raided a storage facility near Broad and Girard avenues in North Philadelphia.
According to court documents, inside the jacket James left on the subway platform was a receipt for the storage unit. Records from ride-sharing app Lyft reveal that James visited the storage unit, which was registered in his name, on Monday evening, the criminal complaint alleges. Law enforcement officers discovered ammunition, a 9mm pistol barrel that allows for a silencer or suppressor to be attached, and targets, among other items, the complaint says.
U.S. & World
Officials also identified an apartment allegedly used by James in Philadelphia. The Lyft records reveal James ordered rides to or from the Philly apartment about 21 times from March 28 through April 10, according to James' criminal complaint. The complaint also states the apartment management company information revealed James rented the apartment for 15 days, beginning on March 28. Inside the apartment, officials allegedly recovered an empty magazine for a Glock handgun, a taser and a blue smoke cannister, and other items, the complaint reads.
Authorities think James might have slept in the truck the night before the shooting, NBC News reported. There was foam rubber padding inside, NBC's Pete Williams reported.
Around 6 a.m., he got out of the van and went into the subway system for at least an hour, Williams reported.
James has no fixed address, Williams reported. He was born in the Bronx, but family say he had no long-term job. He has made several social media postings and YouTube videos expressing his concern about crime and other issues, Williams reported.
Authorities are examining those posts, Police Chief of Detectives James Essig and Police Commissioner Keechant Sewell said. She said the posts were “concerning.”
In a video posted on March 20, a man believed to be James can be heard saying, "I'm on my way to Philadelphia."
James has been arrested nine previous times in New York City between 1992 and 1998, police said at a Wednesday press conference. He was arrested three times between 1991 and 2007 in New Jersey, they said.
At least 10 Brooklyn subway riders were shot Tuesday by a man wearing a gas mask and a green construction vest who tossed a smoke canister in the train car to distract the rush hour crowd before opening fire, officials and law enforcement sources said.
More than a dozen others were hurt in the chaos that followed the shooting aboard the Manhattan-bound N train at the 36th Street and Fourth Avenue station in Sunset Park around 8:30 a.m. The gunman was still on the loose overnight into Wednesday.
Five of the gunshot victims were said to be critically injured. Details on the nature of their wounds weren't immediately clear. No fatalities have been reported.
Investigators believe the weapon jammed, preventing the suspect from continuing to fire, the officials said. The federal Bureau of Alcohol, Tobacco, Firearms and Explosives has completed an urgent trace to identify the gun’s manufacturer, seller and initial owner.
Witnesses said the entire train car smelled of gasoline. Sources with the MTA described a similar smell too, but the law enforcement officials said no gas cans were found.
The smoke canister, and harrowing video from the train, prompted early concerns about possible explosive devices connected to the case, but Commissioner Sewell assured New Yorkers in an early afternoon news conference that there are no known explosive devices on any subway trains in the city at this time.
Authorities found a 9 mm semi-automatic handgun at the scene, along with extended magazines, a hatchet, detonated and undetonated smoke grenades, a black garbage can, a rolling cart, gasoline -- and the key to that U-Haul van, Essig said. | https://www.nbcnewyork.com/news/national-international/man-with-philly-ties-named-suspect-in-brooklyn-subway-shooting/3645409/ | 2022-04-14T03:38:40 | 0 | https://www.nbcnewyork.com/news/national-international/man-with-philly-ties-named-suspect-in-brooklyn-subway-shooting/3645409/ |
The Justice Department has reached a settlement in four cases stemming from law enforcement's response to racial justice demonstrations in Lafayette Square in Washington, D.C., just days after George Floyd's murder.
As part of the settlement, the United States Park Police agreed to revise its policies governing demonstrations and special events.
The new policy, released Wednesday, requires officers, except personnel in plain clothes, to be "clearly identifiable" as Park Police personnel, with fully visible badges and nameplates on outerwear, tactical gear and helmets.
For more on this story, go to NBC News. | https://www.nbcnewyork.com/news/national-international/doj-reaches-settlement-in-2020-cases-involving-lafayette-square-protesters/3645395/ | 2022-04-14T03:38:46 | 0 | https://www.nbcnewyork.com/news/national-international/doj-reaches-settlement-in-2020-cases-involving-lafayette-square-protesters/3645395/ |
Meet the people who want to spend the rest of their lives on cruise ships
Angelyn Burk has been in love with cruising since she boarded a megaship for the first time back in 1992 to sail in the Caribbean.
Now that the 53-year-old is retired from her accounting job, she and her husband, Richard, plan to sail off into the sunset for good — by retiring aboard a cruise ship.
The Burks, who last lived in the Seattle area but have been location independent since May 2021, have done the math for what they can afford to spend for daily living during their retirement years.
Angelyn says the number comes to $100 per day or less for the two of them to cover their living expenses (with a buffer to spend up to $135 per day, if needed).
"Currently, this year, we have secured 86 cruise days with an average all-in cost of $89/day for both of us," she says via email. "Which includes room, food, entertainment, transportation, gratuity, port fees and taxes."
"This is well within our retirement budget," she says, adding that taking frequent cruises has led to the couple being offered deep discounts on future sailings through loyalty programs.
The bulk of the 86 days the Burks have booked this year are on Holland America, with roughly a week on a Carnival ship. And among the many destinations the couple will be visiting are Mexico, Costa Rica, Canada, Alaska, Japan, Indonesia and Vietnam.
"When planning out cruises, I try to stay on the same ship as long as possible, as long as it is cost-effective," says Angelyn, noting the couple plans to spend most of their retirement years living on cruise ships and not on land.
As for the advantages of moving aboard a floating home for their retirement, she says, those are obvious.
"Where else can you have your resort take you to different countries while relaxing by the pool or sleeping in a comfortable bed?"
An enticing retirement or work-from-anywhere plan
Considering retiring on a cruise ship? You're not alone.
Deciding to retire or work aboard a cruise ship is rare overall, but not new.
Before the pandemic, which interrupted some longer-term cruise ship stays, Crystal Cruises (which declared bankruptcy in early 2022) and Royal Caribbean Group had at least two passengers who lived aboard their ships for years on end and who became celebrities in cruising circles.
One of them, Mario Salcedo, is still working while cruising. Nicknamed Super Mario, Salcedo has lived on Royal Caribbean cruise ships for more than two decades. CNN Travel tried to reach him through Royal Caribbean, but the line says their top cruiser doesn't do media interviews anymore.
"There's a sense of home for all of our guests, especially those that spend a majority of the year sailing on our ships," Mark Tamis, a Royal Caribbean International senior vice president, says in a statement to CNN Travel. "For example, one of my favorite guests, Super Mario has an 'office' on the top deck of every ship he sails on and VOOM streaming internet service so that he can work from anywhere in the world."
Another famous long-term cruiser, "Mama" Lee Wachtstetter, spent years aboard Crystal Serenity and wrote a memoir, "I May be Homeless but You Should See my Yacht." It detailed some of her cruising shenanigans, including a rogue wave in the Mediterranean and the time she was kidnapped by a tuk-tuk driver in Thailand.
In March 2017, when cruising website Cruise Critic asked the question "Would you retire at sea?" in a poll on its website, 59% of respondents said they would love to retire at sea or at least try it for a couple of years (another 27% of respondents answered, "Maybe, if the price was right").
"It's something that's certainly aspirational," says Colleen McDaniel, Cruise Critic's editor-in-chief. "We hear from our cruisers all the time that retiring onboard is something they'd be interested in doing."
McDaniel points to the convenience factor of cruising — "getting to see the world from your home where you have all your meals taken care of, great service and things like laundry onboard" — as one of its main appeals for people considering retiring onboard.
Having a built-in community also appeals to people looking to move onto cruise ships longer term. Crew members can become like family for many long-term passengers, says McDaniel.
A potential cost benefit
And the affordability of cruising compared with retired life on land is another selling point, she says.
"Assisted living is not a cheap proposition. It costs thousands and thousands of dollars a month, depending on where you're staying," McDaniel says. "So cruising is potentially a far more cost-effective way to retire."
Malcolm Myers, 88, who once spent 10 straight months aboard Seven Seas Voyager, a Regent Seven Seas ship, says that while the luxury line is not inexpensive, the average cost is comparable to what he pays in his high-end senior living community in Stuart, Florida.
"If I have to move to a senior (more comprehensive care) facility in my community, the cost of living on the ship would definitely be better," Myers says in an email to CNN. "And I would have a variety of entertainment, lectures and restaurants and medical care at my disposal without additional cost."
Cruise Critic's McDaniel notes that while cruise lines have a medical facility onboard, it's not the same as being next door to a hospital.
"There's only so much they can handle onboard," she says, so it's important to have evacuation insurance and land-based options for healthcare should you need medical care while cruising. | https://www.koat.com/article/people-who-want-to-spend-lives-on-cruise-ships/39720446 | 2022-04-14T03:38:48 | 0 | https://www.koat.com/article/people-who-want-to-spend-lives-on-cruise-ships/39720446 |
Miles Bridges hits young fan with mouthpiece after ejection vs. Hawks originally appeared on NBC Sports Washington
Miles Bridges knows he let his emotions get the best of him in Atlanta on Wednesday.
The Charlotte Hornets forward was ejected in the fourth quarter of his team’s play-in game against the Hawks. The State Farm Arena crowd let him hear it as he headed down the tunnel, and Bridges showed his frustration at the expense of a young fan.
Bridges turned to his left and chucked his mouthpiece in the direction of a spectator wearing a yellow hat. The mouthpiece flew past the spectator, though, and wound up hitting a girl standing in a lower row.
The girl told The Charlotte Observer that she is 16 years old but didn’t give her name or interview about the incident.
Following the game, Bridges owned up to his actions, calling the incident “unacceptable.”
The Hornets’ season came to a close after a 132-103 loss, marking the second straight year the team fell in the play-in tournament. Bridges finished the game with 12 points, four rebounds and four assists prior to his ejection. | https://www.nbcnewyork.com/news/sports/miles-bridges-hits-young-fan-with-mouthpiece-after-ejection-vs-hawks/3645416/ | 2022-04-14T03:38:52 | 1 | https://www.nbcnewyork.com/news/sports/miles-bridges-hits-young-fan-with-mouthpiece-after-ejection-vs-hawks/3645416/ |
Netflix launches new way for viewers to ‘like’ their favorite shows
Published: Apr. 13, 2022 at 9:58 PM CDT|Updated: 40 minutes ago
(CNN) - Netflix wants to keep its customers happy with the selections they are making.
The streaming service recently introduced a new recommendation tool - a double thumbs-up button.
Netflix already has thumbs up and thumbs down buttons for viewers to give feedback on what they like and dislike, but the company said it wanted to add another option.
The double thumbs-up tool is a way for viewers to let Netflix know which shows and movies they really like and enjoy.
Representatives with Netflix said it could recommend similar content thanks to the new tool, which ultimately helps customers stick around longer and feel satisfied with their subscription.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.kttc.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ | 2022-04-14T03:39:18 | 0 | https://www.kttc.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ |
Police: Woman dies after getting stuck upside down while climbing US-Mexico border wall
TUCSON, Ariz. (Gray News) - Police in Arizona said a Mexican woman died after illegally attempting to cross into the U.S. earlier this week.
Cochise County Sheriff Mark J. Dannels reports deputies responded to a call from Mexican authorities at about 11 p.m. on Monday concerning a woman stuck on a border fence near Douglas, Ariz.
According to the sheriff’s office, the woman was climbing over the border wall when she got stuck in the ropes of a harness and trapped upside down for a significant amount of time.
The 32-year-old was transported to a local hospital, but she was pronounced deceased. Authorities in Arizona said they notified the Mexican Consulate about the incident.
An autopsy will be completed to determine the woman’s cause of death and the sheriff’s office said its investigation continues.
“These incidents are not political; they are humanitarian realities that someone has lost a loved one in a senseless tragedy,” Sheriff Dannels said. “We have to do better in finding solutions to the challenges facing our border, and we have to do it for the right reasons. Regardless of opinions, the facts should direct our progress, and we will keep working towards a shared goal of border safety and security.”
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.kttc.com/2022/04/14/police-woman-dies-after-getting-stuck-upside-down-while-climbing-us-mexico-border-wall/ | 2022-04-14T03:39:19 | 1 | https://www.kttc.com/2022/04/14/police-woman-dies-after-getting-stuck-upside-down-while-climbing-us-mexico-border-wall/ |
Netflix launches new way for viewers to ‘like’ their favorite shows
Published: Apr. 13, 2022 at 9:58 PM CDT|Updated: 41 minutes ago
(CNN) - Netflix wants to keep its customers happy with the selections they are making.
The streaming service recently introduced a new recommendation tool - a double thumbs-up button.
Netflix already has thumbs up and thumbs down buttons for viewers to give feedback on what they like and dislike, but the company said it wanted to add another option.
The double thumbs-up tool is a way for viewers to let Netflix know which shows and movies they really like and enjoy.
Representatives with Netflix said it could recommend similar content thanks to the new tool, which ultimately helps customers stick around longer and feel satisfied with their subscription.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.1011now.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ | 2022-04-14T03:40:29 | 0 | https://www.1011now.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ |
- Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities
- Data from the clinical trial to be presented at a future medical meeting
- Large B-cell lymphoma (LBCL) is a common form of non-Hodgkin's lymphoma (NHL) and currently has limited treatment options
NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, April 13, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. Based on the topline results, the companies will engage global regulatory authorities.
LBCL is a fast-growing type of non-Hodgkin's lymphoma (NHL) – a cancer that develops in the lymphatic system – that affects B-cell lymphocytes, a type of white blood cell. There are an estimated 150,000 new LBCL cases each year globally. LBCL includes diffuse large B-cell lymphoma (DLBCL), which is the most common type of NHL worldwide and accounts for approximately 31 percent of all NHL cases.1,2,3,4
"We aim to leverage AbbVie's strong blood cancer expertise to further develop epcoritamab, alongside Genmab, for certain blood cancer patients who have limited treatment options," said Mohamed Zaki, M.D., Ph.D., vice president and head, global oncology development, AbbVie.
The topline results from this cohort demonstrated a confirmed overall response rate (ORR) of 63.1 percent by an independent review committee (IRC). The observed median duration of response (DOR) was 12 months. The mean lines of prior therapy in this cohort were 3.5 (2 to 11 lines of therapy). The most common treatment-emergent adverse events of any grade (greater than or equal to 20 percent) included cytokine release syndrome (CRS) (49.7 percent), pyrexia (23.6 percent), fatigue (22.9 percent), neutropenia (21.7 percent), and diarrhea (20.4 percent). The most common Grade 3 or 4 treatment-emergent adverse events (greater than or equal to 5 percent) included neutropenia (14.6 percent), anemia (10.2 percent), neutrophil count decreased (6.4 percent), and thrombocytopenia (5.7 percent). Additionally, the observed Grade 3 CRS was 2.5 percent. The data will be submitted for presentation at a future medical meeting.
Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy for a variety of hematologic malignancies, including an ongoing phase 3, open-label, randomized trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory DLBCL (NCT: 04628494).
"Together with our partner, AbbVie, we will work with regulatory authorities to determine next steps and continue to evaluate epcoritamab in a variety of clinical trials as a potential treatment option for patients with various hematological malignancies," said Jan van de Winkel, Ph.D., chief executive officer, Genmab. "We look forward to sharing the findings at a future medical meeting."
About the EPCORE™ NHL-1 Trial
EPCORE™ NHL-1 an open-label, multi-center safety and preliminary efficacy trial of epcoritamab that consists of two parts: a phase 1 first-in-human, dose escalation part; and a phase 2 expansion part. The trial was designed to evaluate subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-NHL, including LBCL and DLBCL. The dose escalation findings, which determined the recommended phase 2 dose, were published in The Lancet in 2021. In the phase 2 expansion part, additional patients are treated with epcoritamab to further explore the safety and efficacy of epcoritamab in three cohorts of patients with different types of relapsed/refractory B-NHLs who had limited therapeutic options.
The primary endpoint of the phase 2 expansion part was ORR as assessed by an IRC. Secondary efficacy endpoints included duration of response, complete response rate, duration of complete response, progression-free survival, and time to response as determined by the Lugano criteria. Overall survival, time to next therapy, and rate of minimal residual disease negativity were evaluated as secondary efficacy endpoints.
About Epcoritamab
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of lymphoma B cells.5 CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.6,7 Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration.
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Genmab Forward-Looking Statements
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
1 "Diffuse Large B-Cell Lymphoma." Lymphoma Research Foundation, https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/; date accessed: 11 February 2022.
2 "Non-Hodgkin Lymphoma." Lymphoma Research Foundation, https://lymphoma.org/aboutlymphoma/nhl/; date accessed: 7 April 2022.
3 Sehn, Salles. "Diffuse Large B-Cell Lymphoma." N Engl J Med. 2021;384:842-858. DOI: 10.1056/NEJMra2027612
4 Martelli, Ferreri, Agostinelli, et al. "Diffuse large B-cell lymphoma." Crit Rev Oncol Hematol. 2013;87(2):146-71. DOI: 10.1016/j.critrevonc.2012.12.009
5 Engelbert et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020 Feb;52: 102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23. PMID: 31981978; PMCID: PMC6992935.
6 Rafiq, Sarwish, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties." J. Immunol. (Baltimore, Md. 1950), U.S. National Library of Medicine, 15 Mar. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3631574/.
7 Singh, Vijay, et al. "Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." J Cancer Sci Ther., U.S. National Library of Medicine, Nov. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4939752/.
View original content:
SOURCE AbbVie | https://www.1011now.com/prnewswire/2022/04/13/abbvie-genmab-announce-topline-results-epcoritamab-duobody-cd3xcd20-phase-12-trial-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl/ | 2022-04-14T03:40:35 | 1 | https://www.1011now.com/prnewswire/2022/04/13/abbvie-genmab-announce-topline-results-epcoritamab-duobody-cd3xcd20-phase-12-trial-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl/ |
LOS ANGELES, April 13, 2022 /PRNewswire/ -- In honor of National Minority Health Month and Black Maternal Health Week, BabyLiveAdvice (BLA) is proud to announce the completion of an important maternal telehealth project that will soon be launching its second phase, both bringing free virtual telehealth support to minority mothers during pregnancy and postpartum.
Last year, BLA received a large grant to support inner-city minority mothers in Chicago, Illinois, in partnership with local Federally Qualified Health Centers. The project expanded to the state of Georgia, with the help of Johnson & Johnson and in partnership with local community physicians. The project enabled BLA to provide 175 Black and Hispanic mothers with free access to culturally competent virtual care, unbiased advice, support, and group education from BLA's team of Maternal-Infant experts, such as nurses, doulas, lactation consultants and mental health providers in the mothers' language and at their home. This, first of its kind, maternity telehealth demonstration project provided the much-needed evidence that telehealth has immense potential to bridge the gap in access to care, by connecting isolated people, particularly minorities, with health practitioners, and reducing the need for transportation to receive care.
"I never felt that anyone cared about me or my baby," said Letisha R, a South Chicago mom who participated in the project for 15 months. "I could live or die, and no one will care, until I met LaTanya my nurse on BLA. She was there when I needed her throughout my pregnancy and after Shetty was born, talking to her made me trust again that someone cared about us and that we will be all right."
Full data from this project will be available later this year, but early findings show that 78% of the Black and Hispanic mothers were able to adopt and utilize telehealth with high patient satisfaction and low attrition rates. The project also improved the doctor-patient interactions, with a 48% reduction in no-show rates to scheduled medical appointments, and improved overall pregnancy outcomes for the participating mothers.
The success of the initial project has led to approval of a second phase, which will enable BLA to support six hundred Black mothers in the state of Georgia. For this second phase, BabyLiveAdvice is immensely and especially excited to be partnering with the National Black Doulas Association®, whose doulas will serve as a critical part of the BLA provider team, to bring virtual support to Black (BIPOC) birthing families in the State of Georgia, for no cost.
Black mothers face the highest maternal mortality and morbidity rates in the United States. BLA, and the National Black Doulas Association® are both committed to serving these mothers, and their families, in a meaningful way, to improve the birthing experience and help reduce mortality and morbidity rates in their community. Through this project, Black mothers, birthing people, and parents will be able to connect with doulas, midwifes, nutritionists, diabetic educators, lactation consultants, nurse practitioners and nurses to receive free, one-on-one virtual support as well as educational group classes, from preconception to 6 months postpartum.
The next phase of the project will support further evidence around adoption and utilization of telehealth among the urban and rural underserved BIPOC communities in the state with the highest Black maternal mortality rates. BLA is extremely excited to join with the National Black Doulas Association® and continue its mission helping mothers, birthing people, and parents, especially those most in need.
View original content:
SOURCE Baby Live Advice | https://www.1011now.com/prnewswire/2022/04/13/babyliveadvice-partners-with-national-black-doula-association-provide-virtual-telehealth-support-minority-bipoc-mothers-georgia-pregnancy-infancy/ | 2022-04-14T03:40:42 | 0 | https://www.1011now.com/prnewswire/2022/04/13/babyliveadvice-partners-with-national-black-doula-association-provide-virtual-telehealth-support-minority-bipoc-mothers-georgia-pregnancy-infancy/ |
SÃO PAULO, April 13, 2022 /PRNewswire/ -- GOL Linhas Aéreas Inteligentes S.A. ("GOL" or "Company") (NYSE: GOL and B3: GOLL4), Brazil's largest domestic airline, in addition to the Material Facts disclosed on September 15, 2021 and February 7, 2022, announces the closing of the transaction involving the expansion of its commercial cooperation with American Airlines Group Inc. (NASDAQ: AAL) ("American") through an exclusive codeshare agreement for the next three years and an equity investment by American in the amount of US$200 million in 22.2 million newly issued preferred shares of GOL through a capital increase for a 5.3% participation in GOL's economic interest (the "Transaction"). As part of Transaction, on the date hereof American and the controlling shareholder of GOL entered into a shareholders' agreement which grants American the right to appoint a member to GOL's Board of Directors for the term of the exclusivity provided in the Transaction.
Through its exclusivity, the Transaction expands beyond the terms of the existing codeshare partnership between GOL and American, enhancing the travel opportunities for their passengers, the customer experience and the competitive position of GOL on routes connecting North and South America. In place since February 2020, the existing codeshare already represented the largest route network in the Americas, enabling the Company's customers to travel seamlessly to more than 30 destinations in the U.S. The partnership flights currently operate in GOL's hubs in São Paulo (GRU) and Rio de Janeiro (GIG), integrating 34 options of Brazilian and international routes, such as Montevideo, in Uruguay.
Investor Relations
ri@voegol.com.br
www.voegol.com.br/ir
+55(11) 2128-4700
About GOL Linhas Aéreas Inteligentes S.A.
GOL is Brazil's largest airline, leader in the corporate and leisure segments. Since its founding in 2001, it has been the airline with the lowest unit cost in Latin America, which has enabled the democratization of air transportation. The Company has partnerships with American Airlines and Air France-KLM, in addition to making available to Customers many codeshare and interline agreements, bringing more convenience and ease of connections to any place served by these partnerships. With the purpose of "Being First for Everyone", GOL offers the best travel experience to its passengers, including: the largest inventory of seats and the most legroom; the most complete platform with internet, movies and live TV; and the best loyalty program, SMILES. In cargo transportation, GOLLOG delivers parcels to various regions in Brazil and abroad. The Company has a team of 15,000 highly qualified airline professionals focused on Safety, GOL's number one value, and operates a standardized fleet of 135 Boeing 737 aircraft. GOL's shares are traded on the NYSE (GOL) and the B3 (GOLL4). For further information, visit www.voegol.com.br/ir.
About American Airlines Inc.
American's purpose is to care for people on life's journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company's stock is included in the S&P 500. Learn more about what's happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.
Disclaimer
The information contained in this material fact has not been subject to any independent audit or review and contains "forward-looking" statements, estimates and projections that relate to future events, which are, by their nature, subject to significant risks and uncertainties. All statements other than statements of historical fact contained in this material fact including, without limitation, those regarding GOL's future financial position and results of operations, strategy, plans, objectives, goals and targets, future developments in the markets in which GOL operates or is seeking to operate, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "will", "may", "project", "estimate", "anticipate", "predict", "seek", "should" or similar words or expressions, are forward-looking statements. The future events referred to in these forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond GOL's control, that may cause actual results, performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are based on numerous assumptions regarding GOL's present and future business strategies and the environment in which GOL will operate in the future and are not a guarantee of future performance. Such forward-looking statements speak only as at the date on which they are made. None of GOL or any of its affiliates, officers, directors, employees and agents undertakes any duty or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. None of GOL or any of its affiliates, officers, directors, employees, professional advisors and agents make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Although GOL believes that the estimates and projections in these forward-looking statements are reasonable, they may prove materially incorrect and actual results may materially differ. As a result, you should not rely on these forward-looking statements.
View original content:
SOURCE GOL Linhas Aéreas Inteligentes S.A. | https://www.1011now.com/prnewswire/2022/04/13/closing-previously-announced-exclusive-codeshare-agreement-between-gol-american-airlines/ | 2022-04-14T03:40:48 | 0 | https://www.1011now.com/prnewswire/2022/04/13/closing-previously-announced-exclusive-codeshare-agreement-between-gol-american-airlines/ |
Montefiore School Health Program is the largest and most comprehensive school-based health program in the nation, providing primary medical care, counseling, optometry and dentistry to 44,000 children.
BRONX, N.Y., April 13, 2022 /PRNewswire/ -- Today at PS 8 Elementary School, Congressmen Espaillat and Torres joined Montefiore Medicine President and CEO, Dr. Philip O. Ozuah to award more than $3.3 million in federal funding to the Montefiore School Health Program (MSHP), the largest and most comprehensive school-based health program in the country. One in four Bronx students have a MSHP clinic with health experts — from doctors and dentists to therapists — who support children from pre-Kindergarten through 12th grade.
The Bronx is the lowest income congressional district in the United States. This federal funding will upgrade the digital infrastructure and broadband capability across 99 schools, connecting more students and parents to Montefiore's telehealth services and primary care network.
"Congressmen Adriano Espaillat and Ritchie Torres fought hard and delivered in a big way for this program and this community. They know well that the children of The Bronx are the future of The Bronx," said Philip O. Ozuah, M.D., Ph.D., President and Chief Executive Office, Montefiore Medicine.
Between 25-30% of students (>14,000) who utilize MSHP services do so for chronic care conditions. Children with access to the support and resources made available by MSHP are 40% less likely to go home sick, resulting in stronger school performance and fewer workdays missed by parents. Emergency room visits and hospitalizations dropped by half after students started receiving treatment at MSHP clinics.
"This funding is transforming healthcare delivery in the highest-need areas of The Bronx — the increase in broadband and Wi-Fi connectivity will ensure nurses can access student health records quickly and that parents can advocate on their child's behalf without having to leave work," said Representative Adriano Espaillat. "Thanks to the decades-long commitment of Montefiore, 44,000 children — one of whom will likely take my place someday — will have free access to state-of-the-art healthcare services right at their school."
"This $3.3 million will transform the Montefiore program with faster, more reliable internet and secure videoconferencing software," said Representative Ritchie Torres. "The technology ensures that kids can get care when they need it, no matter what else is happening in the world."
About Montefiore Health System
Montefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 10 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
View original content to download multimedia:
SOURCE Montefiore Health System | https://www.1011now.com/prnewswire/2022/04/13/congressmen-espaillat-torres-deliver-more-than-33-million-montefiore-school-health-program/ | 2022-04-14T03:40:55 | 0 | https://www.1011now.com/prnewswire/2022/04/13/congressmen-espaillat-torres-deliver-more-than-33-million-montefiore-school-health-program/ |
TORONTO, April 13, 2022 /PRNewswire/ - Equitable Bank (the "Bank" or "Equitable"), a wholly owned subsidiary of Equitable Group Inc. (the "Company") (TSX: EQB) (TSX: EQB.PR.C) (TSX: EQB.R) today announced it is increasing its prime lending rates by 50 basis points to 3.20% from 2.70%, effective April 14, 2022.
Equitable Group Inc. trades on the Toronto Stock Exchange (TSX: EQB, EQB.PR.C and EQB.R) and serves more than 325,000 Canadians through its wholly-owned subsidiary Equitable Bank, Canada's Challenger Bank™. Equitable Bank has a clear mandate to drive change in Canadian banking to enrich people's lives. Founded over 50 years ago, Equitable Bank provides diversified personal and commercial banking services. Please visit equitablebank.ca for details.
Equitable Group Inc. trades on the Toronto Stock Exchange (TSX: EQB, EQB.PR.C and EQB.R) and serves more than 325,000 Canadians through its wholly-owned subsidiary Equitable Bank, Canada's Challenger Bank™. Equitable Bank has a clear mandate to drive change in Canadian banking to enrich people's lives. Founded over 50 years ago, Equitable Bank provides diversified personal and commercial banking services. Please visit equitablebank.ca for details.
View original content to download multimedia:
SOURCE Equitable Bank | https://www.1011now.com/prnewswire/2022/04/13/equitable-bank-increases-prime-rate/ | 2022-04-14T03:41:02 | 0 | https://www.1011now.com/prnewswire/2022/04/13/equitable-bank-increases-prime-rate/ |
RADNOR, Pa., April 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against SunPower Corporation ("SunPower") (NASDAQ: SPWR). The action charges SunPower with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of SunPower's materially misleading statements to the public, SunPower investors have suffered significant losses.
CLICK HERE TO SUBMIT YOUR SUNPOWER LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/spwr-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=tal&utm_content=sunpower
TO VIEW OUR VIDEO, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: APRIL 18, 2022
CLASS PERIOD: AUGUST 3, 2021 through JANUARY 20, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
SUNPOWER'S ALLEGED MISCONDUCT
SunPower provides solar energy solutions, including sales to its third-party dealer network and resellers, storage solutions, cash and loan sales, and long-term leases directly to end customers, and sells turn-key engineering, procurement, and construction services, as well as energy under power purchase agreements.
On January 21, 2022, SunPower issued a press release revealing that the company had "identified a cracking issue that developed over time in certain factory-installed connectors within third-party commercial equipment supplied to SunPower." As a result, SunPower reported that it "expects approximately $27 million of supplier-quality related charges in fourth quarter 2021 and approximately $4 million in the first quarter of 2022" to replace the faulty connectors.
Following this news, SunPower's stock fell $3.22, or 16.9%, to close at $15.80 on January 21, 2022.
WHAT CAN I DO?
SunPower investors may, no later than April 18, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages SunPower investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View original content to download multimedia:
SOURCE Kessler Topaz Meltzer & Check, LLP | https://www.1011now.com/prnewswire/2022/04/13/final-deadline-approaching-april-18-2022-kessler-topaz-meltzer-amp-check-llp-reminds-sunpower-corporation-investors-class-action-lawsuit-deadline/ | 2022-04-14T03:41:09 | 1 | https://www.1011now.com/prnewswire/2022/04/13/final-deadline-approaching-april-18-2022-kessler-topaz-meltzer-amp-check-llp-reminds-sunpower-corporation-investors-class-action-lawsuit-deadline/ |
- Genesis X Speedium Coupe showcases the future of Genesis' electric vehicle design
- Genesis announces plans to produce the Electrified GV70 in the U.S.
- Genesis Priority One, a personalized GV60 purchase experience, now open to clients in select U.S. markets
NEW YORK, April 13, 2022 /PRNewswire/ -- Today, Genesis premiered the Genesis X Speedium Coupe at Genesis House New York, a cultural space in Manhattan's Meatpacking District. The concept car incorporates Genesis' DNA, while looking ahead to the next wave of EVs and highlighting Genesis' future as a luxury electric vehicle brand.
The brand also announced plans for U.S. production of its upcoming Electrified GV70 SUV at its manufacturing facility in Montgomery, Ala. Production is set to start in December.
In a series of electrification-focused announcements, the brand also revealed its GV60 Priority One program for U.S. consumers.
Envisioning a new styling convention for the future
The Genesis X Speedium Coupe was born out of a "freestyle" design exercise based on the Genesis X Concept. Luc Donckerwolke, Genesis Chief Creative Officer and 2022 World Car Person of the Year led the initiative. It embodies the timeless Genesis' design philosophy, Athletic Elegance, in an even more progressive way.
The name Speedium was inspired by the Korean racetrack in the city of Inje and the passion for motorsport it inspired in Genesis designers. The name also encapsulates Genesis' belief that the emotional value of driving will remain strong in the era of electrification. The addition of the word "coupe" further accentuates the enjoyment of driving through aesthetic designs.
Genesis followed the principle of reductive design, or "less is more," for the concept car. The Genesis X Speedium Coupe stands out for its restrained elegance, clean lines, and subtle curves.
The model challenges the status quo of a defined car type. It is not a conventional concept car that previews plans for the production lineup.
"This car is an open-door moment in Genesis' journey towards our future EV design," said Luc Donckerwolke, chief creative officer of Genesis. "This isn't a show car — it's a look into our design processes as we explore ideas for the next wave of EVs, one that incorporates Genesis' DNA."
On the front of the vehicle, Genesis' signature Two Lines lamps have evolved into a full-width element that encompasses the shape of the crest resembling the Genesis Crest Grille. It was designed to carry the brand signature of the wing face for the electrification era by integrating the daytime running lamps with the low beam and high beam together. It carries an EV face that symbolizes Genesis' transformation towards becoming an all-electric car brand with a six-model lineup by 2030.
From an overhead perspective, the hourglass silhouette highlights the car's passion and character. The curvaceous and sensuous form accentuates the wheel arches creating muscular presence.
Viewed from the side, the Parabolic Line extending from the front to the rear of the car maintains a certain tension in the design as a classic car would. The deliberate "anti-wedge" design culminates in a streamlined look that exudes understated elegance.
Meanwhile, an elliptical tail balances out the look for a visually engaging tension between convex and concave surfaces in the rear. The V-shaped brake lights interrupt the circular shape by producing the striking contrast that is one of the hallmarks of a Genesis vehicle.
"We are giving each design element space to breathe," said Donckerwolke. "It's not about making the design elements compete with each other, but about orchestrating the elements so that they complement and respect one another."
The concept's metallic emerald green shade is referred to as "Inje Green." As expected of a car that was inspired by a Korean racetrack, the color encompasses the mountainous landscape where the track is located, completing the image of a classic car that embodies dynamism, speed, and timeless elegance.
Genesis Priority One
Genesis has shown significant growth in the U.S. market, setting monthly sales records for the past 16 months. The brand recorded 11,723 sales in Q1 2022, the largest quarterly sales achievement since its foray into the U.S. market in 2016.
Starting today, clients in select U.S. markets may enroll in Priority One, a program designed to curate a personalized purchase experience for GV60, the brand's first dedicated electric vehicle. By visiting www.genesis.com and providing their contact information and $500 refundable deposit, a Genesis Concierge will simplify the process and match clients with a qualified retailer.
"We are pleased to bring the highly-anticipated first Genesis EV to market in the U.S. with GV60," said Claudia Marquez, chief operating officer of Genesis Motor North America. "With Genesis Priority One, we are renewing our promise to our clients to provide a purchase experience tailored to them."
Genesis Priority One will be available at launch in California, Connecticut, New Jersey, and New York for a limited time while quantities last.
Production Plans for the Electrified GV70
Genesis announced that the Electrified Genesis GV70 will be its first vehicle produced in the U.S. at its manufacturing facility in Montgomery, Ala. Production is expected to begin in December 2022 with the goal of strengthening Genesis' EV market position in the region and continuing its commitment to electrification.
"We are pleased to bring Genesis production to the United States for the first time," said José Muñoz, president & CEO of Genesis Motor North America. "The GV70 SUV has won the hearts and minds of American consumers and industry experts alike. We are proud to begin offering consumers the new electrified model, built right here in America."
About Genesis House
Genesis House New York opened in November 2021 as the brand's base in the U.S. It's more than just a showroom — it's a cultural oasis in the heart of the city. Measuring over an acre of floorspace (over 46,000 square feet) and consisting of three floors, it carries forward the bold and innovative spirit of the brand by welcoming guests in a gracious manner that is deeply rooted in Korean culture.
The announcements took place during a press-only event at the Cellar Stage — a basement space outfitted with floor-to-ceiling LED-lit staging and state-of-the art audio-visual technology. Genesis holds numerous events at the Cellar Stage in collaboration with artists in the local community.
The first floor is an exhibition space where guests can experience the Genesis vehicle lineup, both existing models and concept cars that express the brand's future vision. The architects used tessellated mirrors to beautifully set off the cars on display, and curators are on hand to provide detailed explanations. The curator service at Genesis House is provided in English, Spanish, French, Chinese, and Korean, among other languages.
On the second floor, guests can enjoy a Korean cultural experience in the library, the Tea Pavilion, Genesis House Restaurant and the Terrace Garden.
Genesis House Restaurant, established in collaboration with Onjium — a Michelin-starred restaurant and traditional cultural research center in Seoul — offers a creative and elegant gastronomic experience that harkens back to the Korean Noble class cuisine that took inspirations from what Joseon-era royalty once enjoyed in their palaces.
At the event, the Genesis House Restaurant unveiled its new Spring menu, curated by Onjium.
The 9,493-square-foot Terrace Garden, located outside on the second floor, overlooks Hudson Yards, the Hudson River, and the High Line. Reminiscent of a courtyard outside a "hanok," or traditional Korean house, it is surrounded by low walls and an alley, serving as a cozy spot to enjoy a cup of coffee or tea.
Building upon the success of Genesis House New York, the brand is exploring future plans to open branded cultural spaces in other regions.
Genesis Gives
To mark the occasion and give back to the local New York community, Genesis presented a $50,000 donation to Girls Who Code, an organization whose mission is to close the gender gap in technology and to change the image of what a programmer looks like and does. Girls Who Code is building the largest pipeline of future female engineers in the world. In nine years, they have reached more than 450,000 girls globally.
This charitable contribution marks the continuation of Genesis Gives, a new initiative that supports STEAM (science, technology, engineering, arts, mathematics) education, sports, and athletics programming for youth. Genesis Gives has contributed more than $300,000 to causes across the United States since its launch in November 2021.
Genesis Motor North America
At Genesis, we put the customer at the center of every decision we make. Genesis is a global automotive brand that delivers the highest standards of performance, design, safety, and innovation while looking towards a more sustainable future. Genesis designs customer experiences that go beyond products, embodying audacious, forward-thinking, and distinctly Korean characteristics within its unique Athletic Elegance design identity. With a growing range of award-winning models — including the 2022 MotorTrend SUV of the Year, GV70, along with G70, G80, G90, GV60, and GV80 — Genesis aims to lead the age of electrification by focusing on a dual electrification strategy involving fuel-cell and battery EVs, starting with its Electrified G80 and GV60 electric models. Genesis has stated its commitment to becoming a 100% zero emission vehicle brand by 2030 and to pursuing carbon neutrality by 2035.
Please visit our media site for the latest news at www.genesisnewsusa.com.
View original content to download multimedia:
SOURCE Genesis Motor America | https://www.1011now.com/prnewswire/2022/04/13/genesis-debuts-new-concept-car-genesis-x-speedium-coupe-ev-focused-event/ | 2022-04-14T03:41:16 | 1 | https://www.1011now.com/prnewswire/2022/04/13/genesis-debuts-new-concept-car-genesis-x-speedium-coupe-ev-focused-event/ |
BOSTON, April 13, 2022 /PRNewswire/ -- Below is the March 2022 Monthly Update for the Liberty All-Star Equity Fund. (NYSE: USA)
Liberty All-Star Equity Fund
Ticker: USA
Monthly Update, March, 2022
Investment Approach:
Fund Style: Large-Cap Core
Fund Strategy: Combines three value-style and two growth-style investment managers. Those selected demonstrate a consistent investment philosophy, decision making process, continuity of key people and above-average long-term results compared to managers with similar styles.
Investment Managers:
Value Managers:
Aristotle Capital Management, LLC
Fiduciary Management, Inc.
Pzena Investment Management, LLC
Growth Managers:
Sustainable Growth Advisers, LP
TCW Investment Management Company
New Holdings
Avery Dennison Corp.
Carlisle Cos., Inc.
CDW Corp.
Enphase Energy, Inc.
Holdings Liquidated
Cenovus Energy, Inc.
The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund's portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.
Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.
Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.
Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2022 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consists of a return of capital. These estimates may not match the final tax characterization (for the full year's distributions) contained in shareholder 1099-DIV forms after the end of the year.
All data is as of March 31, 2022 unless otherwise noted.
Liberty All-Star® Equity Fund
1-800-241-1850
www.all-starfunds.com
libinfo@alpsinc.com
View original content to download multimedia:
SOURCE Liberty All-Star® Equity Fund | https://www.1011now.com/prnewswire/2022/04/13/liberty-all-star-equity-fund-march-2022-monthly-update/ | 2022-04-14T03:41:22 | 1 | https://www.1011now.com/prnewswire/2022/04/13/liberty-all-star-equity-fund-march-2022-monthly-update/ |
MS. LAURYN HILL, MEGAN THEE STALLION, BRITTNEY SPENCER, D-NICE AND DARIN ATWATER & THE SOULFUL SYMPHONY TO PERFORM ALONGSIDE CELEBRITY CHEFS TOM COLICCHIO, MARCUS SAMUELSSON AND GAIL SIMMONS AND BALTIMORE STAR CHEFS SAON BRICE AND MARIO MOISE
CREATED BY 1/ST EXPERIENCE IN PARTNERSHIP WITH BALTIMORE NATIVE AND ENTERTAINMENT VISIONARY KEVIN LILES, PREAKNESS LIVE IS PART OF NEW BALTIMORE 1/ST CAMPAIGN
BALTIMORE, April 13, 2022 /PRNewswire/ -- 1/ST EXPERIENCE, curators of world-class entertainment and hometown hospitality for Preakness 147, announces a collaboration with Baltimore's own Kevin Liles, CEO and Chairman of 300 Entertainment and Elektra Music Group, to launch Preakness LIVE Culinary, Art & Music Festival as part of an expanded Preakness entertainment and cultural celebration set to take place on Black-Eyed Susan Day, Friday, May 20. The festival is just one part of 1/ST's new long-term campaign, Baltimore 1/ST, kicking off this year.
In consultation with Baltimore Mayor Brandon Scott and in collaboration with Baltimore notable, Kevin Liles, Preakness LIVE will be the first event to take place as part of Baltimore 1/ST, a holistic new campaign that heralds the Preakness' lifelong home Baltimore and represents a commitment from 1/ST, owner and operator of the Preakness, to support and build on the optimism and enthusiasm for the future of the city. Baltimore 1/ST will champion the race's connection to Baltimore by leveraging the Preakness platform to highlight and impact local culture year-round across the pillars of music, art, fashion, culinary, sports and community, featuring both international and local Baltimore talent.
"I am incredibly excited about this new collaboration being led by a true son of Baltimore. This will not only improve the Preakness experience, but also support and elevate Baltimore culture through art, sports, fashion, and food year-round," said Mayor Brandon M. Scott. "I look forward to the profound impact this new focus on Baltimore art and culture will have on our city's next generation of creative minds. I want to thank Kevin Liles, 300 Entertainment and Elektra Music Group, and 1/ST EXPERIENCE for their investment in our city and it's unique cultural fabric."
Taking place in the iconic Pimlico infield, Preakness LIVE will feature performances by GRAMMY Award winners Ms. Lauryn Hill and Megan Thee Stallion, NAACP Image Award winner D-Nice and Baltimore-bred talent including rising singer Brittney Spencer, Darin Atwater & The Soulful Symphony, plus a performance of "The Star-Spangled Banner" by WanMor and more. Local talent will also perform on the Charm City Stage throughout the evening. Preakness LIVE is produced in collaboration with Karlitz & Company.
"Baltimore is more than a city, just as Preakness is more than a race," said Kevin Liles, CEO and Chairman of 300 Entertainment and Elektra Music Group. "What we're building with Preakness LIVE is a movement, not a moment. As a native son of this great city and a life-long fan of Preakness, I'm so proud to help bring an event of this scale and scope home, creating a cultural milestone both for residents and visitors rediscovering Baltimore's charms."
Celebrity chefs Tom Colicchio, Marcus Samuelsson, Gail Simmons, and beloved Baltimore chefs Saon Brice of BLK Swan, and Mario Moise of Bar ONE will perform culinary showcases on the main stage. Chefs Colicchio, Samuelsson and Simmons will collaborate to develop unique offerings for guests in the Finish Line Suites, Turfside Terrace and the Home Stretch Pavilions. Preakness LIVE will also debut Restaurant Row made up of a diverse group of local eateries featuring regional culinary delights serving fans on both Black-Eyed Susan Day and Preakness Day.
Baltimore's vibrant art scene will be given a showcase in the Pimlico infield during Preakness weekend with unique installations throughout the art garden, curated by acclaimed Baltimore multidisciplinary artist and founder of "The Last Resort Artist Retreat" Derrick Adams. The art garden will display works from a multitude of local artists as well as entrants of the Preakness 147 Art of Racing campaign, among other exciting activations.
To further connect the Preakness weekend celebrations to Park Heights, Park Heights Renaissance will sponsor and lead the first annual George "Spider" Anderson Preakness Music and Arts Festival in recognition of the first African American jockey to win the Preakness Stakes in 1889. The day-long festival on May 21st will feature live music, arts & crafts, the days' races live streamed, top food trucks and will highlight community businesses and partners.
Park Heights Renaissance Executive Director Yolanda Jiggetts says, "We are committed to engaging the community in the history of Preakness. This will be a celebration of the Preakness in a way that's groundbreaking and we hope connects residents and local businesses like never before. 1/ST continues to show its commitment to strengthening its reach in the community through its growing relationship with Park Heights Renaissance."
During the third running of the George E. Mitchell Black-Eyed Susan Stakes, the recipient of the George E. Mitchell Park Heights Community Fellowship Grant, awarded by Park Heights Renaissance, will be recognized with a special presentation from the Winner's Circle. The iconic race was renamed in 2020 to highlight the extraordinary legacy of Mitchell himself and to create a platform for the recognition of those in the Park Heights community who share in Mitchell's vision and leadership towards revitalization of the Park Heights community.
"The Preakness 147 celebration, including everything we are doing on Black-Eyed Susan Day and on Preakness Day, will bring together entertainers, artists, lifestyle, hospitality and culinary leaders, and the community for weekend of events that will put Baltimore front and center," said Jimmy Vargas, CEO, 1/ST EXPERIENCE. "We are thrilled to be working with Mayor Scott, Kevin Liles, Yolanda Jiggetts and some of the city's top cultural shapeshifters to reaffirm and evolve the connection between the Preakness and the people of Baltimore."
Tickets for Preakness LIVE go on-sale April 13th and range from $49-$175. These and other Preakness weekend tickets can be purchased online by visiting www.preakness.com/tickets. As part of the ongoing partnership between 1/ST and Park Heights Renaissance, tickets for Preakness LIVE and for InfieldFest will be distributed to the Parks Heights community through Park Heights Renaissance.
For more information on Preakness 147, visit www.preakness.com or follow on social @PreaknessStakes #Preakness.
Photo Selects: Please click here
Press Contact:
Vanessa Menkes Communications
vanessa@vanessamenkes.com
The Brand Guild
Preakness@TheBrandGuild.com
ABOUT THE STRONACH GROUP AND 1/ST
The Stronach Group is a world-class technology, entertainment and real estate development company with Thoroughbred horse racing and pari-mutuel wagering at the core. The company's consumer facing brand 1/ST (pronounced "First") powers The Stronach Group's forward-thinking 1/ST RACING, 1/ST CONTENT, 1/ST TECHNOLOGY, 1/ST EXPERIENCE, and 1/ST PROPERTIES businesses, while advocating for and driving the 1/ST HORSE CARE mission. 1/ST represents The Stronach Group's continued movement toward redefining Thoroughbred horse racing and the ecosystem that drives it. 1/ST RACING drives the best-in-class horse racing operations at the company's premier racetracks and training centers including: Santa Anita Park, Golden Gate Fields and San Luis Rey Downs (California); Gulfstream Park – home of the Pegasus World Cup Championship Invitational Series, Gulfstream Park West and Palm Meadows Thoroughbred Training Center (Florida); the Maryland Jockey Club at Laurel Park, Pimlico Race Course - home of the legendary Preakness Stakes, Rosecroft Raceway and Bowie Training Center (Maryland). 1/ST CONTENT is the newly formed operating group for all of 1/ST's media and content companies including: Monarch Content Management, Elite, GWS and XBTV. 1/ST TECHNOLOGY is horse racing's largest racing and gaming technology company offering world-class products via its AmTote, Xpressbet, 1/ST BET, XB SELECT, XB NET, PariMAX and Betmix brands. 1/ST EXPERIENCE blends the worlds of sports, entertainment and hospitality through innovative content development, elevated national and local venue management and hospitality, strategic partnerships, sponsorships, and procurement development. 1/ST PROPERTIES is responsible for the development of the company's live, work and play communities surrounding its racing venues including: The Village at Gulfstream Park (Florida) and Paddock Pointe (Maryland). As the advocate for critical industry reforms and by making meaningful investments into aftercare programs for retired horses and jockeys, 1/ST HORSE CARE represents The Stronach Group's commitment to achieving the highest level of horse and rider care and safety standards in Thoroughbred horse racing on and off the track. For more information, please visit www.1st.com.
View original content to download multimedia:
SOURCE 1/ST | https://www.1011now.com/prnewswire/2022/04/13/preakness-147-announces-addition-preakness-live-culinary-art-amp-music-festival-celebrating-best-baltimore-black-eyed-susan-day-part-preakness-weekend-may-20-amp-may-21/ | 2022-04-14T03:41:29 | 0 | https://www.1011now.com/prnewswire/2022/04/13/preakness-147-announces-addition-preakness-live-culinary-art-amp-music-festival-celebrating-best-baltimore-black-eyed-susan-day-part-preakness-weekend-may-20-amp-may-21/ |
New year, new Precision Medical Products: the company will have a new leader at its helm, partnering with longtime founder and current CEO Jeremy Perkins. Stepping into Perkins' shoes will be well-respected industry veteran Steven Ingel, who will immediately become President & CEO of Precision Medical Products, Inc.
CARROLLTON, Texas, April 13, 2022 /PRNewswire/ -- Precision Medical Products today announced the appointment of Steven Ingel to President & CEO of Precision Medical Products, Inc. Ingel's official start date was April 4, 2022. At that time, he succeeded Precision Medical's current President and CEO, Jeremy Perkins, who will remain with the company and assume the role of Executive Chairman of the Board. In this new role, Mr. Perkins will identify strategies, business opportunities, and new technology architectures to grow Precision Medical Products. "Steve Ingel brings a wealth of medical device and digital health experience with a well-established proven track record of driving growth, margin expansion, and overall financial performance. His broad and deep industry experience combined with his respected leadership and team-building style make him the right fit to continue our important work at Precision Medical," said Jeremy Perkins.
Ingel is a seasoned leader with over 30+ years of experience in the healthcare sector. He most recently served as President of Footcare Solutions and National Accounts for Enovis, formerly DJO Global. Before that role, Steve held various executive and divisional leadership roles spanning multiple disciplines including Sales, Marketing, R & D, Operations, and Digital Health Solutions during his 28-year tenure at DJO Global. "I am honored to have the opportunity to lead Precision Medical and to begin working with its outstanding leadership team and talented organization of professionals," said Ingel. "There are tremendous opportunities ahead given the company's existing technologies, robust pipeline, and manufacturing platforms, and I'm looking forward to leading its next stage of growth. Together with Jeremy and the team, I am confident that we can continue to set the standards for excellence and drive innovation in the industry for our customers, patients, and employees."
Since becoming the market leader in mobile compression devices and completing the acquisition of Innovamed Health and VenaGroup earlier in 2021, the company has been hard at work building the corporate infrastructure and necessary strategic talent needed to continue to deliver double-digit growth and open new markets. Precision has demonstrated twelve years of consecutive year-over-year growth and significantly outpaced the market. This consistent success has positioned them to continually expand and innovate in a historically stagnant DVT prevention market. The addition of Ingel is a significant milestone for Precision and the healthcare industry, showing that innovation and patient-focused solutions continue to drive industry change.
About Precision Medical Products®
Founded in 2010, Precision Medical Products is a 12-year-old privately-owned growth stage company that provides recovery and prevention solutions to patients and healthcare organizations. Our products are intuitively designed to increase patient compliance, increase patient mobility, and increase staff and patient safety by eliminating tubes and cords. As the Nationwide leader in mobile DVT prevention therapy, Precision's goal is to improve the quality of patient care, decrease "never events," and reduce costs for patients and healthcare organizations across the US.
Join us on our mission to cut the cord and save countless lives.
View original content to download multimedia:
SOURCE Precision Medical Products Inc. | https://www.1011now.com/prnewswire/2022/04/13/precision-medical-products-inc-announces-steve-ingel-new-ceo/ | 2022-04-14T03:41:36 | 1 | https://www.1011now.com/prnewswire/2022/04/13/precision-medical-products-inc-announces-steve-ingel-new-ceo/ |
CHICAGO, April 13, 2022 /PRNewswire/ -- Ryerson Holding Corporation (NYSE: RYI), a leading value-added processor and distributor of industrial metals, announced today that it will host a conference call to discuss first quarter 2022 financial results for the period ended March 31, 2022, on Thursday, May 5th, at 10 a.m. Eastern Time. The live online broadcast will be available on the Company's investor relations website, ir.ryerson.com. Ryerson will report earnings after the market close on Wednesday, May 4th.
Ryerson Holding Corporation's First Quarter
2022 Earnings Call Details:
DATE: Thursday, May 5, 2022
TIME: 10:00 a.m. ET / 9:00 a.m. CT
DIAL-IN: 888-394-8218 (U.S. & Canada) / 646-828-8193 (International)
CONFERENCE ID: 5210309
An online replay of the call will be posted on the investor relations website, ir.ryerson.com, and remain available for 90 days.
Ryerson is a leading value-added processor and distributor of industrial metals, with operations in the United States, Canada, Mexico, and China. Founded in 1842, Ryerson has around 4,000 employees in approximately 100 locations. Visit Ryerson at www.ryerson.com.
View original content to download multimedia:
SOURCE Ryerson Holding Corporation | https://www.1011now.com/prnewswire/2022/04/13/ryerson-host-earnings-call-thursday-may-5th-discuss-first-quarter-2022-results/ | 2022-04-14T03:41:42 | 0 | https://www.1011now.com/prnewswire/2022/04/13/ryerson-host-earnings-call-thursday-may-5th-discuss-first-quarter-2022-results/ |
SALADO, Texas, April 13, 2022 /PRNewswire/ -- U-Haul® is offering 30 days of free self-storage and U-Box® container usage at five Central Texas facilities to residents impacted by the Salado tornado and severe storms that hit the region early Tuesday evening.
Hail and high-speed winds damaged multiple buildings and homes across Bell and Williamson Counties. Accessibility to local storage can assist in the community's recovery and rebuilding after natural disasters.
"As our neighbors begin the process of cleaning up, we want to provide them with a secure place to store their possessions," stated Matthew McMillan, U-Haul Area District Vice President of Central Texas. "These storms have left destruction behind. Those in need can give us a call and receive a storage unit or U-Box container for their belongings free for one month."
U-Haul is offering to deliver U-Box containers to residents' homes in Central Texas at no cost as part of the goodwill gesture. This includes the retrieval of U-Box containers after 30 days of free usage.
Additionally, U-Haul has a variety of boxes and other moving supplies it is making available to assist those in need. The free supplies are available on a first-come, first-serve basis for a limited time at participating locations.
Customers needing boxes can also utilize the Take a Box, Leave a Box program. U-Haul offers an in-store area where customers can drop off used boxes in good condition, and other members of the community can access the boxes at no cost. U-Haul encourages anyone who has reusable boxes to drop them at the nearest U-Haul store location for this purpose.
People seeking more information about the U-Haul disaster relief program or needing to arrange 30 days of free self-storage should contact the participating facility nearest them:
U-Haul Moving & Storage of Midway
3914 S. General Bruce Drive
Temple, TX 76502
(254) 727-7216
U-Haul Moving & Storage of South Temple
215 SW H K Dodgen Loop
Temple, TX 76502
(254) 770-3001
U-Haul Moving & Storage of Centex
3501 E. Central TX Expressway
Killeen, TX 76543
(254) 699-8334
U-Haul Moving & Storage of Killeen
102 E. Veterans Memorial Blvd.
Killeen, TX 76541
(254) 526-9626
U-Haul Moving & Storage of Twin Creek
1507 Martin Luther King Jr. Blvd.
Killeen, TX 76543
(254) 532-3001
In addition to its 30 days free self-storage disaster relief program, U-Haul is proud to be at the forefront of aiding communities in times of need as an official American Red Cross Disaster Responder.
Since 1945, U-Haul has been the No. 1 choice of do-it-yourself movers, with a network of more than 23,000 locations across all 50 states and 10 Canadian provinces. U-Haul Truck Share 24/7 offers secure access to U-Haul trucks every hour of every day through the customer dispatch option on their smartphones and our proprietary Live Verify technology. Our customers' patronage has enabled the U-Haul fleet to grow to approximately 176,000 trucks, 126,000 trailers and 46,000 towing devices. U-Haul offers nearly 855,000 rentable storage units and 73.6 million square feet of self-storage space at owned and managed facilities throughout North America. U-Haul is the largest retailer of propane in the U.S., and continues to be the largest installer of permanent trailer hitches in the automotive aftermarket industry. U-Haul has been recognized repeatedly as a leading "Best for Vets" employer and was recently named one of the 15 Healthiest Workplaces in America.
Andrea Batchelor
Jeff Lockridge
E-mail: publicrelations@uhaul.com
Phone: 602-263-6981
Website: uhaul.com
View original content to download multimedia:
SOURCE U-Haul | https://www.1011now.com/prnewswire/2022/04/13/tornado-recovery-u-haul-offers-30-days-free-storage-central-texas/ | 2022-04-14T03:41:49 | 0 | https://www.1011now.com/prnewswire/2022/04/13/tornado-recovery-u-haul-offers-30-days-free-storage-central-texas/ |
SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has presented the latest results from six preclinical studies of the company's five investigational drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key candidates in the company's apoptosis-targeted pipeline, as well as the FAK inhibitor APG-2449, the EED inhibitor APG-5918 and the KRAS inhibitor APG-1842, at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
The AACR Annual Meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research. Covering cutting-edge advances in all the areas of cancer research and innovation, the annual event attracts tremendous interest from the global cancer research community.
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said: "At this year's AACR Annual Meeting, we presented preclinical data that support potential combination approaches between our lead candidates with drugs of different targets and mechanism of actions. These studies represent our ongoing effort in addressing important unmet medical needs in cancer treatment. It is worth pointing out that the results from three preclinical studies of the MDM2-p53 inhibitor alrizomadlin have demonstrated broad therapeutic potential and highlighted a novel mechanism of action. Meanwhile, we also reported encouraging results supporting the upcoming clinical development of the EED inhibitor APG-5918. We will actively advance these programs to bring meaningful clinical benefits to patients."
The details of these posters presented at AACR 2022 are as follows:
Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models
- Abstract/Poster Number: 3964
- Introduction:
The BCL-2 inhibitor venetoclax, although efficacious in patients with chronic lymphocytic leukemia, meets significant resistance in a large number of patients due to acquired BCL-2 gene mutations. Among acquired mutations, those proximal to BH3 binding motifs (e.g., G101V, D103E, and V156D) have the most significant impact on BCL-2 binding to BH3-only pro-death proteins and BH3 mimetics (e.g., venetoclax). Hence, it is important to identify novel therapeutics that address this emerging unmet need.
- Conclusions:
Our study demonstrates, alrizomadlin combined with lisaftoclax synergistically inhibited the proliferation of RS4:11-BCL-2 mutant cell lines and the growth of cell-derived xenografts in vivo. Co-targeting BCL-2 and MDM2-p53 apoptosis pathways represents a new and effective strategy to overcome drug resistance conferred by clinically BCL-2 gene mutations.
Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115) induces pyroptotic cell death in gasdermin E (GSDME)-expressing cancer cells
- Abstract/Poster Number: 2998
- Introduction:
The mouse double minute-2 (MDM2)-p53 inhibitor alrizomadlin (APG-115) is an investigational agent known to induce apoptosis of TP53-wild type cancer cells (Aguilar et al, J Med Chem 2017). Emerging evidence suggests that activation of p53 by alrizomadlin also promotes antitumor immunity in the tumor microenvironment (Fang et al, JITC 2019; Zhou et al, Nat Immunol 2021), but the links between these processes are not yet completely understood. Pyroptosis refers to inflammatory programmed cell death. Central to this process is the family of gasdermins, which can form pores in cell plasma membranes, resulting in lysis and release of immune stimulants. In cells expressing these proteins, GSDME can be cleaved by caspase-3, which converts noninflammatory apoptosis to pyroptosis (Zhang et al, Nature 2020). In this context, caspase-3/GSDME appears to represent a switch between apoptosis and pyroptosis. Given that alrizomadlin elicits its apoptogenic activity primarily by activating caspase-3, we hypothesized that the MDM2-p53 inhibitor might also induce pyroptosis in GSDME-expressing cells by cleaving caspases.
- Conclusions:
Our study demonstrates that, in addition to apoptosis, MDM2-p53 inhibitor alrizomadlin induces caspase-mediated pyroptosis in GSDME-expressing cancer cells. In this study, we reveal for the first time that apoptosis-inducing, alrizomadlin induces both apoptosis and pyroptosis in GSDME-expressing cancer cells. GSDME-dependent pyroptosis is a previously unrecognized mechanism of action for alrizomadlin to exert antitumor immunity, with potentially important implications for clinical development of therapy involving MDM2-p53 inhibition.
MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma
- Abstract/Poster Number: 5439
- Introduction:
Multiple myeloma (MM) accounts for about 2% of all cancers and 18% of all hematologic malignancies in the US. Recent therapeutic advances (e.g., immunomodulators, proteasome inhibitors, monoclonal antibodies) have improved outcomes, but MM inevitably relapses and is considered incurable. Genomic analysis shows that the TP53 gene encoding tumor suppressor protein p53 is infrequently mutated in patients with MM, of whom about 82% retain wildtype (WT) TP53. Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase that inhibits p53 via proteasome degradation. Proteasome inhibitors might help to stabilize p53 and synergize with MDM2 inhibitors. Therefore, MDM2 inhibitors that activate p53 might constitute an attractive pharmacologic approach to MM. Alrizomadlin is an investigational, novel small molecule targeting the p53/MDM2 interaction and is in clinical development for solid and hematologic cancers. This study aimed to evaluate whether alrizomadlin can potentiate the antitumor effects of proteasome inhibitors in MM.
- Conclusions:
The results demonstrate that the combination of MDM2 inhibitor alrizomadlin and proteasome inhibitors have synergistic antitumor effects on MM tumors harboring WT TP53 in animal models. These data warrant clinical studies to test this novel therapeutic option for patients with refractory MM.
FAK inhibitor APG-2449 and CDK4/6 inhibitor palbociclib synergistically suppress mesothelioma tumor growth via autophagy induction
- Abstract/Poster Number: 2563
- Introduction:
Malignant mesothelioma is a rare but highly lethal malignancy, with a 5-year survival rate of less than 10%. Among the most common genomic abnormalities are alterations of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and neurofibromin 2 (NF2). Mesothelioma cells lacking expression of CDKN2A/B or NF2 are reported to be sensitive to CDK4/6 or focal adhesion kinase (FAK) inhibition. In this study, APG-2449 as a clinical stage FAK/ALK/ROS1 multi-kinase inhibitor combined with CDK4/6 inhibitor palbociclib demonstrated anti-tumor activity.
- Conclusions:
These results demonstrate that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.
Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy
- Abstract/Poster Number: 3939
- Introduction:
Three core components constitute the polycomb repressive complex 2 (PRC2), a multiprotein complex that catalyzes the methylation of histone H3 at lysine 27 (H3K27me3): enhancer of zeste homolog 2 (EZH2), embryonic ectoderm development (EED) and suppressor of zeste 12 protein homolog (SUZ12). Dysregulated function of PRC2 has been implicated in the development of a variety of cancer types. With the use of tazemetostat, an EZH2 inhibitor, inhibition of PRC2 functions has been proven to be a successful cancer therapeutic strategy. Nevertheless, the activity of an EZH2 inhibitor might be compensated due to acquired resistance through secondary mutations in EZH2 or its paralog EZH1. Because binding of EED with trimethylated H3K27 (H3K27me3) is the prerequisite for the activation of the methyltransferase activity of EZH2, allosterically targeting EED is emerging as a novel approach to inhibit PRC2. APG-5918/EEDi-5273 has been reported as a novel, bioactive, and potent EED inhibitor. In this study, we further characterized APG-5918 for cancer therapy in a preclinical setting.
- Conclusions:
APG-5918 was thoroughly characterized in the preclinical stage, with potent biochemical binding activity to EED protein, in vitro anti-proliferatively activity, and in vivo antitumor activities. APG-5918 showed definitive in vitro and in vivo target engagement and on-target antitumor activity. APG-5918 demonstrated strong PD/PK correlation in mice bearing KARPAS-422 xenograft tumors. APG-5918 appeared to be similar or more potent than MAK683, an EED inhibitor under clinical development, in terms of biochemical, in vitro, and in vivo activities. In summary, our results suggest potential utility of APG-5918 in cancer therapy and it deserves further clinical investigation.
Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
- Abstract/Poster Number: 2664
- Introduction:
The KRAS gene is frequently mutated in human cancers, and the KRASG12C mutation occurs in approximately 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other solid tumors. KRASG12C small molecule inhibitors, AMG510 and MRTX849, have been investigated as treatment options for solid tumors with the KRAS G12C mutation. In this study, APG-1842 was characterized as a potent, selective, and covalent KRASG12C inhibitor with demonstrated inhibition on KRAS-dependent signaling and anti-tumor activity both in vitro and in vivo.
- Conclusions:
Collectively, these results demonstrate that APG-1842 is a potent, bioavailable, and highly selective KRASG12C inhibitor. Our data provide the preclinical evidence for clinical development of APG-1842 in patients with KRASG12C-mutant solid tumors.
About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 50 Phase I/II clinical trials in the US, Australia, Europe, and China. Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), was granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), and is already approved for the indication. In addition, the olverembatinib was also granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EU. To date, Ascentage Pharma has obtained a total of 15 ODDs, 2 FTDs and 2 Rare Pediatric Disease (RPD) designations from the US FDA and 1 ODD from the EU for four of the company's investigational drug candidates. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five National Major New Drug Discovery and Manufacturing projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, AstraZeneca, and Pfizer. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.
Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
View original content to download multimedia:
SOURCE Ascentage Pharma | https://www.1011now.com/prnewswire/2022/04/14/aacr-2022-ascentage-pharma-presents-latest-results-six-preclinical-studies-aacr-annual-meeting-2022/ | 2022-04-14T03:41:57 | 1 | https://www.1011now.com/prnewswire/2022/04/14/aacr-2022-ascentage-pharma-presents-latest-results-six-preclinical-studies-aacr-annual-meeting-2022/ |
Attracting almost 500 applicants from 91 countries or regions, the unique 100% A-level Scholarships Programme gives the global community access to Harrow's 450 years of educational excellence
HONG KONG, April 13, 2022 /PRNewswire/ -- The AISL Harrow Scholarships Programme is the most prestigious award available across the AISL Harrow family. First launched in 2021, the Scholarships received an overwhelming global response. Moving into the second year, with almost 500 of exceptionally talented students from 91 countries or regions applying, six Scholarships have been awarded, offering opportunity to the full access of a Harrow A-Level (pre-university) education - a values-based education that provides 'Educational Excellence for Life and Leadership'.
The selection process was rigorous, fair and balanced. From hundreds of applicants, 12 were selected for interview and, from these, 6 successful candidates were chosen based on their outstanding academic performance, English fluency, and extracurricular talents, alongside their commitment to leadership and service activities.
AISL is delighted to announce that the 2022/24 recipients of the AISL Harrow Scholarships are (from left to right): Pui Yan Sham Peony (Hong Kong SAR, China), Ka Hin Cheung Kyan (UK), Lauren Saunders (UK), Kaijun Chang (USA), Eaint Aunt Auw (Thailand) and Yoon Yati (Myanmar). The AISL Harrow family extends a warm welcome to each of these scholarship awardees. They will join AISL Harrow Hong Kong, AISL Harrow Shanghai and AISL Harrow Bangkok from September of this year.
In response to the awards, Dr. Rosanna Wong, Chairman of Asia International School Limited, praised the six recipients of the AISL Harrow Scholarships as "truly outstanding". She noted, "they exemplify the very best of academic and extra-curricular excellence; we are proud to have them joined the AISL Harrow family."
EDUCATIONAL EXCELLENCE FOR LIFE AND LEADERSHIP
The establishment of the AISL Harrow Scholarships Programme is another milestone in AISL Harrow's long history of educational excellence. The Programme seeks to enhance the diversity of the AISL Harrow community by attracting academically gifted students from around the world. The scholarships give students the chance to experience all that a Harrow education affords: Excellence in and out of the classroom, the development of leadership skills, and a commitment to service.
Through the AISL Harrow Scholarships Programme, AISL is proud to be giving back to the global community, extending the availability of an excellent AISL Harrow education to students from around the world, allowing them access to a prestigious British education and, subsequently, to top universities.
As exemplified by the AISL Harrow scholars, graduates leave as capable, confident and caring individuals, their well-rounded skills-base and holistic nature provide the foundation for them to become future leaders.
Alongside the AISL Harrow Scholarships, the individual Harrow-branded schools in Asia also provide scholarship opportunities for gifted students. To learn more, please subscribe to AISL Harrow's official Facebook Page (AISL Harrow Schools) and view the AISL Harrow Schools website at https://www.harrowschools.com/.
About Asia International School Limited (AISL) GROUP
Asia International School Limited (AISL) is a leading provider of world-class K-12 education in Asia. Through our wholly owned subsidiary Harrow International Management Services Limited and affiliates, AISL sub-licenses the Harrow brand and provides professional educational services to our Harrow branded schools, including AISL Harrow International Schools, AISL Harrow Innovation Leadership Academies and AISL Harrow Little Lions Early Years Centres. In the academic year of 2021/2022, the Group has 17 schools and early years centres in the network.
View original content to download multimedia:
SOURCE AISL Harrow Schools | https://www.1011now.com/prnewswire/2022/04/14/aisl-harrow-scholarships-202224-winners-announced/ | 2022-04-14T03:42:06 | 1 | https://www.1011now.com/prnewswire/2022/04/14/aisl-harrow-scholarships-202224-winners-announced/ |
HONG KONG, April 13, 2022 /PRNewswire/ -- Laifen ("the Company"), an emerging Chinese personal care brand will officially release its high-speed brushless motor hair dryer - Laifen Swift on Amazon and Laifentech.com by April 30th, with 100 special limited edition red units available in the United States, Canada, and Europe. Laifen Swift was launched via Indiegogo on February 20th, equipped with industry-leading technology, including an unrivaled 110,000 RPM brushless motor that generates powerful 22m/s airflow, 200 million negative ions, four smart temperature settings, and a hot and cool air circulation function.
"In the past, the smartphone revolution brought everyone a colorful, fast, convenient, and higher-quality life. Today, the same revolution is taking place in the field of personal care, and Laifen is one such revolutionary," Hongxin Ye, CEO of Laifen remarked in reference to the launch of the Laifen Swift. "We are driven by a vision to bring new experiences to our customers, with each product proving a complete upgrade to traditional products of the same kind."
The Laifen Swift uses innovative technology to solve general hair problems largely ignored by consumers. The powerful 110,000 RPM brushless motor with advanced internal aerodynamics creates a high degree of air pressure through the "Kanda effect" to produce strong airflow of up to 22m/s to smoothen hair. Also, the built-in high-precision temperature sensor and microprocessor achieve real-time calibration of air temperature up to 100 times per second to ensure the air outlet temperature does not exceed 176℉ and scalp temperature is controlled at about 122℉, effectively avoiding the risk of scalding.
With a built-in tri-color light ring, the Laifen Swift makes temperature changes more intuitive. Aimed at solving hair quality issues for users, the device contains 200 million highly-concentrated negative ions that neutralize static electricity and smooth out frizz. Compared to traditional hair dryers.The Laifen Swift adopts various noise reduction technologies to bring noise levels down to 59dB.
The series comes in four color styles with a magnetic suction nozzle for quick styling for only $159.
For more information, please visit Laifen page.
About Laifen
Founded in 2019, Laifen is located in Hong Kong, China, and its founder, Hongxin Ye, is committed to promoting the popularity of high-speed hair dryers and bringing cutting-edge technology into the lives of the masses. With rich experience dealing with motor technology and structural innovation, Laifen has 26 patents, passed hundreds of professional tests, and has been granted patents in the US and EU.
Media Contact:
Carlin Duan
marketing@laifentech.com
+86 755 8666 5249
View original content to download multimedia:
SOURCE Laifen | https://www.1011now.com/prnewswire/2022/04/14/brand-new-laifen-swift-hair-dryer-sale-soon/ | 2022-04-14T03:42:12 | 1 | https://www.1011now.com/prnewswire/2022/04/14/brand-new-laifen-swift-hair-dryer-sale-soon/ |
MCKINNEY, Texas, April 13, 2022 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) will release First Quarter 2022 earnings after the market closes on Wednesday, April 20, 2022. At that time a copy of the Company's Q1 - 2022 earnings press release and any other financial and statistical information about the quarter will be available on the Company's website at https://investors.globelifeinsurance.com/ under Financial Reports and Other Financial Information. In conjunction with the First Quarter 2022 Earnings Release of Globe Life Inc. you are invited to listen to a conference call that will be broadcast live over the Internet on Thursday, April 21, 2022 at 11:00 am Eastern (10:00 am Central).
First Quarter Conference Call
Thursday, April 21, 2022
11:00 a.m. (Eastern)
Listen live and as a replay at https://investors.globelifeinsurance.com/ under
Calls and Meetings
or
Call-In Number:
1-323-794-2588
(Pass Code: Globe Life Inc.)
Globe Life Inc. is a holding company specializing in life and supplemental health insurance for "middle income" Americans marketed through multiple distribution channels including direct to consumer, and exclusive and independent agencies.
View original content to download multimedia:
SOURCE Globe Life Inc. | https://www.1011now.com/prnewswire/2022/04/14/globe-life-inc-announces-first-quarter-2022-earnings-release-conference-call/ | 2022-04-14T03:42:19 | 0 | https://www.1011now.com/prnewswire/2022/04/14/globe-life-inc-announces-first-quarter-2022-earnings-release-conference-call/ |
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr. Humphrey Gardner as Chief Medical Officer (CMO). Dr. Gardner will be responsible for leading the global product development of the Company, including pipeline strategy, clinical development plan and operations, and product registration.
Dr. Gardner has more than 30 years industry experience, achievement and leadership in clinical development and translational medicine, including over 20 years of experience in the pharmaceutical industry and over 10 years of experience in academia. Before joining the Company, he served as the chief medical officer at Silicon Therapeutics and the chief of medical oncology at Evelo Biosciences. He also served critical leadership roles at Novartis, AstraZeneca and Biogen.
"I am delighted to welcome Dr. Gardner, an industry veteran and highly respected scientist, to Harbour BioMed. Dr. Gardner's extensive experience in drug development from conception to approval will be instrumental to advancing our innovative therapeutics through global clinical trials and on to registration," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer. "He is joining HBM at a very important time and will be a tremendous asset to our organization, strengthening our mission to deliver breakthrough medicines for healthy life."
With Dr. Gardner's appointment, the Company will further strengthen its global clinical development capability and continue to advance the global development of its clinical products, including next-generation anti-CTLA-4 antibody HBM4003 and B7H4x4-1BB bispecific antibody HBM7008, whilst enriching the pipeline strategy of the global development of its immune-oncology pipeline.
"I am profoundly excited to bring my experience to HBM, an organization I have long admired," said Dr. Gardner. "I am looking forward to working with the Company's talented teams to advance novel and highly innovative antibody-based therapeutics in the areas of oncology and immunological diseases and to build a robust pipeline that has the opportunity to transform care for many more patients in need around the world."
Dr. Gardner holds a bachelor's degree in Biochemistry and his medical degree from the University of Cambridge, and an MS in Bioinformatics from Brandeis University. He completed his residency in Anatomic Pathology at Beth Israel Hospital, Harvard Medical School, and postdoctoral training at Whitehead Institute, Massachusetts Institute of Technology (MIT).
Dr. Gardner is an expert in oncology, rheumatology, and infectious disease. He published approximately one hundred papers in international academic journals, and has been an active influential speaker at international conferences. He is also a fellow of the College of American Pathologists, and a member of American Society of Clinical Oncology, and has previously been a member of a variety of professional organizations including the European Society of Clinical Microbiology and Infectious Diseases and the American Association for Clinical Chemistry.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
View original content to download multimedia:
SOURCE Harbour BioMed | https://www.1011now.com/prnewswire/2022/04/14/harbour-biomed-appoints-dr-humphrey-gardner-chief-medical-officer/ | 2022-04-14T03:42:25 | 0 | https://www.1011now.com/prnewswire/2022/04/14/harbour-biomed-appoints-dr-humphrey-gardner-chief-medical-officer/ |
Hodlnaut celebrates its third year with the launch of two new assets, TerraUSD (UST) and Terra (LUNA).
SINGAPORE, April 13, 2022 /PRNewswire/ -- Singapore-based crypto lending and borrowing firm, Hodlnaut, has just announced the launch of two new assets namely, TerraUSD (UST) and Terra (LUNA).
Hodlers are able to earn interest in a total of eight supported assets: BTC, ETH, USDC, USDT, DAI, WBTC, and the newly launched UST and LUNA. The effective rates for both open and fixed terms for UST and LUNA are as follows.
"The Luna Foundation Guard (LFG) has proven to support the growth of the Bitcoin ecosystem, which is in line with Hodlnaut's vision. Therefore, we are proud to announce the support of Luna and UST on the Hodlnaut platform," said Juntao, CEO and Co-Founder of Hodlnaut.
Users can start earning in both UST and LUNA from 7 April 2022, 7:30 pm (GMT+8) and utilize the entire suite of features supported. This includes Hodlnaut's Token Swap, Preferred Interest Payout, Fixed Term Deposits, and Interest Account functions. To celebrate the launch, Hodlnaut will be holding a US$2,000 worth of UST and LUNA giveaway. Click here for more information.
Currently, Hodlnaut only supports the deposit and withdrawal of wormhole UST and wormhole LUNA via the ERC-20 network. Hodlnaut is continuously working towards ensuring the firm meets its rigorous regulatory and security framework and is expected to accept the support of UST and LUNA on the native terra chain by the end of April.
About Hodlnaut
Hodlnaut is a Singapore-based cryptocurrency lending and borrowing platform that allows users to earn interest of up to 13.8% on their cryptocurrencies by lending them to vetted institutions. Founded in April 2019 by Bitcoin maximalists Juntao Zhu and Simon Lee, Hodlnaut has grown tremendously over the years.
Hodlnaut has received an in-principle approval (IPA) for a Major Payment Institution License in Singapore from the Monetary Authority of Singapore (MAS) under the Payment Services Act (PS Act) for its Token Swap feature. The firm is also a certified Fintech by the Singapore Fintech Association, an accreditation recognized by the MAS.
For more information, please visit www.hodlnaut.com.
CONTACT: Sten Ivan, Head of Growth at Hodlnaut, sten@hodlnaut.com
View original content to download multimedia:
SOURCE Hodlnaut | https://www.1011now.com/prnewswire/2022/04/14/hodlnaut-officially-launches-two-new-assets-terrausd-ust-terra-luna/ | 2022-04-14T03:42:33 | 1 | https://www.1011now.com/prnewswire/2022/04/14/hodlnaut-officially-launches-two-new-assets-terrausd-ust-terra-luna/ |
SAN FRANCISCO and SUZHOU, China, April 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI310 in combination with sintilimab for the treatment of patients with recurrent or metastatic cervical cancer.
The NMPA BTD for IBI310 was based on results from First part of a Phase 2 trial (CDE Registration No. CTR20202017). This study enrolled 205 patients in patients with advanced cervical cancer. The safety profile in this study was consistent with that observed in previously reported studies, and no additional safety signals were identified for the combination of IBI310 and sintilimab. Relevant study results will be published at an upcoming medical conference in 2022.
"We are glad to see the NMPA grant Breakthrough Therapy Designation based on the results of First part of Phase 2 data of IBI310," said Dr. Hui Zhou, Senior Vice President of Innovent. "Patients with advanced cervical cancer currently have limited treatment options. Patients treated with chemotherapy show limited clinical benefit and the overall survival is limited to a few months. The results of First part of the Phase 2 study of IBI310 in combination with sintilimab show potential for this combination as a new treatment option for patients in need. We look forward to obtaining more data from the ongoing pivotal Phase 2 trial which may support a future regulatory application in China for IBI310 in combination with sintilimab in recurrent or metastatic cervical cancer."
NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of an investigational drug to treat a serious disease or condition when preliminary clinical evidence indicates that the drug has demonstrated substantial improvement over current therapies. The BTD will not only qualify a drug candidate to receive status for rapid review by the CDE, but it will also allow the sponsor to obtain timely advice and communication from the CDE to accelerate the approval and launch to address the unmet clinical need of patients at an accelerated pace. Click here for the published list of drugs which have been granted BTD by NMPA.
About Cervical Cancer
According to GLOBOCAN 2020 report,there were approximately 110,000 new cases and 60,000 death cases of cervical cancer in China in 2020, making cervical cancer one of the most common malignant tumor types in gynecology. There is an urgent clinical need for more treatment options, especially for recurrent or metastatic cervical cancer, as traditional treatments such as surgery, chemotherapy and radiotherapy are ineffective with a low overall survival rate for those patients with recurrent or metastatic cervical cancer.
About IBI310
IBI310 is a recombinant fully-human IgG1 monoclonal antibody against cytotoxic T lymphocytic associated antigen 4 (CTLA-4) developed independently by Innovent Biologics. IBI310 can bind to CTLA-4 molecules and block the inhibition of T cells induced by CTLA-4, thereby leading to T cell activation and proliferation, and enhancing the anti-tumor activity of immune system to achieve the goal of tumor treatment.
About Sintilimab
Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody developed by Eli Lilly and Company and Innovent. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials.
In China, sintilimab has been approved and included in the National Reimbursement Drug List (NRDL) for four indications, including:
- The treatment of relapsed or refractory classic Hodgkins lymphoma after two lines or later of systemic chemotherapy;
- In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of non-squamous non-small cell lung cancer lacking EGFR or ALK driver mutations;
- In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of squamous non-small cell lung cancer;
- In combination with BYVASDA® (bevacizumab biosimilar injection) for the first-line treatment of unresectable or advanced hepatocellular carcinoma.
Additionally, Innovent currently has three regulatory submissions under review in China's NMPA for sintilimab:
- In combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil for the first-line treatment of esophageal squamous cell carcinoma;
- In combination with chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma;
- In combination with bevacizumab biosimilar and chemotherapy for EGFR-mutated non-squamous NSCLC following EGFR-TKI treatment.
- Phase 2 study as second-line treatment of esophageal squamous cell carcinoma;
- Phase 3 study as second-line treatment for squamous NSCLC with disease progression following platinum-based chemotherapy.
About Innovent
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 32 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 7 products approved for marketing in China – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) , Pemazyre® (pemigatinib oral inhibitor) and olverembatinib (BCR-ABL TKI) and Cyramza® (ramucirumab), 1 asset under NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials, and an additional 19 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection, Innovent)
BYVASDA® (bevacizumab biosimilar injection, Innovent)
HALPRYZA® (rituximab biosimilar injection, Innovent)
SULINNO® (adalimumab biosimilar injection, Innovent)
Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.
Disclaimer:
1. This indication is still under clinical study, which hasn't been approved in China.
2. Innovent does not recommend any off-label usage.
Innovent's Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
View original content:
SOURCE Innovent Biologics | https://www.1011now.com/prnewswire/2022/04/14/innovent-receives-nmpa-breakthrough-designation-ibi310-anti-ctla-4-monoclonal-antibody-combined-with-sintilimab-advanced-cervical-cancer-treatment/ | 2022-04-14T03:42:40 | 1 | https://www.1011now.com/prnewswire/2022/04/14/innovent-receives-nmpa-breakthrough-designation-ibi310-anti-ctla-4-monoclonal-antibody-combined-with-sintilimab-advanced-cervical-cancer-treatment/ |
Netflix launches new way for viewers to ‘like’ their favorite shows
Published: Apr. 13, 2022 at 10:58 PM EDT|Updated: 44 minutes ago
(CNN) - Netflix wants to keep its customers happy with the selections they are making.
The streaming service recently introduced a new recommendation tool - a double thumbs-up button.
Netflix already has thumbs up and thumbs down buttons for viewers to give feedback on what they like and dislike, but the company said it wanted to add another option.
The double thumbs-up tool is a way for viewers to let Netflix know which shows and movies they really like and enjoy.
Representatives with Netflix said it could recommend similar content thanks to the new tool, which ultimately helps customers stick around longer and feel satisfied with their subscription.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wflx.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ | 2022-04-14T03:42:43 | 0 | https://www.wflx.com/2022/04/14/netflix-introduces-new-way-recommend-content-viewers-like/ |
NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin. InxMed plans to disclose more data on IN10018 at the Annual Meeting of the American Society of Clinical Oncology in June 2022 and initiate a pivotal trial in the second half of the year.
Breakthrough Therapy Designation aims to help companies work closely with authorities to accelerate research, development, and approval of innovative therapies that can address unmet medical needs. IN10018 received fast track designation from the U.S. Food and Drug Administration for the treatment of patients with platinum-resistant ovarian cancer in August 2021. InxMed will live up to the high expectations and strive to deliver the benefits of innovative drugs to patients as quickly as possible.
FAK is a non-receptor tyrosine kinase and transmitter that plays an important role in cell adhesion, migration, and regulation. It exhibits expression upregulation in multiple tumor types. Researchers have found that inhibiting the FAK signaling pathway can effectively reverse previously failed chemotherapy and targeted therapy caused by drug resistance and enhance the response and efficacy of immunotherapy for solid tumors.
IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. InxMed Nanjing Translational Medicine Center has conducted extensive original exploratory research on IN10018 and FAK targets and has published research results in renowned academic journals. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy.
InxMed set up a global clinical development program for IN10018. Clinical trials currently underway in the US and China are designed for platinum-resistant ovarian cancer, NRAS mutant metastatic melanoma, triple-negative breast cancer, head and neck cancer, pancreatic cancer, and other solid tumors that are still lacking effective treatment.
For more information, visit http://en.inxmed.com/
About InxMed
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact. We have built translational medicine and clinical development team across Shanghai, Beijing, Nanjing, United States, Canada and Australia. We have built a highly differentiated pipeline and established partnership with various multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim.
View original content to download multimedia:
SOURCE InxMed (Nanjing) Co., Ltd. | https://www.1011now.com/prnewswire/2022/04/14/inxmed-fak-inhibitor-in10018-received-breakthrough-therapy-designation-by-china-national-medical-products-administration-platinum-resistant-ovarian-cancer/ | 2022-04-14T03:42:46 | 0 | https://www.1011now.com/prnewswire/2022/04/14/inxmed-fak-inhibitor-in10018-received-breakthrough-therapy-designation-by-china-national-medical-products-administration-platinum-resistant-ovarian-cancer/ |
Police: Woman dies after getting stuck upside down while climbing US-Mexico border wall
TUCSON, Ariz. (Gray News) - Police in Arizona said a Mexican woman died after illegally attempting to cross into the U.S. earlier this week.
Cochise County Sheriff Mark J. Dannels reports deputies responded to a call from Mexican authorities at about 11 p.m. on Monday concerning a woman stuck on a border fence near Douglas, Ariz.
According to the sheriff’s office, the woman was climbing over the border wall when she got stuck in the ropes of a harness and trapped upside down for a significant amount of time.
The 32-year-old was transported to a local hospital, but she was pronounced deceased. Authorities in Arizona said they notified the Mexican Consulate about the incident.
An autopsy will be completed to determine the woman’s cause of death and the sheriff’s office said its investigation continues.
“These incidents are not political; they are humanitarian realities that someone has lost a loved one in a senseless tragedy,” Sheriff Dannels said. “We have to do better in finding solutions to the challenges facing our border, and we have to do it for the right reasons. Regardless of opinions, the facts should direct our progress, and we will keep working towards a shared goal of border safety and security.”
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.wflx.com/2022/04/14/police-woman-dies-after-getting-stuck-upside-down-while-climbing-us-mexico-border-wall/ | 2022-04-14T03:42:50 | 0 | https://www.wflx.com/2022/04/14/police-woman-dies-after-getting-stuck-upside-down-while-climbing-us-mexico-border-wall/ |
BEIJING, April 13, 2022 /PRNewswire/ -- The UNESCO Netexplo Innovation Forum has taken place on the 13th April, 2022. During this event, the Netexplo Observatory issued the "Top 10 Global Science and Technology Innovation Awards" to the 10 most inspiring, powerful and surprising innovations in the past year that may change our future. LLVSION AR smart subtitle glasses is the only award from China and also the only one in AR sector.
This innovative product creatively solves the real-time communication problem of the hearing-impaired people, breaks down the barriers in the silent world and helps them communicate with others face to face freely and confidently. More importantly, considering that many people wear masks during the pandemic, allergy seasons, etc., this technology will be of great help to those who are lip-reading.
Netexplo is an independent observatory that studies the impact of digital technology on society and business, it is an UNESCO partner since 2011. Every year, 2-3,000 innovations in all continents and all walks of life are brought together with the help of the UNESCO Netexplo Committee, which is composed of renowned lecturers and researchers in digital and related fields. Then, the Netexplo Observatory will select the 10 most outstanding winners, who represent the trend of digital innovation and will profoundly reshape our future. The award-giving ceremony successfully held at UNESCO headquarters for 15 years and has international influence and authority. In 2021, Pan Jianwei, an academician of the Chinese Academy of Science, and his quantum-science satellite project won this award.
This award represents UNESCO's recognition of LLVISION's contribution to digital innovation. The founder and CEO of LLVISON, Mr. Fei WU, expressed after the award-giving ceremony that he hoped the AR technology would help build a much more friendly society for the disabled and pave the way for a more accessible world. He also believes that the Chinese technological innovation will bring more surprises to the world.
If you are interested in LLVISION AR smart subtitle glass, please visit https://www.llvision.com/en/h-col-215.html or contact global@llvision.com.
View original content to download multimedia:
SOURCE Beijing LLVision Technology Co.,LTD | https://www.1011now.com/prnewswire/2022/04/14/llvision-chinese-ar-technology-company-won-award-netexplo-global-innovation-15th-unesco-netexplo-innovation-forum/ | 2022-04-14T03:42:53 | 1 | https://www.1011now.com/prnewswire/2022/04/14/llvision-chinese-ar-technology-company-won-award-netexplo-global-innovation-15th-unesco-netexplo-innovation-forum/ |
- Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities
- Data from the clinical trial to be presented at a future medical meeting
- Large B-cell lymphoma (LBCL) is a common form of non-Hodgkin's lymphoma (NHL) and currently has limited treatment options
NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, April 13, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. Based on the topline results, the companies will engage global regulatory authorities.
LBCL is a fast-growing type of non-Hodgkin's lymphoma (NHL) – a cancer that develops in the lymphatic system – that affects B-cell lymphocytes, a type of white blood cell. There are an estimated 150,000 new LBCL cases each year globally. LBCL includes diffuse large B-cell lymphoma (DLBCL), which is the most common type of NHL worldwide and accounts for approximately 31 percent of all NHL cases.1,2,3,4
"We aim to leverage AbbVie's strong blood cancer expertise to further develop epcoritamab, alongside Genmab, for certain blood cancer patients who have limited treatment options," said Mohamed Zaki, M.D., Ph.D., vice president and head, global oncology development, AbbVie.
The topline results from this cohort demonstrated a confirmed overall response rate (ORR) of 63.1 percent by an independent review committee (IRC). The observed median duration of response (DOR) was 12 months. The mean lines of prior therapy in this cohort were 3.5 (2 to 11 lines of therapy). The most common treatment-emergent adverse events of any grade (greater than or equal to 20 percent) included cytokine release syndrome (CRS) (49.7 percent), pyrexia (23.6 percent), fatigue (22.9 percent), neutropenia (21.7 percent), and diarrhea (20.4 percent). The most common Grade 3 or 4 treatment-emergent adverse events (greater than or equal to 5 percent) included neutropenia (14.6 percent), anemia (10.2 percent), neutrophil count decreased (6.4 percent), and thrombocytopenia (5.7 percent). Additionally, the observed Grade 3 CRS was 2.5 percent. The data will be submitted for presentation at a future medical meeting.
Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy for a variety of hematologic malignancies, including an ongoing phase 3, open-label, randomized trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory DLBCL (NCT: 04628494).
"Together with our partner, AbbVie, we will work with regulatory authorities to determine next steps and continue to evaluate epcoritamab in a variety of clinical trials as a potential treatment option for patients with various hematological malignancies," said Jan van de Winkel, Ph.D., chief executive officer, Genmab. "We look forward to sharing the findings at a future medical meeting."
About the EPCORE™ NHL-1 Trial
EPCORE™ NHL-1 an open-label, multi-center safety and preliminary efficacy trial of epcoritamab that consists of two parts: a phase 1 first-in-human, dose escalation part; and a phase 2 expansion part. The trial was designed to evaluate subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-NHL, including LBCL and DLBCL. The dose escalation findings, which determined the recommended phase 2 dose, were published in The Lancet in 2021. In the phase 2 expansion part, additional patients are treated with epcoritamab to further explore the safety and efficacy of epcoritamab in three cohorts of patients with different types of relapsed/refractory B-NHLs who had limited therapeutic options.
The primary endpoint of the phase 2 expansion part was ORR as assessed by an IRC. Secondary efficacy endpoints included duration of response, complete response rate, duration of complete response, progression-free survival, and time to response as determined by the Lugano criteria. Overall survival, time to next therapy, and rate of minimal residual disease negativity were evaluated as secondary efficacy endpoints.
About Epcoritamab
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of lymphoma B cells.5 CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.6,7 Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration.
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Genmab Forward-Looking Statements
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
1 "Diffuse Large B-Cell Lymphoma." Lymphoma Research Foundation, https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/; date accessed: 11 February 2022.
2 "Non-Hodgkin Lymphoma." Lymphoma Research Foundation, https://lymphoma.org/aboutlymphoma/nhl/; date accessed: 7 April 2022.
3 Sehn, Salles. "Diffuse Large B-Cell Lymphoma." N Engl J Med. 2021;384:842-858. DOI: 10.1056/NEJMra2027612
4 Martelli, Ferreri, Agostinelli, et al. "Diffuse large B-cell lymphoma." Crit Rev Oncol Hematol. 2013;87(2):146-71. DOI: 10.1016/j.critrevonc.2012.12.009
5 Engelbert et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020 Feb;52: 102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23. PMID: 31981978; PMCID: PMC6992935.
6 Rafiq, Sarwish, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties." J. Immunol. (Baltimore, Md. 1950), U.S. National Library of Medicine, 15 Mar. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3631574/.
7 Singh, Vijay, et al. "Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." J Cancer Sci Ther., U.S. National Library of Medicine, Nov. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4939752/.
View original content:
SOURCE AbbVie | https://www.wflx.com/prnewswire/2022/04/13/abbvie-genmab-announce-topline-results-epcoritamab-duobody-cd3xcd20-phase-12-trial-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl/ | 2022-04-14T03:42:56 | 1 | https://www.wflx.com/prnewswire/2022/04/13/abbvie-genmab-announce-topline-results-epcoritamab-duobody-cd3xcd20-phase-12-trial-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:
- AbbVie Inc. (NYSE: ABBV)
The company, its officers, or directors misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis. As a result of the alleged wrongful acts and omissions, AbbVie's securities have experienced a significant decline in market value and AbbVie investors have suffered significant damages.
- International Business Machines Corporation (NYSE: IBM)
Please contact only if you acquired shares before April 4, 2017.
After the close of the market on October 16, 2018, IBM revealed a shortfall in revenue and disappointing 3Q2018 growth associated with the Company's Strategic Imperatives and CAMSS lines of business, particularly its Cloud business line.
On October 20, 2021, after the close of the market, the Company issued a press release announcing its 3Q2021 results. The Company announced total revenues for the quarter of $17.62 billion, a shortfall of $191.84 million based on analyst estimates. The main culprit was the Cloud & Cognitive Software segment, which had revenues of $5.69 billion, a shortfall of approximately $80 million based on analyst estimates of $5.77 billion. Over 42% of the $191 million shortfall was attributable to the Company's Cloud & Cognitive Software segment – where most of the strategic revenue produced by the fraudulent scheme and wrongful reclassification of revenues from non-strategic to strategic historically went.
Shareholders of ABBV or IBM should contact Fletcher Moore, Esq. by email at fmoore@moorekuehn.com or telephone at (212) 709-8245.
Moore Kuehn is a New York-based law firm with attorneys representing investors, stockholders, unitholders, and consumers. Attorney advertising. Prior results do not guarantee similar outcomes.
Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
fmoore@moorekuehn.com
(212) 709-8245
View original content to download multimedia:
SOURCE Moore Kuehn, PLLC | https://www.1011now.com/prnewswire/2022/04/14/moore-kuehn-pllc-encourages-investors-abbvie-inc-or-international-business-machines-corporation-contact-law-firm/ | 2022-04-14T03:43:02 | 1 | https://www.1011now.com/prnewswire/2022/04/14/moore-kuehn-pllc-encourages-investors-abbvie-inc-or-international-business-machines-corporation-contact-law-firm/ |
OnScale will augment Ansys' cloud portfolio by providing a cloud-native, web-based user interface and framework
/ Key Highlights
- Ansys' current marketplace and managed cloud portfolio provide scalable location-independent access to Ansys' industry-leading simulation technology via full-featured user interfaces (UIs)
- This portfolio will be extended with the addition of a cloud-native, web-based user interface from OnScale
- Once OnScale's technology is integrated with Ansys' portfolio, customers will enjoy device-independent access to Ansys simulation via both full-featured UIs and a new fully web-based UI
- OnScale technology will also support Ansys' ongoing extensible platform-centric approach to enabling a new class of simulation-based, vertical applications
PITTSBURGH, April 13, 2022 /PRNewswire/ -- Ansys (NASDAQ: ANSS) announced today that it has signed a definitive agreement to acquire cloud simulation provider OnScale. Once integrated into Ansys' existing cloud portfolio, this technology acquisition will help provide a cloud-native, web-based user interface (UI) for device-independent access to Ansys' broad array of simulation technologies. Terms of the deal were not disclosed. The acquisition is not expected to have a material impact on Ansys' consolidated financial statements in 2022.
Currently, Ansys' industry-leading cloud portfolio, comprising a marketplace offering (Ansys Gateway powered by AWS) and a managed cloud offering (Ansys Cloud, which runs on Azure), gives customers scalable location-independent access to Ansys simulation. Additionally, PyAnsys (Ansys' open-source Python API software package for a broad development ecosystem) provides an extensible platform-centric approach to the development and deployment of new verticalized, or use-case-specific, applications that leverage simulation. These capabilities and emerging new applications will now be strengthened by the addition of a cloud-native framework from OnScale that will support a user-friendly, web-based UI.
With a cloud portfolio that supports device-independent, location-independent, and platform-centric access to Ansys' industry-leading technology, customers will enjoy maximum flexibility in leveraging simulation via full-featured UIs, a web-based UI, as well as through a new class of simulation-based tools accessible by all engineers, scientists, professionals, and students.
"Customer needs are varied, and any successful cloud strategy must give customers the flexibility to adapt the use of cloud to their unique simulation challenges. To that end, our cloud strategy addresses the needs of not only existing customers, but any engineer, scientist or professional who can benefit from simulation technology," said Shane Emswiler, senior vice president of products at Ansys. "From enterprise customers who have invested heavily in simulation, to startups seeking flexible, scalable purchasing – Ansys provides organizations of all sizes with flexibility to leverage the cloud in ways that create maximum value for their teams."
"OnScale's cloud-native technology combines the limitless compute power of cloud supercomputers with an intuitive web-based front end, making simulation accessible to anyone. Knowing that OnScale's technology will now run simulations using Ansys' industry-leading technology is incredibly exciting for me and my team. We are thrilled to be joining the Ansys family," said Ian Campbell, CEO of OnScale.
To learn more about Ansys' expanding cloud offerings, register to attend Simulation World 2022 – a virtual event taking place May 18, 2022.
If you've ever seen a rocket launch, flown on an airplane, driven a car, used a computer, touched a mobile device, crossed a bridge, or put on wearable technology, chances are you've used a product where Ansys software played a critical role in its creation. Ansys is the global leader in engineering simulation. Through our strategy of Pervasive Engineering Simulation, we help the world's most innovative companies deliver radically better products to their customers. By offering the best and broadest portfolio of engineering simulation software, we help them solve the most complex design challenges and create products limited only by imagination. Founded in 1970, Ansys is headquartered south of Pittsburgh, Pennsylvania, U.S.A. Visit www.ansys.com for more information.
Ansys and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.
ANSS–F
This information contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the acquisition, including statements regarding the benefits of the acquisition and the products and markets of each company. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "future," "opportunity," "plan," "may," "should," "will," "would," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements including but not limited to: (i) the risk that the acquisition may not be completed in a timely manner or at all; (ii) the failure to satisfy the conditions to the consummation of the acquisition; (iii) risks that the proposed transaction disrupts current plans and operations of OnScale and potential difficulties in OnScale employee retention as a result of the transaction; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; (v) risks related to diverting management's attention from OnScale's ongoing business operations; (vi) the ability of Ansys to successfully integrate OnScale's operations, product lines, and technology; (vii) the short- and longer-term effects of the COVID-19 pandemic; (viii) the ability of Ansys to implement its plans, forecasts, and other expectations with respect to OnScale's business after the completion of the acquisition and realize additional opportunities for growth and innovation; and (ix) adverse changes in the economic and political conditions in the regions in which Ansys and OnScale operate. In addition, please refer to the documents that Ansys files with the SEC on Forms 10-K, 10-Q and 8-K. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth herein. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ansys assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
/ Contacts
View original content to download multimedia:
SOURCE Ansys | https://www.wflx.com/prnewswire/2022/04/13/ansys-expand-cloud-portfolio-with-technology-acquisition-onscale/ | 2022-04-14T03:43:03 | 0 | https://www.wflx.com/prnewswire/2022/04/13/ansys-expand-cloud-portfolio-with-technology-acquisition-onscale/ |
HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH. Co-formulation of the peptide agonist with an oral absorption enhancer prevents deactivation in the digestive tract and allows for daily oral administration. Preclinical studies have demonstrated good safety and efficacy profiles for XW004.
The single-center, double-blind, placebo-controlled, and multiple ascending dose (MAD) study will evaluate XW004 at doses of up to 30 mg daily in approximately 56 healthy volunteers. Participants in the trial, which is being conducted in Australia, will be treated with the study drug once daily for 15 days with a 21-day treatment-free follow-up period. The objective of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW004.
"As a once-daily oral GLP-1 tablet, XW004 has the potential to offer a more convenient treatment option for patients with metabolic disease and improve the overall compliance in broader patient populations. It is also amenable to developing oral combination treatments with other drugs to further enhance treatment outcomes," said Dr. Hai Pan, founder and CEO of Sciwind. "Initiation of this Phase 1 MAD study is an important first step towards developing XW004 as a safe and effective treatment for patients living with metabolic disease."
About Sciwind Biosciences
Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates. Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com.
View original content:
SOURCE Hangzhou Sciwind Biosciences Co., Ltd. | https://www.1011now.com/prnewswire/2022/04/14/sciwind-biosciences-announces-initiation-dosing-phase-1-clinical-trial-evaluating-xw004-an-oral-tablet-formulation-its-proprietary-glp-1-analogue-ecnoglutide/ | 2022-04-14T03:43:09 | 0 | https://www.1011now.com/prnewswire/2022/04/14/sciwind-biosciences-announces-initiation-dosing-phase-1-clinical-trial-evaluating-xw004-an-oral-tablet-formulation-its-proprietary-glp-1-analogue-ecnoglutide/ |
Expands Aviat's Private Networks Offering with Private LTE/5G, Unlicensed Wireless Access Solutions
- Creates an integrated end-to-end offering for wireless access and transport in the Private Networks segment
- Leverages Aviat's sales channel to address a $8 billion Private LTE/5G addressable market
- Increases Aviat's reach in mission-critical industrial Private Networks
- Expected to be accretive to Gross Margin %, Adjusted EBITDA, Non-GAAP EPS, and Free Cash Flow in first year
- Aviat to host conference call Thursday, April 14th, at 8:30am (ET)
AUSTIN, Texas and TORONTO, April 13, 2022 /PRNewswire/ -- Aviat Networks, Inc. ("Aviat") (Nasdaq: AVNW)) , the leading expert in wireless transport solutions, and Redline Communications Group, Inc. ("Redline") (TSX: RDL), a leading provider in mission-critical data infrastructure, announced today that they have entered into an arrangement agreement (the "Arrangement Agreement") under which Aviat will acquire all outstanding shares of Redline for CAD$0.90 per common share (approximately USD$0.71 per share), in an all-cash transaction (the "Transaction") valued at approximately CAD $16.2 million (approximately USD$12.9 million). Aviat expects to fully fund the acquisition from cash on hand. Subject to customary closing conditions and necessary regulatory approvals, the transaction is expected to close within four months.
Commenting on the Transaction, Pete Smith, Aviat CEO, said, "This is an exciting opportunity for both Aviat and Redline. The acquisition expands Aviat's share in private networks by adding Redline's wireless network access capabilities in industrial PTP/PTMP and licensed Private LTE and 5G to Aviat's existing wireless transport backhaul solutions. Redline products will leverage Aviat's sales and marketing presence for broader reach. Likewise, Aviat will benefit from Redline's presence in the Oil & Gas, and Transportation verticals."
Smith continued, "We expect this deal to be immediately accretive to Aviat's gross margin %, Adjusted EBITDA, non-GAAP EPS, and Free Cash Flow all in the first year. We look forward to finalizing this transaction which we believe will generate significant value for our shareholders."
Richard Yoon, President and CEO, Redline added that, "Aviat is a great partner for Redline. We look forward to leveraging our portfolio in conjunction with Aviat's global scale."
This Transaction is expected to provide both Aviat and Redline customers with a broader, more integrated portfolio of wireless access and transport solutions and reinforces Aviat's roadmap and commitment to the future of Private Networks as the environment evolves to 5G and beyond.
Transaction Details
Aviat intends to fund the acquisition with cash from the balance sheet.
Aviat and Redline will run independently until the closing of the Transaction.
The Transaction will be carried out by way of a Court-approved plan of arrangement (the "Arrangement") under the Canada Business Corporations Act, pursuant to which Aviat will acquire all the outstanding common shares of Redline (the "Redline Shares"). The implementation of the Arrangement will be subject to the approval of at least 66 2/3% of the votes cast by Redline shareholders present in person or represented by proxy at the annual general and special meeting of Redline shareholders (the "Meeting") and a majority of all of the votes cast by Redline shareholders present in person or represented by proxy at the Meeting after excluding votes of certain persons whose votes must be excluded in accordance with Canadian Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, and the receipt of applicable approvals from the Ontario Superior Court of Justice. The implementation of the Arrangement will also be subject to the completion of a reduction in the stated capital of the Redline Shares, which will require the approval of at least 66 2/3% of the votes cast by Redline shareholders present in person or represented by proxy at the Meeting.
The Arrangement Agreement provides for, among other things, customary representations, warranties and covenants, including a non-solicitation covenants from Redline, subject to customary "fiduciary out" provisions that allow Redline to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of Aviat. The Arrangement Agreement also provides for the payment of a termination fee of CAD$ 0.65 million to Aviat in the event the Transaction is terminated in certain specified circumstances, including if Aviat does not exercise its right to match in the context of a superior proposal supported by Redline. The completion of the transaction is not subject to any financing condition.
All directors and executive officers of Redline and certain other shareholders of Redline, holding approximately 29.7% of the issued and outstanding Redline Shares as of the date hereof, have entered into voting and support agreements in favour of Aviat pursuant to which, among other things, they have agreed to vote their Redline Shares in favour of the Transaction.
A management information circular relating to the Meeting and containing further details regarding the Arrangement and the Arrangement Agreement will be mailed to Redline shareholders and made available on SEDAR under Redline's profile at www.sedar.com. Further details related to the Transaction can be also found on the Investor Relations tab at www.aviatnetworks.com.
Board of Director Approvals
The Transaction has been unanimously approved by Aviat's Board of Directors.
Redline's Board of Directors established a Special Committee of independent directors (D. Neil McDonnell and Josef Vejvoda) to oversee the Transaction discussions and the Arrangement. The Special Committee unanimously recommended the Transaction to the Board of Directors, and the full Board of the Directors of Redline unanimously approved the Transaction, determined that the Transaction is fair to Redline shareholders and in the best interests of Redline, and passed a resolution to recommend that Redline shareholders vote in favour of the Transaction. Evans & Evans, Inc , financial advisor to Redline, has provided a fairness opinion to the Board of Directors of Redline that, subject to the assumptions, limitations and qualifications set out in such fairness opinion, the Consideration to be received by Redline shareholders pursuant to the Transaction is fair from a financial point of view to Redline shareholders.
D. Neil McDonnell, Chair of the Company's Board of Directors and Special Committee, commented: "We are pleased to announce our acquisition by Aviat, which strategically aligns Redline with a proven market leader, providing access to additional customers and markets and generating operational efficiencies. After careful deliberation, the Special Committee and Redline's Board of Directors have unanimously concluded that the Transaction is fair to Redline's shareholders from a financial point of view offering an opportunity to monetize their investment and is in the best interests of Redline and its employees."
The Arrangement Agreement will be available on SEDAR under Redline's profile at www.sedar.com within 10 days following the date of this press release.
Conference Call
Aviat will host a conference call for investors and industry analysts to discuss the transaction at 8:30am (ET) Thursday, April 14th.
To listen to the live conference call, please dial toll-free (US/CAN) 800-289-0438 or toll-free (INTL) 1 323-794-2423 conference ID: 8638497. We ask that you dial-in approximately 10 minutes prior to the start time.
About Aviat Networks
Aviat Networks, Inc. is the leading expert in wireless transport solutions and works to provide dependable products, services and support to its customers. With more than one million systems sold in 170 countries worldwide, communications service providers and private network operators including state/local government, utility, federal government and defense organizations trust Aviat with their critical applications. Coupled with a long history of microwave innovations, Aviat provides a comprehensive suite of localized professional and support services enabling customers to simplify both their networks and their lives. For more than 70 years, the experts at Aviat have delivered high-performance products, simplified operations, and the best overall customer experience. Aviat Networks is headquartered in Austin, Texas. For more information, visit www.aviatnetworks.com or connect with Aviat Networks on Twitter, Facebook and LinkedIn.
About Redline Communications
Redline Communications (TSX:RDL) designs and manufactures powerful wide-area wireless networks for mission-critical applications in challenging locations. Redline networks are used by Oil & Gas companies onshore and offshore, Mining companies on surface and underground operations, by municipalities to remotely monitor infrastructure, and by specialized telecom service providers to deliver premium services. Thousands of businesses worldwide rely on Redline to engineer, plan and deliver ruggedized, secure and reliable networks for their IoT, voice, data, and video communications needs. For more information visit www.rdlcom.com.
Forward-Looking Statements
The information contained in this document includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, and "forward looking information" under the provisions of Canadian provincial securities laws. Such statements include with respect to Aviat and Redline, their beliefs and expectations regarding the ability to close the Transaction, the ability to obtain the approval of Redline shareholders, the satisfaction of other conditions to the closing of the Transaction on proposed terms and in the time assumed, expectations regarding business conditions, new product solutions, customer positioning, revenue, future orders, bookings, new contracts, cost structure, operating income, profitability in fiscal 2022, process improvements, realignment plans and review of strategic alternatives. All statements, trend analyses and other information contained herein regarding the foregoing beliefs and expectations, as well as about the markets for the services and products of Aviat and Redline and trends in revenue, and other statements identified by the use of forward-looking terminology, including, without limitation, "anticipate," "believe," "plan," "estimate," "expect," "goal," "will," "see," "continue," "delivering," "view," and "intend," or the negative of these terms or other similar expressions, constitute forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, forward-looking statements are based on estimates reflecting the current beliefs, expectations and assumptions of the senior management of Aviat and Redline regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Such forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements should therefore be considered in light of various important factors, including those set forth in this document. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include the following:
- the ability to close the Transaction;
- the ability of Redline to obtain the approval of Redline shareholders and the satisfaction of other conditions to the closing of the Transaction on proposed terms and in the time assumed;
- the impact of COVID-19 on our business, operations and cash flows;
- continued price and margin erosion as a result of increased competition in the microwave transmission industry;
- the impact of the volume, timing, and customer, product, and geographic mix of our product orders;
- the timing of our receipt of payment for products or services from our customers;
- our ability to meet projected new product development dates or anticipated cost reductions of new products;
- our suppliers' inability to perform and deliver on time as a result of their financial condition, component shortages, the effects of COVID-19 or other supply chain constraints;
- the effects of inflation and the timing and extent of changes in the prices and overall demand for and availability of our inputs;
- customer acceptance of new products;
- the ability of our subcontractors to timely perform;
- weakness in the global economy affecting customer spending;
- retention of our key personnel;
- our ability to manage and maintain key customer relationships;
- uncertain economic conditions in the telecommunications sector combined with operator and supplier consolidation;
- our failure to protect our Intellectual property rights or defend against Intellectual property infringement claims by others;
- the results of our restructuring efforts;
- the ability to preserve and use our net operating loss carryforwards;
- the effects of currency and interest rate risks;
- the effects of current and future government regulations, including the effects of current restrictions on various commercial and economic activities in response to the COVID-19 pandemic;
- general economic conditions, including uncertainty regarding the timing, pace and extent of an economic recovery in the United States and other countries where we conduct business;
- the conduct of unethical business practices in developing countries;
- the impact of political turmoil in countries where we have significant business;
- the impact of tariffs, the adoption of trade restrictions affecting our products or suppliers, a United States withdrawal from or significant renegotiation of trade agreements, the occurrence of trade wars, the closing of border crossings, and other changes in trade regulations or relationships; and
- Aviat's ability to implement its stock repurchase program or the extent to which it enhances long-term stockholder value.
For more information regarding the risks and uncertainties for Aviat's business, see "Risk Factors" in Aviat's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on August 25, 2021 as well as other reports filed by Aviat with the SEC from time to time. For additional information on the risks and uncertainties for Redline's business and the Arrangement, see Redline's most recently filed Annual Information Form and Annual Management Discussion & Analysis, which are available on SEDAR at www.sedar.com and on Redline's website at www.rdlcom.com. Neither Aviat nor Redline undertakes any obligation to update publicly any forward-looking statement, whether written or oral, for any reason, except as required by law, even as new information becomes available or other events occur in the future.
For further information:
Aviat Contact(s):
Investor Relations:
Keith Fanneron
Vice President Global Finance & Investor Relations
Phone: (512) 861-1022
Email: keith.fanneron@aviatnet.com
Redline Contact(s):
Richard Yoon
Chief Executive Officer
+1-905-479-8344
ryoon@rdlcom.com
Investor Relations:
Ron Shuttleworth
Partner
OakHill Financial
+1-647-500-7371
rshuttleworth@oakhillfinancial.ca
View original content to download multimedia:
SOURCE Aviat Networks, Inc. | https://www.wflx.com/prnewswire/2022/04/13/aviat-networks-announces-intent-acquire-redline-communications/ | 2022-04-14T03:43:10 | 0 | https://www.wflx.com/prnewswire/2022/04/13/aviat-networks-announces-intent-acquire-redline-communications/ |
CALGARY, AB, April 13, 2022 /PRNewswire/ - Sundial Growers Inc. (NASDAQ: SNDL) ("Sundial" or the "Company") reports that the Company's external auditor has advised that it now expects to complete its audit and release its audit opinion and report on the Company's consolidated financial statements for the year ended December 31, 2021 on or before April 29, 2022. The Company expects to file its audited consolidated financial statements for the year ended December 31, 2021, annual management's discussion and analysis for the same period, annual information form for the same period (which will be reported as an Annual Report on Form 20-F) and management certifications of annual filings (collectively, the "Filings"), on or before April 29, 2022, which will be within the applicable U.S. filing deadline.
The principal reason for the delay is the significant amount of additional work and in-depth procedures required to be performed by the Company and its external auditor as 2021 is the first year that the Company is required to have an auditor attestation report on its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. The Company becoming subject to the requirement to obtain an auditor attestation report on internal control over financial reporting is a function of the rapid growth in scale and level of corporate activity Sundial has achieved over the last two years. The process of obtaining such a report will assist the Company in identifying improvements to corporate controls and processes that will ultimately benefit Sundial shareholders through best practices in risk management.
Sundial and its auditor have made significant progress and continue to work diligently toward completing the audit and the Filings as soon as possible. The Company's auditor has confirmed it will not seek reappointment at the Company's 2022 annual shareholder meeting, but will complete the review of the Company's 2022 first quarter financial statements in order to assist the Company with transition to a new auditor, at Sundial's request. There have been no disagreements between the Company and the auditor regarding any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures. Sundial believes that there will be no restatement of previously released financial statements of Sundial.
Sundial is also providing this bi-weekly update on the status of the management cease trade order granted on April 1, 2022 (the "MCTO") by its principal Canadian regulator, the Alberta Securities Commission (the "ASC"), under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). The Company has requested an extension of the MCTO from the ASC.
The MCTO restricts the Chief Executive Officer and Chief Financial Officer from all trading in securities of Sundial until such time as the Filings have been filed by the Company and the MCTO has been lifted. The MCTO does not affect the ability of other shareholders to trade in securities of the Company.
Sundial confirms that since its April 1, 2022 press release: (i) there has been no material change to the information set out in the April 1, 2022 press release that has not been generally disclosed other than as set forth herein; (ii) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the "alternative information guidelines" under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Filings is continuing, each of which will be issued in the form of a news release; (iii) there has not been any other specified default by the Company under NP 12-203; (iv) the Company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the Company that has not been generally disclosed.
Sundial is a public company whose shares are traded on Nasdaq under "SNDL". Its business is reported and analyzed under three operating segments: Cannabis Operations, Retail Operations (Cannabis and Liquor), and Investment Operations.
As a licensed producer that crafts small-batch cannabis using state-of-the-art indoor facilities, Sundial's 'craft-at-scale' modular growing approach, award-winning genetics, and experienced growers set us apart. Sundial's brand portfolio includes Top Leaf, Sundial Cannabis, Palmetto, and Grasslands. Sundial also operates the Spiritleaf retail banner. Spiritleaf aims to be the most knowledgeable and trusted source of recreational cannabis by offering a premium consumer experience, and quality curated cannabis products. Sundial has acquired Alcanna Inc. and is now the largest private sector cannabis and liquor retailer in Canada.
Sundial's investment operations seek to deploy strategic capital through direct and indirect investments and partnerships throughout the global cannabis industry.
Sundial is proudly Albertan, headquartered in Calgary, AB. For more information on Sundial, please go to www.sndlgroup.com.
Forward-Looking Information
This news release contains statements and information that, to the extent that they are not historical facts, may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable securities legislation ("forward-looking information"). Forward-looking information is typically, but not always, identified by the use of words such as "will", "expected", "projected", "to be" and similar words, including negatives thereof, or other similar expressions concerning matters that are not historical facts. Forward-looking information in this news release includes, but is not limited to, the expectations of management with respect to the anticipated filing of the Filings and the duration of the MCTO, as well as Sundial's expectation that it will file its Annual Report on Form 20-F.
Such forward-looking information is based on various assumptions and factors that may prove to be incorrect, including, but not limited to, factors and assumptions with respect to: Sundial's belief that its external auditor will complete its audit and release its audit opinion in a timely manner that will allow Sundial to file the Filings on or before April 29, 2022; that the unaudited financial statements prepared by management of the Company will not differ materially from audited financial statements once available; that the Company will receive an extension of the MCTO from the ASC; Sundial's belief that there will be no restatements of its previously released financial statements; and the ability of Sundial's management to execute its business strategy, objectives and plans. As a result, although Sundial believes that the assumptions and factors on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Sundial can give no assurance that it will prove to be correct or that any of the events anticipated by such forward-looking information will transpire or occur, or if any of them do so, what benefits Sundial will derive therefrom.
The forward-looking information contained in this news release is made as of the date hereof. Except as expressly required by applicable securities laws, Sundial does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release are expressly qualified by this cautionary statement.
View original content to download multimedia:
SOURCE Sundial Growers Inc. | https://www.1011now.com/prnewswire/2022/04/14/sundial-growers-announces-filing-annual-report-by-april-29-provides-bi-weekly-mcto-status-update/ | 2022-04-14T03:43:15 | 0 | https://www.1011now.com/prnewswire/2022/04/14/sundial-growers-announces-filing-annual-report-by-april-29-provides-bi-weekly-mcto-status-update/ |
LOS ANGELES, April 13, 2022 /PRNewswire/ -- In honor of National Minority Health Month and Black Maternal Health Week, BabyLiveAdvice (BLA) is proud to announce the completion of an important maternal telehealth project that will soon be launching its second phase, both bringing free virtual telehealth support to minority mothers during pregnancy and postpartum.
Last year, BLA received a large grant to support inner-city minority mothers in Chicago, Illinois, in partnership with local Federally Qualified Health Centers. The project expanded to the state of Georgia, with the help of Johnson & Johnson and in partnership with local community physicians. The project enabled BLA to provide 175 Black and Hispanic mothers with free access to culturally competent virtual care, unbiased advice, support, and group education from BLA's team of Maternal-Infant experts, such as nurses, doulas, lactation consultants and mental health providers in the mothers' language and at their home. This, first of its kind, maternity telehealth demonstration project provided the much-needed evidence that telehealth has immense potential to bridge the gap in access to care, by connecting isolated people, particularly minorities, with health practitioners, and reducing the need for transportation to receive care.
"I never felt that anyone cared about me or my baby," said Letisha R, a South Chicago mom who participated in the project for 15 months. "I could live or die, and no one will care, until I met LaTanya my nurse on BLA. She was there when I needed her throughout my pregnancy and after Shetty was born, talking to her made me trust again that someone cared about us and that we will be all right."
Full data from this project will be available later this year, but early findings show that 78% of the Black and Hispanic mothers were able to adopt and utilize telehealth with high patient satisfaction and low attrition rates. The project also improved the doctor-patient interactions, with a 48% reduction in no-show rates to scheduled medical appointments, and improved overall pregnancy outcomes for the participating mothers.
The success of the initial project has led to approval of a second phase, which will enable BLA to support six hundred Black mothers in the state of Georgia. For this second phase, BabyLiveAdvice is immensely and especially excited to be partnering with the National Black Doulas Association®, whose doulas will serve as a critical part of the BLA provider team, to bring virtual support to Black (BIPOC) birthing families in the State of Georgia, for no cost.
Black mothers face the highest maternal mortality and morbidity rates in the United States. BLA, and the National Black Doulas Association® are both committed to serving these mothers, and their families, in a meaningful way, to improve the birthing experience and help reduce mortality and morbidity rates in their community. Through this project, Black mothers, birthing people, and parents will be able to connect with doulas, midwifes, nutritionists, diabetic educators, lactation consultants, nurse practitioners and nurses to receive free, one-on-one virtual support as well as educational group classes, from preconception to 6 months postpartum.
The next phase of the project will support further evidence around adoption and utilization of telehealth among the urban and rural underserved BIPOC communities in the state with the highest Black maternal mortality rates. BLA is extremely excited to join with the National Black Doulas Association® and continue its mission helping mothers, birthing people, and parents, especially those most in need.
View original content:
SOURCE Baby Live Advice | https://www.wflx.com/prnewswire/2022/04/13/babyliveadvice-partners-with-national-black-doula-association-provide-virtual-telehealth-support-minority-bipoc-mothers-georgia-pregnancy-infancy/ | 2022-04-14T03:43:17 | 0 | https://www.wflx.com/prnewswire/2022/04/13/babyliveadvice-partners-with-national-black-doula-association-provide-virtual-telehealth-support-minority-bipoc-mothers-georgia-pregnancy-infancy/ |
OSAKA, Japan, April 13, 2022 /PRNewswire/ -- Toyobo Co., Ltd. has launched a major U.S. marketing initiative for Nerbridge TM ("the product", hereafter), a conduit for peripheral nerve regeneration.
On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held in Carlsbad, California, by three societies – the American Association for Hand Surgery (AAHS), the American Society for Peripheral Nerve (ASPN) and the American Society for Reconstructive Microsurgery (ASRM). The campaign is being conducted in partnership with the exclusive U.S. distributor of Nerbridge TM, Synovis Micro Companies Alliance, Inc. (hereafter Synovis), a subsidiary of Baxter International Inc., a global medtech leader.
The global nerve conduit market is estimated at around 150,000 units as of 2021 and has been growing at a rate of 15 percent per annum*1. The U.S. accounts for about 70 percent of the share, making it the biggest market of its kind in the world.
Toyobo plans to feature the product in collaboration with Synovis at conferences held by various societies. At the events, the company plans to present data*2,3 on clinical tests, post-sale surveys and clinical practice it has accumulated since the company started marketing the product in Japan in 2013. The societies to which Toyobo will showcase the product are those holding conferences across the United States, including ASRM, ASSH and the American Society of Plastic Surgeons.
The product is a medical device used with the aim of facilitating regeneration and reconstructing functions of peripheral nerves severed or lost due to external injury. The device is a tube made of polyglycolic acid filled with sponge-shaped collagen, which enables the creation of an environment to induce nerve growth and reconstruct the severed section. The sponge-like structure of collagen has been confirmed as effective in multiplying nerve cells. The nerve conduit products made of synthesized materials that are available on the overseas market have reportedly caused some instances of triggering inflammatory reactions when the materials have decomposed inside the body*4. However, such events were not found with Nerbridge TM in a systematic literature search Toyobo has been making for the past several years in Japan. Using Nerbridge TM makes it unnecessary to harvest healthy peripheral nerves for autografting, reducing the patient's burden and shortening the time needed for surgical treatment.
Toyobo plans to enhance the production capacity of the product by the end of 2025 as well as expanding the scope of its clinical applications. To respond to the increasing demand expected for nerves conduits in the U.S. and elsewhere in the world, Toyobo will strengthen its production and sales capacities, thus becoming the leading company in the nerve conduit business field.
About Nerbridge TM
Brand name: Nerbridge TM
US FDA 510(k): Clearance No. K152967／Nerve Cuff
JP MHLW: Approval No.22500BZX00106000／Absorbent nerve regeneration inducer with the use of collagen
*1 Global Nerve Conduit, Nerve Wrap and Nerve Graft Repair Product Market Growth 2021-2026
*2 Product document of Nerbridge TM
*3 Kusuhara H, et al. A clinical multi-center registry study on digital nerve repair using a biodegradable nerve conduit of PGA with external and internal collagen scaffolding.、Microsurgery. 2018;1–5.
*4 Kehoe S, et al., FDA approved guidance conduits and wraps for peripheral nerve injury: A review of materials and efficacy、Injury, Int. J. Care Injured 43 (2012) 553–572.
View original content:
SOURCE Toyobo Co., Ltd. | https://www.1011now.com/prnewswire/2022/04/14/toyobo-launches-major-marketing-initiative-nerbridgetm-us-setting-sights-global-nerve-conduit-market/ | 2022-04-14T03:43:22 | 1 | https://www.1011now.com/prnewswire/2022/04/14/toyobo-launches-major-marketing-initiative-nerbridgetm-us-setting-sights-global-nerve-conduit-market/ |
Data Counters Sentiment Surveys that say Spending is Weakening
NEW YORK, April 13, 2022 /PRNewswire/ -- The Bank of America Institute published a new article today which provides evidence that consumers' finances, particularly of those in lower-income groups, are holding up, contrary to findings of sentiment surveys about the impact of higher prices.
Citing strong growth in credit and debit card spending – up 11% year over year in March, and continued strength into April – as well as a booming labor market and elevated cash levels in checking and savings accounts, the data shows that lower-income consumers are not reacting to this inflationary environment as adversely as one might gather from reports.
Highlights of the publication:
- Aggregate Bank of America credit and debit card spending was up 15% in the first eight days of April compared to the same period in 2021.
- Among cardholders with less than $50,000 in annual income, card spending per household is up 33.3% in early April compared to the same time period in 2019.
- Bank of America ACH, Wire and P2P payments were up 26% in the first eight days of April year over year.
- Checking and savings balances of households with less than $50,000 annual income have at least $1,500 more than they started in 2019.
"While sentiment surveys show that consumers are inclined to cut back in response to higher prices, people don't always do what they say they are doing," said David Tinsley, senior economist for the Bank of America Institute. "Leveraging the breadth and depth of our comprehensive payments and spending data from 67 million consumer and small business clients, we are able to get a richer and deeper assessment of the consumer than small-scale surveys can ever achieve. Our data does not support all the gloom."
Bank of America Institute
The Bank of America Institute is dedicated to uncovering powerful insights that move business and society forward. Established in 2022, the Institute is a think tank that draws on data and analyses from across the bank and the world to provide timely and original perspectives on the economy, Environmental, Social and Governance (ESG), and global transformation. The Institute leverages the depth and breadth of the bank's proprietary data, from 67 million consumer and small business clients, 54 million verified digital users, $3.8T in total payments in 2021 and $1.4T in consumer and wealth management deposits. From this robust data set, the Institute provides a unique perspective on the health of the economy. It also elevates thought leadership from throughout the bank that addresses long-term trends and shares these findings with the general public.
Bank of America
Bank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 67 million consumer and small business clients with approximately 4,200 retail financial centers, approximately 16,000 ATMs, and award-winning digital banking with more than 54 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and approximately 35 countries. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.
For more Bank of America news, including dividend announcements and other important information visit the Bank of America newsroom and register for email news alerts.
Reporters may contact:
Melissa Anchan, Bank of America
Phone: 1.646.532.9241
melissa.anchan@bofa.com
View original content to download multimedia:
SOURCE Bank of America Corporation | https://www.wflx.com/prnewswire/2022/04/13/bank-america-card-spending-up-15-april-even-amidst-backdrop-rising-inflation/ | 2022-04-14T03:43:23 | 0 | https://www.wflx.com/prnewswire/2022/04/13/bank-america-card-spending-up-15-april-even-amidst-backdrop-rising-inflation/ |
Agreements Subject to Court Approval
TORONTO, April 13, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that it has reached an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action ("US Class Action") pending against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021. The Company also announced it has signed a settlement agreement (the "Canadian Settlement") to resolve a class action lawsuit ("Canadian Class Action") that was filed in the British Columbia Supreme Court in May 2021 against the Company its CEO, certain of its former officers, a shareholder, and underwriters.
The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class Action. The Canadian Settlement contemplates a cash payment of CDN $1.9 million, of which the Company will be paying CDN $1.6 million.
After available insurance, the total cost to the Company to settle both class actions will be approximately CDN $1.36 million. This does not include legal expenses incurred by the Company, estimated at approximately CDN $950,000, of which approximately CDN $750,000 has been paid.
Both the US Settlement and the Canadian Settlement are subject to court approval at hearings expected later in 2022. Under the respective settlement agreement, once the US Settlement and the Canadian Settlement receive court approval, both class actions will be dismissed against all defendants, including the Company and its officers. Approval by the respective courts, notice to the putative classes, and the satisfaction of customary conditions to effectiveness will take several months.
As previously disclosed, given the uncertainties of litigation, the Company had not been in a position to assess the likelihood of any potential loss or adverse effect on its financial condition or to reasonably estimate the amount of potential loss in connection with the class actions. As a result of the entry into the US Settlement and the Canadian Settlement, the Company expects that the above-referenced total cost to settle will be incorporated into its results of operations and financial condition for the fiscal quarter ending June 30, 2022.
The Company announces that Dr. David Greenberg has resigned as a director. The resignation is not connected to the class actions or the settlement. Dr Greenberg is not a party to the class actions.
The Company appreciates David's meaningful contribution to the Company and wishes him well in future endeavours.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre
Chairman & CEO
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
View original content to download multimedia:
SOURCE Braxia Scientific Corp. | https://www.1011now.com/prnewswire/2022/04/14/update-braxia-scientific-reaches-agreements-settle-class-actions-us-canada/ | 2022-04-14T03:43:29 | 0 | https://www.1011now.com/prnewswire/2022/04/14/update-braxia-scientific-reaches-agreements-settle-class-actions-us-canada/ |
Plus Solutions revenue is up 81% year over year for February 2022 year-to-date, as BBTV executes ahead of plan
VANCOUVER, BC, April 13, 2022 /PRNewswire/ - BBTV Holdings Inc. (TSX: BBTV) (OTCQX: BBTVF) (Frankfurt: 64V) ("BBTV" or the "Company"), the leading creator monetization company with a mission to help creators become more successful, provides a corporate update highlighting 81% revenue growth for its Plus Solutions in the first two months of the 2022 fiscal year.
- Each of BBTV's Plus Solutions revenue streams, including Content Management, Direct Advertising Sales, and Mobile Gaming Apps, are ahead of BBTV's guided 23% sustainable annual revenue growth rate for our Plus Solutions.
- In the Company's Content Management division, following notable renewals with the NBA, CMF and TEGNA, as well as BBTV's expanded partnership with Paramount Global (formerly ViacomCBS), BBTV continues to deepen and add additional partnerships to its leading portfolio of enterprise clients.
- The Company continues to see momentum in its Direct Advertising Sales division following the addition of new clients in Q4 2021, including a top three player in the auto industry, a new major studio client, and BBTV's first client in the non-profit public health space.
- In February 2022, the Company launched its first Mobile Gaming App in partnership with a major studio client: Jackass Human Slingshot in partnership with Paramount Global and Johnny Knoxville. The Company also continues to see growth in Lifetime Value (LTV) performance following the launch of the Company's Live Events strategy, increasing revenue month over month as high as 300% for apps with millions of players.
Shahrzad Rafati, Chairperson and CEO, BBTV, comments: "The management team at BBTV is hyper focused on increasing Plus Solutions revenue and driving strong gross margins for the business. Building off of the 21% revenue increase for our Plus Solutions in fiscal 2021, 2022 is really about continued momentum in Content Management, Direct Advertising Sales, Mobile Gaming Apps, and expanding our financial solutions for our creators. The latter includes BBTV Fast Pay which has seen strong adoption rates so far, demonstrating that our solutions are essential to our creators. We're at the center of the $100 billion dollar creator economy, where the two pillars of making money are reach and engagement. BBTV is a global leader for both, and we are uniquely positioned to capitalize on our scale and our massive library of content."
BBTV is a global media and technology company headquartered in Vancouver, Canada. The Company's mission is to help content creators become more successful. With creators ranging from individuals to global media brands, BBTV provides comprehensive, end-to-end Solutions to increase viewership and drive revenue powered by its innovative technology, while allowing creators to focus on their core competency – content creation. In December 2021, BBTV had the fourth most unique monthly viewers among digital platforms with more than 600 million globally, who consumed more than 35 billion minutes of video content [1]. (www.bbtv.com)
[1] Calculations and classifications made by BBTV based on data from Comscore's "Top 12 Countries = December 2021 comScore Video Metrix Media Trend – Multi-Platform – Top 100 Video Properties Report"; Top 12 countries represent ~50% of world's digital population.
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking information"). Forward-looking information is not information about historical facts but instead represents the Company's intentions, beliefs, plans, goals, objectives and strategies regarding future events and results. Forward-looking information contained in this press release includes statements that BBTV has provided guidance that Plus Solutions will have a 23% sustainable annual revenue growth rate; BBTV continues to deepen and add additional partnerships to its leading portfolio of enterprise clients; the management team at BBTV is hyper focused on increasing Plus Solutions revenue and driving strong gross margins for the business; and we are uniquely positioned to capitalize on our scale and our massive library of content. Forward-looking information is necessarily based on a number of estimates and assumptions that the Company considered appropriate and reasonable as of the date such information is given, including but not limited to the Company's assumptions that that the Company's current growth plans will not change in any material respect; that its internal financial forecasts and models, including its estimates of costs and revenue are accurate are accurate; that its assumptions regarding continued growth, changes and trends in the Company's industry and the global economy will be met; that the Company's Plus Solutions revenue will continue to grow as expected; that the Company will enter into an increasing number of Direct Advertising Sales Deals, Content Management agreements and initiatives; the timely receipt of required regulatory approvals and strategic partner support; the absence of new laws, regulations, rules or policies of governments, platforms and other strategic partners, that may negatively impact the business of BBTV; our ability to build our market share, enter new markets and maintain and expand geographic scope; our ability to obtain and maintain financing on acceptable terms; as well as the Company's assumptions regarding foreign exchange rates. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risk that the Company's assumptions on which its forward-looking information is based may not be accurate; the effect of competition; that the Company has a history of losses and negative cash flow; that the Company's agreements with platforms, creators or others may terminate early or not be renewed either on similar terms or at all; that the Company's Plus Solutions may not continue to be attractive to creators and may not realize our expectations; the regulatory environment; litigation risk; intellectual property risks; the Company's need for timely performance by its creators and strategic partners; and the impact of the continuing COVID-19 pandemic; as well as the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 29, 2022 and its prospectus dated October 22, 2020, both filed on Sedar at www.sedar.com, and in the Company's other filings with the Canadian securities regulatory authorities at www.sedar.com. The Company does not undertake any obligation to update any forward–looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Contacts:
Media Relations
Mark Funston
Head of Marketing and PR
778-288-4950
mfunston@bbtv.com
Investor Relations
ir@bbtv.com
Ron Shuttleworth
Partner
Oak Hill Financial Inc
(647)–500–7371
rshuttleworth@oakhillfinancial.ca
BBTV-C
View original content to download multimedia:
SOURCE BBTV Holdings Inc. | https://www.wflx.com/prnewswire/2022/04/13/bbtv-provides-corporate-update-outlining-plus-solutions-growth-momentum/ | 2022-04-14T03:43:31 | 0 | https://www.wflx.com/prnewswire/2022/04/13/bbtv-provides-corporate-update-outlining-plus-solutions-growth-momentum/ |
Achievement of excellent dynamic performance and downsizing, helping increase electric mileage
KARIYA, Japan, April 13, 2022 /PRNewswire/ -- BluE Nexus Corporation, AISIN Corporation, and DENSO Corporation today announced that they have jointly developed an eAxle for Toyota's new battery electric vehicle (BEV), bZ4X scheduled to be released in May 12, 2022. BluE's first eAxle has achieved excellent dynamic performance and downsizing and helps vehicles increase their electric mileage.
BluE was established in April 2019 to develop and sell electric systems and driving modules. By combining the strengths of AISIN, DENSO and Toyota in electrification, BluE aims to further develop and popularize electric vehicles and to help realize a carbon-neutral society by meeting the needs of customers around the world.
The eAxle is an electric driving module that integrates a motor, an inverter, and a transaxle. BluE, AISIN, and DENSO have jointly developed three new models: a 150kW specification (front) for FWD vehicles and 80kW specifications (front and rear) for 4WD vehicles.
This product has achieved excellent dynamic performance and high torque by increasing output density. Optimizing cooling inside the eAxle utilizing simulations and technologies nurtured so far, adapting heat management technology and improving the double-sided cooling technology for inverter layers help to increase output density. Furthermore, top-class electric mileage has also been achieved through the optimal magnetic design of the motor, the joining technology to shorten coil ends, low-viscosity oil for the eAxle, and loss reduction technologies such as the new RC-IGBT.
Moreover, the eAxle has been significantly downsized through our technologies, including a built-in structure that incorporates an inverter into the transaxle, a downsized motor, and the shortened distance between the shafts by adopting an output shaft. The eAxle to be mounted in the front of a vehicle has a reduced longitudinal length, and the one to be mounted in the rear of a vehicle has a reduced height, helping expand the passenger and luggage compartment spaces.
AISIN has developed and produced more than 5 million electric units since the launch of its first hybrid transmission in 2004. Meanwhile, DENSO has developed and produced more than 20 million inverters since the launch of the first Prius in 1997.
In addition to the expertise of the AISIN and DENSO, the three companies have developed BluE's first eAxle by utilizing BluE's know-how regarding the optimization and modularization of components, and the company's capability to adapt to a variety of vehicles.
BluE, AISIN, and DENSO will continue to develop compact, highly efficient, low-cost products by leveraging their respective strengths and know-how. The companies will also contribute to the realization of a carbon-neutral society through by installing products in electric vehicles of every description via BluE.
View original content to download multimedia:
SOURCE DENSO | https://www.wflx.com/prnewswire/2022/04/13/blue-nexuss-first-eaxle-adopted-toyotas-bz4x/ | 2022-04-14T03:43:38 | 0 | https://www.wflx.com/prnewswire/2022/04/13/blue-nexuss-first-eaxle-adopted-toyotas-bz4x/ |
MINNEAPOLIS, April 13, 2022 /PRNewswire/ -- Centerspace (NYSE: CSR) announces that it will release its operating results for the quarter ended March 31, 2022, after the market closes on May 2, 2022.
Conference Call:
Management will host a conference call to discuss those results on the following day, Tuesday, May 3, 2022, at 10:00 a.m. Eastern Time.
Interested parties may access the live conference call via the following:
Live webcast: http://ir.centerspacehomes.com
About Centerspace
Centerspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, the company currently owns 84 apartment communities consisting of 14,840 homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, and South Dakota. Centerspace was named a Top Workplace for 2021 by the Minneapolis Star Tribune. For more information, please visit www.centerspacehomes.com.
If you would like more information about this topic, please contact Emily Miller, Investor Relations, at (701) 837-7104 or IR@centerspacehomes.com.
Contact Information
Emily Miller, Investor Relations
Phone : (701) 837-7104
E-mail : IR@centerspacehomes.com
View original content to download multimedia:
SOURCE Centerspace | https://www.wflx.com/prnewswire/2022/04/13/centerspace-announces-dates-earnings-release-conference-call-first-quarter-2022/ | 2022-04-14T03:43:46 | 1 | https://www.wflx.com/prnewswire/2022/04/13/centerspace-announces-dates-earnings-release-conference-call-first-quarter-2022/ |
SÃO PAULO, April 13, 2022 /PRNewswire/ -- GOL Linhas Aéreas Inteligentes S.A. ("GOL" or "Company") (NYSE: GOL and B3: GOLL4), Brazil's largest domestic airline, in addition to the Material Facts disclosed on September 15, 2021 and February 7, 2022, announces the closing of the transaction involving the expansion of its commercial cooperation with American Airlines Group Inc. (NASDAQ: AAL) ("American") through an exclusive codeshare agreement for the next three years and an equity investment by American in the amount of US$200 million in 22.2 million newly issued preferred shares of GOL through a capital increase for a 5.3% participation in GOL's economic interest (the "Transaction"). As part of Transaction, on the date hereof American and the controlling shareholder of GOL entered into a shareholders' agreement which grants American the right to appoint a member to GOL's Board of Directors for the term of the exclusivity provided in the Transaction.
Through its exclusivity, the Transaction expands beyond the terms of the existing codeshare partnership between GOL and American, enhancing the travel opportunities for their passengers, the customer experience and the competitive position of GOL on routes connecting North and South America. In place since February 2020, the existing codeshare already represented the largest route network in the Americas, enabling the Company's customers to travel seamlessly to more than 30 destinations in the U.S. The partnership flights currently operate in GOL's hubs in São Paulo (GRU) and Rio de Janeiro (GIG), integrating 34 options of Brazilian and international routes, such as Montevideo, in Uruguay.
Investor Relations
ri@voegol.com.br
www.voegol.com.br/ir
+55(11) 2128-4700
About GOL Linhas Aéreas Inteligentes S.A.
GOL is Brazil's largest airline, leader in the corporate and leisure segments. Since its founding in 2001, it has been the airline with the lowest unit cost in Latin America, which has enabled the democratization of air transportation. The Company has partnerships with American Airlines and Air France-KLM, in addition to making available to Customers many codeshare and interline agreements, bringing more convenience and ease of connections to any place served by these partnerships. With the purpose of "Being First for Everyone", GOL offers the best travel experience to its passengers, including: the largest inventory of seats and the most legroom; the most complete platform with internet, movies and live TV; and the best loyalty program, SMILES. In cargo transportation, GOLLOG delivers parcels to various regions in Brazil and abroad. The Company has a team of 15,000 highly qualified airline professionals focused on Safety, GOL's number one value, and operates a standardized fleet of 135 Boeing 737 aircraft. GOL's shares are traded on the NYSE (GOL) and the B3 (GOLL4). For further information, visit www.voegol.com.br/ir.
About American Airlines Inc.
American's purpose is to care for people on life's journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company's stock is included in the S&P 500. Learn more about what's happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.
Disclaimer
The information contained in this material fact has not been subject to any independent audit or review and contains "forward-looking" statements, estimates and projections that relate to future events, which are, by their nature, subject to significant risks and uncertainties. All statements other than statements of historical fact contained in this material fact including, without limitation, those regarding GOL's future financial position and results of operations, strategy, plans, objectives, goals and targets, future developments in the markets in which GOL operates or is seeking to operate, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "will", "may", "project", "estimate", "anticipate", "predict", "seek", "should" or similar words or expressions, are forward-looking statements. The future events referred to in these forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond GOL's control, that may cause actual results, performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are based on numerous assumptions regarding GOL's present and future business strategies and the environment in which GOL will operate in the future and are not a guarantee of future performance. Such forward-looking statements speak only as at the date on which they are made. None of GOL or any of its affiliates, officers, directors, employees and agents undertakes any duty or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. None of GOL or any of its affiliates, officers, directors, employees, professional advisors and agents make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Although GOL believes that the estimates and projections in these forward-looking statements are reasonable, they may prove materially incorrect and actual results may materially differ. As a result, you should not rely on these forward-looking statements.
View original content:
SOURCE GOL Linhas Aéreas Inteligentes S.A. | https://www.wflx.com/prnewswire/2022/04/13/closing-previously-announced-exclusive-codeshare-agreement-between-gol-american-airlines/ | 2022-04-14T03:43:53 | 0 | https://www.wflx.com/prnewswire/2022/04/13/closing-previously-announced-exclusive-codeshare-agreement-between-gol-american-airlines/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2022 financial results after the market closes on Wednesday, April 20, 2022. The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Press Releases."
The company will host a conference call on Thursday, April 21, 2022 at 10:00 a.m. (ET) with access available via webcast and telephone. Chief executive officer and president, Joseph Harvey, chief financial officer, Matthew Stadler, and chief investment officer, Jon Cheigh, will review the company's financial results and outlook and be available for questions.
Investors and analysts can access the live conference call by dialing 877-384-2165 (U.S.) or +1-212-231-2930 (international); passcode: 22017395. Participants should plan to register at least 10 minutes before the conference call begins. A replay of the call will be available for two weeks starting at approximately 12:00 p.m. (ET) on April 21, 2022 and can be accessed at 800-633-8284 (U.S.) or +1-402-977-9140 (international); passcode: 22017395. Internet access to the webcast, which includes audio (listen-only), will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Overview." The webcast will be archived on the website for one month.
About Cohen & Steers
Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong and Tokyo.
View original content:
SOURCE Cohen & Steers, Inc. | https://www.wflx.com/prnewswire/2022/04/13/cohen-amp-steers-inc-release-first-quarter-2022-financial-results-april-20-2022/ | 2022-04-14T03:43:59 | 1 | https://www.wflx.com/prnewswire/2022/04/13/cohen-amp-steers-inc-release-first-quarter-2022-financial-results-april-20-2022/ |
Montefiore School Health Program is the largest and most comprehensive school-based health program in the nation, providing primary medical care, counseling, optometry and dentistry to 44,000 children.
BRONX, N.Y., April 13, 2022 /PRNewswire/ -- Today at PS 8 Elementary School, Congressmen Espaillat and Torres joined Montefiore Medicine President and CEO, Dr. Philip O. Ozuah to award more than $3.3 million in federal funding to the Montefiore School Health Program (MSHP), the largest and most comprehensive school-based health program in the country. One in four Bronx students have a MSHP clinic with health experts — from doctors and dentists to therapists — who support children from pre-Kindergarten through 12th grade.
The Bronx is the lowest income congressional district in the United States. This federal funding will upgrade the digital infrastructure and broadband capability across 99 schools, connecting more students and parents to Montefiore's telehealth services and primary care network.
"Congressmen Adriano Espaillat and Ritchie Torres fought hard and delivered in a big way for this program and this community. They know well that the children of The Bronx are the future of The Bronx," said Philip O. Ozuah, M.D., Ph.D., President and Chief Executive Office, Montefiore Medicine.
Between 25-30% of students (>14,000) who utilize MSHP services do so for chronic care conditions. Children with access to the support and resources made available by MSHP are 40% less likely to go home sick, resulting in stronger school performance and fewer workdays missed by parents. Emergency room visits and hospitalizations dropped by half after students started receiving treatment at MSHP clinics.
"This funding is transforming healthcare delivery in the highest-need areas of The Bronx — the increase in broadband and Wi-Fi connectivity will ensure nurses can access student health records quickly and that parents can advocate on their child's behalf without having to leave work," said Representative Adriano Espaillat. "Thanks to the decades-long commitment of Montefiore, 44,000 children — one of whom will likely take my place someday — will have free access to state-of-the-art healthcare services right at their school."
"This $3.3 million will transform the Montefiore program with faster, more reliable internet and secure videoconferencing software," said Representative Ritchie Torres. "The technology ensures that kids can get care when they need it, no matter what else is happening in the world."
About Montefiore Health System
Montefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 10 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
View original content to download multimedia:
SOURCE Montefiore Health System | https://www.wflx.com/prnewswire/2022/04/13/congressmen-espaillat-torres-deliver-more-than-33-million-montefiore-school-health-program/ | 2022-04-14T03:44:06 | 1 | https://www.wflx.com/prnewswire/2022/04/13/congressmen-espaillat-torres-deliver-more-than-33-million-montefiore-school-health-program/ |
PANAMA CITY, Panama, April 13, 2022 /PRNewswire/ -- Copa Holdings, S.A. (NYSE: CPA), today released preliminary passenger traffic statistics for March 2022:
Given the irregular nature of the Company's operations starting in March 2020 due to the Covid-19 pandemic, we will compare this and future traffic reports to 2019 statistics.
Consolidated capacity (ASMs) came in 8.4% lower than March 2019, while passenger traffic (RPMs) decreased 6.8%, which resulted in an 84.8% load factor.
Copa Holdings is a leading Latin American provider of passenger and cargo services. The Company, through its operating subsidiaries, provides service to countries in North, Central and South America and the Caribbean. For more information visit www.copaair.com.
CPA-G
CONTACT: Daniel Tapia – Panamá
Director – Investor Relations
011 (507) 304-2774
View original content:
SOURCE Copa Holdings, S.A. | https://www.wflx.com/prnewswire/2022/04/13/copa-holdings-announces-monthly-traffic-statistics-march-2022/ | 2022-04-14T03:44:13 | 1 | https://www.wflx.com/prnewswire/2022/04/13/copa-holdings-announces-monthly-traffic-statistics-march-2022/ |
NOVI, Mich., April 13, 2022 /PRNewswire/ -- DexKo Global Inc., the global leader in highly engineered trailer running gear, chassis assemblies, and related components, announces that its wholly-owned subsidiary, DEXTER Axle Company LLC ("DEXTER"), has acquired the business and assets of Premium Supply Ltd. ("Premium" or the "Company") located in Greenville, TX. DEXTER, headquartered in Elkhart, Indiana, employs over 3,800 people in the U.S. and Canada and operates 18 manufacturing facilities and over 30 company-owned distribution locations. Founded in 1960, Dexter has built a reputation as a trusted brand serving utility trailer, recreational vehicle, marine, heavy-duty, agricultural, specialty equipment manufacturers and distribution partners.
For over 25 years, Premium Supply has specialized in custom trailer hoists, hydraulic kits, pumps, controls, and accessories. The Company has distributed these quality products and kits to the tilt, dump, and utility trailer markets from a warehousing and kitting facility in Greenville, TX.
"Over the past six decades, DEXTER has developed the most diverse product offering in the industry," states Adam Dexter, President and CEO of DEXTER. "The Premium Supply business is a natural fit with the DEXTER organization. Their industry and product knowledge will enable our companies to better serve the marketplace."
"Together, we will drive exciting industry developments and offer a full range of towing solutions for our dump and tilt customers," adds Fred Bentley, CEO of DexKo Global. "Premium Supply customers should expect to see substantial benefits from DEXTER's extensive national footprint for servicing large and small OEMs, dealers and service centers in the dump trailer market. Additionally, our combined supply chain expertise will enhance our ability to service customers with just-in-time delivery."
"This partnership is a great cultural fit, aligning resources to further our goal of providing the best service and customer experience in the industry," Mark Huddleston, President of Premium Supply.
"I'm very excited to work with DEXTER and help bring hydraulics to their portfolio. With our knowledge of the hydraulic side of the industry and DEXTER's resources and customer relationships, this seems like a natural fit," adds Jeff Murphy, Shareholder of Premium Supply.
Please send inquiries to:
2900 Industrial Parkway East Stacey K. Miller, Director of Marketing
Elkhart, Indiana 46515 smiller@dexteraxle.com
Phone: 574.295.7888 Phone: 574.296.7228
Fax: 574.296.7368
DexKo Global Inc. is the world's leading supplier of advanced chassis technology, chassis assemblies and related components with more than 130 years of experience in trailer and caravan components. DexKo Global was founded at the end of 2015 through the combination of DEXTER and AL-KO Vehicle Technology. With its headquarters in Novi, Michigan, the company employs more than 7,000 associates with 52 production facilities and 49 distribution centers. For more information, please go to www.dexko.com
View original content to download multimedia:
SOURCE DexKo Global Inc. | https://www.wflx.com/prnewswire/2022/04/13/dexter-subsidiary-dexko-global-acquires-business-premium-supply/ | 2022-04-14T03:44:20 | 0 | https://www.wflx.com/prnewswire/2022/04/13/dexter-subsidiary-dexko-global-acquires-business-premium-supply/ |
MIDLAND, Mich., April 13, 2022 /PRNewswire/ -- Dow (NYSE: DOW) announced today that its board of directors has approved a new share buyback program for the repurchase of up to $3 billion of the Company's common stock. Additionally, Dow has declared a dividend of 70 cents per share, payable June 10, 2022, to shareholders of record on May 31, 2022. This marks the 443rd consecutive dividend payment by the Company or its affiliates since 1912.
"These actions reflect our continued focus to deliver leading cash flow generation and value growth as well as our ongoing commitment to disciplined and balanced capital allocation, where shareholder remuneration remains a key priority for Dow," said Jim Fitterling, Dow chairman and CEO. "Since spin in April 2019, we have returned a total of $8.4 billion to shareholders through our share repurchases and industry-leading dividend – well above our target, which is to return 65% of operating net income to shareholders across the economic cycle."
The $3 billion share repurchase program announced today does not have an expiration date and is additive to the current outstanding program, which has approximately $775 million of authorization remaining that the Company intends to repurchase by mid-2022.
About Dow
Dow (NYSE: DOW) combines global breadth; asset integration and scale; focused innovation and materials science expertise; leading business positions; and environmental, social and governance (ESG) leadership to achieve profitable growth and deliver a sustainable future. The Company's ambition is to become the most innovative, customer centric, inclusive and sustainable materials science company in the world. Dow's portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated, science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility and consumer applications. Dow operates 104 manufacturing sites in 31 countries and employs approximately 35,700 people. Dow delivered sales of approximately $55 billion in 2021. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visit www.dow.com or follow @DowNewsroom on Twitter.
For further information, please contact:
Investors:
Pankaj Gupta
+1 989-638-5265
pgupta@dow.com
Media:
Kyle Bandlow
+1 989-638-2417
kbandlow@dow.com
Twitter: https://twitter.com/DowNewsroom
Facebook: https://www.facebook.com/dow/
LinkedIn: http://www.linkedin.com/company/dow-chemical
Instagram: http://instagram.com/dow_official
Cautionary Statement about Forward-Looking Statements
Certain statements in this report are "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements often address expected future business and financial performance, financial condition, and other matters, and often contain words or phrases such as "anticipate," "believe," "estimate," "expect," "intend," "may," "opportunity," "outlook," "plan," "project," "seek," "should," "strategy," "target," "will," "will be," "will continue," "will likely result," "would" and similar expressions, and variations or negatives of these words or phrases.
Forward-looking statements are based on current assumptions and expectations of future events that are subject to risks, uncertainties and other factors that are beyond Dow's control, which may cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements and speak only as of the date the statements were made. These factors include, but are not limited to: sales of Dow's products; Dow's expenses, future revenues and profitability; the continuing global and regional economic impacts of the coronavirus disease 2019 ("COVID-19") pandemic and other public health-related risks and events on Dow's business; any sanctions, export restrictions, supply chain disruptions or increased economic uncertainty related to the ongoing conflict between Russia and Ukraine; capital requirements and need for and availability of financing; unexpected barriers in the development of technology, including with respect to Dow's contemplated capital and operating projects; Dow's ability to realize its commitment to carbon neutrality on the contemplated timeframe; size of the markets for Dow's products and services and ability to compete in such markets; failure to develop and market new products and optimally manage product life cycles; the rate and degree of market acceptance of Dow's products; significant litigation and environmental matters and related contingencies and unexpected expenses; the success of competing technologies that are or may become available; the ability to protect Dow's intellectual property in the United States and abroad; developments related to contemplated restructuring activities and proposed divestitures or acquisitions such as workforce reduction, manufacturing facility and/or asset closure and related exit and disposal activities, and the benefits and costs associated with each of the foregoing; fluctuations in energy and raw material prices; management of process safety and product stewardship; changes in relationships with Dow's significant customers and suppliers; changes in consumer preferences and demand; changes in laws and regulations, political conditions or industry development; global economic and capital markets conditions, such as inflation, market uncertainty, interest and currency exchange rates, and equity and commodity prices; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war including the ongoing conflict between Russia and Ukraine; weather events and natural disasters; disruptions in Dow's information technology networks and systems; and risks related to Dow's separation from DowDuPont Inc. such as Dow's obligation to indemnify DuPont de Nemours, Inc. and/or Corteva, Inc. for certain liabilities.
Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. A detailed discussion of principal risks and uncertainties which may cause actual results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. These are not the only risks and uncertainties that Dow faces. There may be other risks and uncertainties that Dow is unable to identify at this time or that Dow does not currently expect to have a material impact on its business. If any of those risks or uncertainties develops into an actual event, it could have a material adverse effect on Dow's business. Dow and TDCC assume no obligation to update or revise publicly any forward-looking statements whether because of new information, future events, or otherwise, except as required by securities and other applicable laws.
View original content to download multimedia:
SOURCE The Dow Chemical Company | https://www.wflx.com/prnewswire/2022/04/13/dow-announces-new-3-billion-share-repurchase-program-declares-quarterly-dividend-70-cents-per-share/ | 2022-04-14T03:44:26 | 1 | https://www.wflx.com/prnewswire/2022/04/13/dow-announces-new-3-billion-share-repurchase-program-declares-quarterly-dividend-70-cents-per-share/ |
TORONTO, April 13, 2022 /PRNewswire/ - Equitable Bank (the "Bank" or "Equitable"), a wholly owned subsidiary of Equitable Group Inc. (the "Company") (TSX: EQB) (TSX: EQB.PR.C) (TSX: EQB.R) today announced it is increasing its prime lending rates by 50 basis points to 3.20% from 2.70%, effective April 14, 2022.
Equitable Group Inc. trades on the Toronto Stock Exchange (TSX: EQB, EQB.PR.C and EQB.R) and serves more than 325,000 Canadians through its wholly-owned subsidiary Equitable Bank, Canada's Challenger Bank™. Equitable Bank has a clear mandate to drive change in Canadian banking to enrich people's lives. Founded over 50 years ago, Equitable Bank provides diversified personal and commercial banking services. Please visit equitablebank.ca for details.
Equitable Group Inc. trades on the Toronto Stock Exchange (TSX: EQB, EQB.PR.C and EQB.R) and serves more than 325,000 Canadians through its wholly-owned subsidiary Equitable Bank, Canada's Challenger Bank™. Equitable Bank has a clear mandate to drive change in Canadian banking to enrich people's lives. Founded over 50 years ago, Equitable Bank provides diversified personal and commercial banking services. Please visit equitablebank.ca for details.
View original content to download multimedia:
SOURCE Equitable Bank | https://www.wflx.com/prnewswire/2022/04/13/equitable-bank-increases-prime-rate/ | 2022-04-14T03:44:33 | 1 | https://www.wflx.com/prnewswire/2022/04/13/equitable-bank-increases-prime-rate/ |
RADNOR, Pa., April 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against SunPower Corporation ("SunPower") (NASDAQ: SPWR). The action charges SunPower with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of SunPower's materially misleading statements to the public, SunPower investors have suffered significant losses.
CLICK HERE TO SUBMIT YOUR SUNPOWER LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/spwr-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=tal&utm_content=sunpower
TO VIEW OUR VIDEO, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: APRIL 18, 2022
CLASS PERIOD: AUGUST 3, 2021 through JANUARY 20, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
SUNPOWER'S ALLEGED MISCONDUCT
SunPower provides solar energy solutions, including sales to its third-party dealer network and resellers, storage solutions, cash and loan sales, and long-term leases directly to end customers, and sells turn-key engineering, procurement, and construction services, as well as energy under power purchase agreements.
On January 21, 2022, SunPower issued a press release revealing that the company had "identified a cracking issue that developed over time in certain factory-installed connectors within third-party commercial equipment supplied to SunPower." As a result, SunPower reported that it "expects approximately $27 million of supplier-quality related charges in fourth quarter 2021 and approximately $4 million in the first quarter of 2022" to replace the faulty connectors.
Following this news, SunPower's stock fell $3.22, or 16.9%, to close at $15.80 on January 21, 2022.
WHAT CAN I DO?
SunPower investors may, no later than April 18, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages SunPower investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View original content to download multimedia:
SOURCE Kessler Topaz Meltzer & Check, LLP | https://www.wflx.com/prnewswire/2022/04/13/final-deadline-approaching-april-18-2022-kessler-topaz-meltzer-amp-check-llp-reminds-sunpower-corporation-investors-class-action-lawsuit-deadline/ | 2022-04-14T03:44:40 | 1 | https://www.wflx.com/prnewswire/2022/04/13/final-deadline-approaching-april-18-2022-kessler-topaz-meltzer-amp-check-llp-reminds-sunpower-corporation-investors-class-action-lawsuit-deadline/ |
LOS ANGELES, April 13, 2022 /PRNewswire/ -- Flyer Defense, LLC is strengthening its reputation as one of the most reliable internally air transportable light tactical mobility vehicles on the market with the start of production on its single largest direct commercial sales contract to date.
In partnership with the International Golden Group (IGG) in the United Arab Emirates, Flyer Defense completed initial shipment of its highly configurable Flyer 72 vehicle to the UAE Armed Forces and is set to enter full rate production by mid-2022.
Billed as a replacement for the High Mobility Multipurpose Wheeled Vehicle (popularly known as the Humvee), the Flyer vehicle supports field-installable armor and is cutting edge in its design, capabilities and modularity.
Selected for its uniquely adaptable platform, unmatched payload-to-weight ratio, and highly lauded maneuverability and ride quality, Flyer Defense will deliver its Flyer 72 vehicles to the UAE over a multiyear contract.
"We prioritize the user," said Flyer Defense Founder and CEO Oded Nechushtan. "Our tailorable engineering yields a flexible product, bendable to the will and need of any customer. We are proud to offer our proven solution to the UAE as we simultaneously continue to grow our manufacturing capabilities with strategic partnerships."
Flyer Defense is responsible for the design and sustainment of the successfully fielded USSOCOM Program of Record Ground Mobility Vehicle 1.1 (GMV 1.1) and directed requirement Army Ground Mobility Vehicle (A-GMV), with a combined total of more than 1,000 fielded vehicles now trusted and utilized by the U.S. Army and U.S. Special Forces (Army, Navy, Marines and Air Force).
The company has partnered with JWF Defense, LLC (JWF) to manufacture the Flyer 72 family of vehicles. Based in Johnstown, PA, JWF has nearly a decade of experience producing the body and chassis of Flyer's fielded vehicles and will provide the capacity for growth for both current and future contracts.
"We have spent decades fielding a platform superior in every way that counts," said Nechushtan. "We have the capability, experience and, most importantly, the product to meet the need of any military with a gap in light tactical mobility."
About Flyer Defense
Flyer Defense, LLC was formed to provide mission-specialized, lightweight, high mobility, all- terrain tactical wheeled vehicles capable of internal transport in rotary and tilt wing aircraft. Flyer provides purpose-built vehicles and logistics support for U.S. Army, special operations forces and global allies. Always prioritizing the users and their missions, Flyer vehicles increase ground mobility, allow rapid deployment into contested areas, and enable military ground forces to move quickly for extended distances and over difficult terrain. The Flyer® family of successfully tested and certified vehicles are modular platforms, allowing rapid vehicle customization for immediate operation-relevant configuration.
To learn more about Flyer Defense, please visit www.flyerdefense.com.
View original content to download multimedia:
SOURCE Flyer Defense LLC | https://www.wflx.com/prnewswire/2022/04/13/flyer-defense-begins-production-multiyear-contract-with-united-arab-emirates-armed-forces/ | 2022-04-14T03:44:46 | 1 | https://www.wflx.com/prnewswire/2022/04/13/flyer-defense-begins-production-multiyear-contract-with-united-arab-emirates-armed-forces/ |
- Genesis X Speedium Coupe showcases the future of Genesis' electric vehicle design
- Genesis announces plans to produce the Electrified GV70 in the U.S.
- Genesis Priority One, a personalized GV60 purchase experience, now open to clients in select U.S. markets
NEW YORK, April 13, 2022 /PRNewswire/ -- Today, Genesis premiered the Genesis X Speedium Coupe at Genesis House New York, a cultural space in Manhattan's Meatpacking District. The concept car incorporates Genesis' DNA, while looking ahead to the next wave of EVs and highlighting Genesis' future as a luxury electric vehicle brand.
The brand also announced plans for U.S. production of its upcoming Electrified GV70 SUV at its manufacturing facility in Montgomery, Ala. Production is set to start in December.
In a series of electrification-focused announcements, the brand also revealed its GV60 Priority One program for U.S. consumers.
Envisioning a new styling convention for the future
The Genesis X Speedium Coupe was born out of a "freestyle" design exercise based on the Genesis X Concept. Luc Donckerwolke, Genesis Chief Creative Officer and 2022 World Car Person of the Year led the initiative. It embodies the timeless Genesis' design philosophy, Athletic Elegance, in an even more progressive way.
The name Speedium was inspired by the Korean racetrack in the city of Inje and the passion for motorsport it inspired in Genesis designers. The name also encapsulates Genesis' belief that the emotional value of driving will remain strong in the era of electrification. The addition of the word "coupe" further accentuates the enjoyment of driving through aesthetic designs.
Genesis followed the principle of reductive design, or "less is more," for the concept car. The Genesis X Speedium Coupe stands out for its restrained elegance, clean lines, and subtle curves.
The model challenges the status quo of a defined car type. It is not a conventional concept car that previews plans for the production lineup.
"This car is an open-door moment in Genesis' journey towards our future EV design," said Luc Donckerwolke, chief creative officer of Genesis. "This isn't a show car — it's a look into our design processes as we explore ideas for the next wave of EVs, one that incorporates Genesis' DNA."
On the front of the vehicle, Genesis' signature Two Lines lamps have evolved into a full-width element that encompasses the shape of the crest resembling the Genesis Crest Grille. It was designed to carry the brand signature of the wing face for the electrification era by integrating the daytime running lamps with the low beam and high beam together. It carries an EV face that symbolizes Genesis' transformation towards becoming an all-electric car brand with a six-model lineup by 2030.
From an overhead perspective, the hourglass silhouette highlights the car's passion and character. The curvaceous and sensuous form accentuates the wheel arches creating muscular presence.
Viewed from the side, the Parabolic Line extending from the front to the rear of the car maintains a certain tension in the design as a classic car would. The deliberate "anti-wedge" design culminates in a streamlined look that exudes understated elegance.
Meanwhile, an elliptical tail balances out the look for a visually engaging tension between convex and concave surfaces in the rear. The V-shaped brake lights interrupt the circular shape by producing the striking contrast that is one of the hallmarks of a Genesis vehicle.
"We are giving each design element space to breathe," said Donckerwolke. "It's not about making the design elements compete with each other, but about orchestrating the elements so that they complement and respect one another."
The concept's metallic emerald green shade is referred to as "Inje Green." As expected of a car that was inspired by a Korean racetrack, the color encompasses the mountainous landscape where the track is located, completing the image of a classic car that embodies dynamism, speed, and timeless elegance.
Genesis Priority One
Genesis has shown significant growth in the U.S. market, setting monthly sales records for the past 16 months. The brand recorded 11,723 sales in Q1 2022, the largest quarterly sales achievement since its foray into the U.S. market in 2016.
Starting today, clients in select U.S. markets may enroll in Priority One, a program designed to curate a personalized purchase experience for GV60, the brand's first dedicated electric vehicle. By visiting www.genesis.com and providing their contact information and $500 refundable deposit, a Genesis Concierge will simplify the process and match clients with a qualified retailer.
"We are pleased to bring the highly-anticipated first Genesis EV to market in the U.S. with GV60," said Claudia Marquez, chief operating officer of Genesis Motor North America. "With Genesis Priority One, we are renewing our promise to our clients to provide a purchase experience tailored to them."
Genesis Priority One will be available at launch in California, Connecticut, New Jersey, and New York for a limited time while quantities last.
Production Plans for the Electrified GV70
Genesis announced that the Electrified Genesis GV70 will be its first vehicle produced in the U.S. at its manufacturing facility in Montgomery, Ala. Production is expected to begin in December 2022 with the goal of strengthening Genesis' EV market position in the region and continuing its commitment to electrification.
"We are pleased to bring Genesis production to the United States for the first time," said José Muñoz, president & CEO of Genesis Motor North America. "The GV70 SUV has won the hearts and minds of American consumers and industry experts alike. We are proud to begin offering consumers the new electrified model, built right here in America."
About Genesis House
Genesis House New York opened in November 2021 as the brand's base in the U.S. It's more than just a showroom — it's a cultural oasis in the heart of the city. Measuring over an acre of floorspace (over 46,000 square feet) and consisting of three floors, it carries forward the bold and innovative spirit of the brand by welcoming guests in a gracious manner that is deeply rooted in Korean culture.
The announcements took place during a press-only event at the Cellar Stage — a basement space outfitted with floor-to-ceiling LED-lit staging and state-of-the art audio-visual technology. Genesis holds numerous events at the Cellar Stage in collaboration with artists in the local community.
The first floor is an exhibition space where guests can experience the Genesis vehicle lineup, both existing models and concept cars that express the brand's future vision. The architects used tessellated mirrors to beautifully set off the cars on display, and curators are on hand to provide detailed explanations. The curator service at Genesis House is provided in English, Spanish, French, Chinese, and Korean, among other languages.
On the second floor, guests can enjoy a Korean cultural experience in the library, the Tea Pavilion, Genesis House Restaurant and the Terrace Garden.
Genesis House Restaurant, established in collaboration with Onjium — a Michelin-starred restaurant and traditional cultural research center in Seoul — offers a creative and elegant gastronomic experience that harkens back to the Korean Noble class cuisine that took inspirations from what Joseon-era royalty once enjoyed in their palaces.
At the event, the Genesis House Restaurant unveiled its new Spring menu, curated by Onjium.
The 9,493-square-foot Terrace Garden, located outside on the second floor, overlooks Hudson Yards, the Hudson River, and the High Line. Reminiscent of a courtyard outside a "hanok," or traditional Korean house, it is surrounded by low walls and an alley, serving as a cozy spot to enjoy a cup of coffee or tea.
Building upon the success of Genesis House New York, the brand is exploring future plans to open branded cultural spaces in other regions.
Genesis Gives
To mark the occasion and give back to the local New York community, Genesis presented a $50,000 donation to Girls Who Code, an organization whose mission is to close the gender gap in technology and to change the image of what a programmer looks like and does. Girls Who Code is building the largest pipeline of future female engineers in the world. In nine years, they have reached more than 450,000 girls globally.
This charitable contribution marks the continuation of Genesis Gives, a new initiative that supports STEAM (science, technology, engineering, arts, mathematics) education, sports, and athletics programming for youth. Genesis Gives has contributed more than $300,000 to causes across the United States since its launch in November 2021.
Genesis Motor North America
At Genesis, we put the customer at the center of every decision we make. Genesis is a global automotive brand that delivers the highest standards of performance, design, safety, and innovation while looking towards a more sustainable future. Genesis designs customer experiences that go beyond products, embodying audacious, forward-thinking, and distinctly Korean characteristics within its unique Athletic Elegance design identity. With a growing range of award-winning models — including the 2022 MotorTrend SUV of the Year, GV70, along with G70, G80, G90, GV60, and GV80 — Genesis aims to lead the age of electrification by focusing on a dual electrification strategy involving fuel-cell and battery EVs, starting with its Electrified G80 and GV60 electric models. Genesis has stated its commitment to becoming a 100% zero emission vehicle brand by 2030 and to pursuing carbon neutrality by 2035.
Please visit our media site for the latest news at www.genesisnewsusa.com.
View original content to download multimedia:
SOURCE Genesis Motor America | https://www.wflx.com/prnewswire/2022/04/13/genesis-debuts-new-concept-car-genesis-x-speedium-coupe-ev-focused-event/ | 2022-04-14T03:44:54 | 1 | https://www.wflx.com/prnewswire/2022/04/13/genesis-debuts-new-concept-car-genesis-x-speedium-coupe-ev-focused-event/ |
ATLANTA, April 13, 2022 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC) announced today an acquisition for its European Automotive business. Effective April 12, 2022, Alliance Automotive Group (AAG), the Company's wholly-owned automotive distribution company based in London, U.K., acquired Lausan Group (Lausan).
Lausan, founded in 1953 and based in Bilbao, Spain, is a leading distributor of automotive aftermarket parts in Spain and Portugal, which represent the 5th largest car parc in Europe. Lausan serves its customers from an established network, including one national distribution center, nine regional hubs and 37 stores. The Company expects Lausan to generate annual revenue of approximately €115 million ($125 million USD).
"We are pleased to expand our European automotive footprint with the addition of Lausan," said Paul Donahue, Chairman and Chief Executive Officer of GPC. "With our entry into Spain and Portugal, we expect to further strengthen Lausan's market-leading position by capitalizing on our European scale and purchasing expertise, as well as leveraging the roll-out of our NAPA brand across this region. We welcome the Lausan team to the GPC and AAG family and are excited to work together to maximize the growth opportunities in our European business."
With the addition of Lausan, AAG operates in nine European countries: France, the UK, Ireland, Germany, the Netherlands, Belgium, Poland, Spain and Portugal.
Forward Looking Statements
This press release contains "forward-looking statements" that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in the future tense and all statements accompanied by words such as "expected," "opportunities," "look forward," or similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements regarding the acquisition of Lausan by GPC's subsidiary, AAG, including those relating to the revenues expected to be generated by Lausan and AAG's ability to further strengthen Lausan's market position. Forward-looking statements are based on information currently available to GPC and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed acquisition, these risks, uncertainties and factors include, but are not limited to: the risk that Lausan will not be integrated successfully; the risk that the cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; and the risk that costs associated with the integration of the business are higher than anticipated.
Additional information regarding other risks and uncertainties that may impact GPC and its operations are also contained in GPC's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission.
Many of these risks, uncertainties and assumptions are beyond GPC's ability to control or predict. Because of these risks, uncertainties and assumptions, actual results may vary materially, and you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and GPC does not undertake any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of such communication, except as required by law.
Forward-looking statements are only as of the date they are made, and the Company undertakes no duty to update any forward-looking statements except as required by law. You are advised, however, to review any further disclosures we make on related subjects in our subsequent Forms 10-K, 10-Q, 8-K and other reports filed with the SEC.
About Genuine Parts Company
Founded in 1928, Genuine Parts Company is a global service organization engaged in the distribution of automotive and industrial replacement parts. The Company's Automotive Parts Group distributes automotive replacement parts in the U.S., Canada, Mexico, Australasia, France, the U.K., Ireland, Germany, Poland, the Netherlands, Belgium, Spain and Portugal. The Company's Industrial Parts Group distributes industrial replacement parts in the U.S., Canada, Mexico and Australasia. In total, the Company serves its global customers from an extensive network of more than 10,000 locations in 17 countries and has approximately 52,000 employees. Further information is available at www.genpt.com.
About Alliance Automotive Group
Alliance Automotive Group is a leading distributor of light and commercial vehicle parts to the independent aftermarket in France, the U.K., Ireland, Germany, Poland, the Netherlands, Belgium, Spain and Portugal. AAG does business under the Groupauto France, Precisium Group and Pièces Auto in France, Groupauto UK and UAN in the UK, Groupauto Ireland in Ireland, Alliance Automotive Group Germany in Germany, Groupauto Poland in Poland, Partspoint, Precisium and Winparts in the Netherlands and Belgium and Lausan and Soulima in Spain and Portugal. AAG serves approximately 50,000 garages with over 100,000 different parts for repair and maintenance from a network of more than 700 company-owned stores and more than 1,700 affiliated outlets. Further information is available at www.allianceautomotivegroup.eu.
Source: Genuine Parts Company
View original content to download multimedia:
SOURCE Genuine Parts Company | https://www.wflx.com/prnewswire/2022/04/13/genuine-parts-company-announces-automotive-acquisition-europe-expanding-presence-into-key-new-markets-spain-portugal/ | 2022-04-14T03:45:01 | 0 | https://www.wflx.com/prnewswire/2022/04/13/genuine-parts-company-announces-automotive-acquisition-europe-expanding-presence-into-key-new-markets-spain-portugal/ |
Company recognized as top gaming supplier in acclaimed global awards program
LONDON, April 13, 2022 /PRNewswire/ -- International Game Technology PLC ("IGT") (NYSE: IGT) announced today that it recently won the "Casino Supplier of the Year" award at the 2022 Global Gaming Awards London. This marks the second year in a row that the Company received the notable honor.
The annual EMEA-focused awards program, led by Gambling Insider magazine, recognizes the gaming industry's strongest performers across the previous 12 months. Winners were selected by a panel of 60 gaming industry executives and announced during an awards ceremony on April 11, 2022.
"Once again, IGT has confirmed its position as the industry's leading end-to-end casino supplier by winning this distinguished award at the 2022 Global Gaming Awards London," said Renato Ascoli, IGT CEO Global Gaming. "This significant recognition is a reflection of IGT's dedicated employees worldwide and our commitment to developing and supplying superior products and services to our customers that drive outstanding results."
"IGT has proven that it continues to lead the industry by providing casinos with exceptional products that create best-in-class user experiences for their customers," said Julian Perry, Gambling Insider Chief Operating Officer. "It is an honor to recognize IGT's position as a leading global casino supplier with this highly regarded award for the second year in a row."
To learn more about the Global Gaming Awards London, click here. For more information, visit IGT.com, follow us on Facebook, LinkedIn, and Twitter, or watch IGT videos on YouTube.
About IGT
IGT (NYSE:IGT) is a global leader in gaming. We deliver entertaining and responsible gaming experiences for players across all channels and regulated segments, from Lotteries and Gaming Machines to Sports Betting and Digital. Leveraging a wealth of compelling content, substantial investment in innovation, player insights, operational expertise, and leading-edge technology, our solutions deliver unrivaled gaming experiences that engage players and drive growth. We have a well-established local presence and relationships with governments and regulators in more than 100 countries around the world, and create value by adhering to the highest standards of service, integrity, and responsibility. IGT has approximately 10,500 employees. For more information, please visit www.igt.com.
Contact:
Phil O'Shaughnessy, Global Communications, toll free in U.S./Canada +1 (844) IGT-7452; outside U.S./Canada +1 (401) 392-7452
Francesco Luti, +39 06 5189 9184; for Italian media inquiries
James Hurley, Investor Relations, +1 (401) 392-7190
© 2022 IGT
The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.
View original content to download multimedia:
SOURCE International Game Technology PLC | https://www.wflx.com/prnewswire/2022/04/13/igt-wins-second-consecutive-casino-supplier-year-honor-2022-global-gaming-awards-london/ | 2022-04-14T03:45:08 | 1 | https://www.wflx.com/prnewswire/2022/04/13/igt-wins-second-consecutive-casino-supplier-year-honor-2022-global-gaming-awards-london/ |
The Santa Barbara & Ventura Colleges of Law launches new identity and rebrand
SANTA BARBARA, Calif. and VENTURA, Calif., April 13, 2022 /PRNewswire/ -- The Santa Barbara & Ventura Colleges of Law (COL) is changing its name. The nonprofit law school with campuses in Ventura and Santa Barbara is introducing a new identity, rebranding as "The Colleges of Law."
With the change comes a new logo that showcases a foundation in law using classic pillars, signifying traditional legal education with forward momentum that captures the college's commitment to innovation and progress. The column iconography represents something being built and still taking shape—a modern take on a classic design feature. It will be the school's first brand update since 2010 while streamlining its various naming conventions—Ventura College of Law, Santa Barbara College of Law, The Santa Barbara & Ventura Colleges of Law—into one.
"It's a project more than 50 years in the making," said The Colleges of Law President Matthew Nehmer, Ph.D. "We were founded in Ventura in 1969 with Santa Barbara forming five years later. We've been using 'The Colleges of Law' informally for years. Our new identity simply makes it official with a look that communicates a school committed to innovation and building something new."
The rebrand is among the signature initiatives featured in COL's current strategic plan. Key stakeholders—including students, faculty, alumni, and trustees—contributed to the effort through focus groups and other feedback channels.
"We learned that the Ventura and Santa Barbara campuses are an important part of the COL legacy," said Alison Baumann, vice president of marketing at TCS Education System and COL's brand manager. "We took this feedback to heart and created variations of the logo that identifies the school's founding locations."
The new identity debuted on the COL website on April 12 and will eventually be featured on campus signage, advertisements, and other places in the weeks to come. Read an FAQ about the project.
About The Colleges of Law
Established in 1969, The Colleges of Law (COL) was founded to expand opportunities and broaden access to legal education. COL is dedicated to a student-centered approach that affords students of diverse backgrounds the opportunity to pursue careers in law or legal-related fields. COL's faculty advances a real-world perspective and practicality on the application of law and includes practicing attorneys, judges, public servants, and leaders in business and nonprofit organizations. An accredited nonprofit institution, COL offers a Juris Doctor (J.D.) and a Master of Arts in Law (M.A.L.) program. Additionally, in the fall of 2018, COL became the first accredited law school in California to offer a hybrid J.D. degree. COL is accredited by the WASC Senior College and University Commission (WSCUC). The Juris Doctor program is accredited by the Committee of Bar Examiners (CBE) of the State Bar of California. For more information, visit www.collegesoflaw.edu.
View original content to download multimedia:
SOURCE The Colleges of Law | https://www.wflx.com/prnewswire/2022/04/13/introducing-colleges-law/ | 2022-04-14T03:45:15 | 1 | https://www.wflx.com/prnewswire/2022/04/13/introducing-colleges-law/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- Spark451, advised by JEGI CLARITY, has been sold to Jenzabar.
Based in Westbury, NY, Spark451 is a full-service marketing and technology firm providing enrollment strategies for the higher education market. The firm specializes in enrollment marketing, student search, creative services, and digital media, serving over 200 higher education institutions. Since its inception in 2011, Spark451 has been renowned for its creative enrollment marketing strategies.
With the acquisition of Spark451, Jenzabar can offer even deeper enrollment strategy expertise and full-service marketing capabilities, including more complete support for institutional enrollment, retention, operations, management, and digital transformation initiatives. The addition of Spark451's renowned use of data and strategic marketing techniques, including analytics and predictive modeling, helps colleges build or rebuild their brands, which has proven to achieve far-reaching enrollment goals by attracting a new student demographic.
Commenting on the transaction, the Spark451 Founders said, "The JEGI CLARITY team helped us cast a wide net and manage a thorough process to position Spark451 with a partner that will accelerate our distribution and growth. The team demonstrated a thorough understanding of our industry and was energized to learn more and present the business's strengths. Their work helped us describe our business clearly. A dedication to remain unbiased while moving us towards the best outcome was core to their approach and made for constructive dialogue and decision making along the way. Contemplating a combination for one's business could be daunting or unthinkable. JEGI CLARITY's approach and range of abilities made the process manageable and ultimately fruitful. We could not have dreamed up a better team."
About JEGI CLARITY
JEGI CLARITY is a pre-eminent M&A advisory firm for the media, marketing, information and technology industries. With a global reach from New York, London, Boston, Sydney and San Francisco, we have closed more than 800 transactions during our 30+ year history. For more information, visit www.jegiclarity.com.
Contact: Kelsey Kovachik, Marketing Director
+1 212 754 0710 | kkovachik@jegiclarity-us.com |
www.jegiclarity.com
View original content to download multimedia:
SOURCE JEGI CLARITY | https://www.wflx.com/prnewswire/2022/04/13/jegi-clarity-has-advised-spark451-their-sale-jenzabar/ | 2022-04-14T03:45:22 | 0 | https://www.wflx.com/prnewswire/2022/04/13/jegi-clarity-has-advised-spark451-their-sale-jenzabar/ |
Veteran industry executive to direct Washington, D.C. office, spearhead resiliency funding opportunity
NEW ORLEANS, April 13, 2022 /PRNewswire/ -- Entergy today announced that John O. Hudson III has been named senior vice president, federal policy, regulatory and government affairs. He will report to Marcus Brown, executive vice president and general counsel, and will join the company effective April 22.
"John brings proven executive level utility leadership and a wide range of critically important experiences to this role," said Brown. "We are excited to welcome John as a new leader. In particular, he will help us listen to and engage our stakeholders as he drives important conversations around federal policy related to the reduction of carbon emissions and investments in electric infrastructure and resiliency."
Hudson will be responsible for several key groups focused on Federal Energy Regulatory Commission issues, sustainability and environmental policy, federal governmental affairs and corporate social responsibility. Of particular importance will be John's strategic direction of a recently established team directing the company's efforts to secure infrastructure funding through the federal government's $1.2 trillion Infrastructure Investment and Jobs Act. The law includes $62 billion targeted specifically for clean energy and resiliency investments that could further serve as an economic development engine for the communities in Entergy's service areas.
"A major component of implementing this law will be stakeholder engagement and coordination," added Brown. "John will oversee those vital efforts and partner with senior leaders, technical team members and others throughout the company to ensure alignment and accountability as we serve our customers across the Gulf South region."
Hudson will replace Mike Twomey, who is retiring from Entergy after having served in several roles over the last 20 years.
Prior to joining Entergy, Hudson served as president and chief executive officer of Nicor Gas Corporation, Illinois' largest gas distribution company, which reached more than 2.2 million customers. Previously, Hudson was executive vice president and chief external affairs officer at Southern Company Gas, where he was responsible for the company's external affairs, customer operations, environmental affairs, corporate communications, and marketing efforts.
Hudson received an MBA from Georgia Tech Scheller College of Business, a Juris Doctor from Miles College School of Law, and a bachelor's degree in political science from Alabama A&M University. He also completed the executive accounting and finance program at the University of Pennsylvania Wharton School of Business and the Young American Leaders Program at Harvard Business School.
About Entergy
Entergy (NYSE: ETR), a Fortune 500 company headquartered in New Orleans, powers life for 3 million utility customers across Arkansas, Louisiana, Mississippi and Texas. Entergy is creating a cleaner, more resilient energy future for everyone with our diverse power generation portfolio, including increasingly carbon-free energy sources. With roots in the Gulf South region for more than a century, Entergy is a recognized leader in corporate citizenship, delivering more than $100 million in economic benefits to local communities through philanthropy and advocacy efforts annually over the last several years. Our approximately 12,500 employees are dedicated to powering life today and for future generations. Learn more at entergy.com and follow @Entergy on social media. #WePowerLife
Download a high-resolution Entergy logo here.
View original content to download multimedia:
SOURCE Entergy Corporation | https://www.wflx.com/prnewswire/2022/04/13/john-o-hudson-iii-joins-entergy-senior-vice-president-federal-policy-regulatory-government-affairs/ | 2022-04-14T03:45:29 | 1 | https://www.wflx.com/prnewswire/2022/04/13/john-o-hudson-iii-joins-entergy-senior-vice-president-federal-policy-regulatory-government-affairs/ |
Wendell Dallas named president and CEO of Nicor Gas
ATLANTA, April 13, 2022 /PRNewswire/ -- John O. Hudson, III, president and CEO of Nicor Gas, will be retiring effective April 22. He has accepted another executive position with Entergy Corporation.
In his more than 22 years with Southern Company, Hudson, who served in executive leadership roles at Southern Company Gas and Alabama Power Company, has made significant contributions in many areas of the company.
"John is a respected leader who has been instrumental to several important company, customer and community initiatives that have been integral to our organizational evolution, growth and success," said Kim Greene, chairman, president, and CEO of Southern Company Gas. "He has brought creative thinking and a passion for innovation to the forefront of our business, and I know he will continue to be successful in his new position with Entergy."
Prior to serving as president and CEO of Nicor Gas, Hudson served as executive vice president and chief external and public affairs officer at Southern Company Gas. Before assuming that role, Hudson served in several executive positions at Alabama Power.
Dallas takes over at Nicor Gas
With Hudson's retirement, Wendell Dallas has been named president and CEO of Nicor Gas, the largest natural gas distribution company in the state of Illinois, serving more than 2.2 million homes and businesses in over 650 northern Illinois communities.
"Wendell is uniquely qualified to take the reins at Nicor Gas having spent more than 25 years in the natural gas industry," Greene said. "His broad experience across operations, marketing and engineering — as well as his external focus on customers and communities — makes him the ideal person to lead the organization at this crucial time. I am confident that under his leadership, Nicor Gas will continue to thrive, not only providing clean, safe, reliable and affordable natural gas, but also serving as an innovator and economic driver as well."
Dallas most recently served as vice president of sales and marketing for Georgia Power Company. In this role, he led the implementation of the company's topline revenue growth strategy. He was responsible for new product development, product distribution, e-commerce, sales management, and energy efficiency.
Prior to his role at Georgia Power Company, Dallas served as vice president of operations for two Southern Company Gas subsidiaries, Atlanta Gas Light and Chattanooga Gas. In this role, he was responsible for ensuring the company's operational excellence in delivering clean, safe, reliable, and affordable natural gas to more than 700,000 customers in five Georgia and Tennessee regions. He also served as Vice President of Economic Development.
Very active in the community, Dallas has served on several non-profit, community and energy industry boards including serving as co-chair of the Georgia Literacy Commission, a business-led commission of the Georgia Chamber of Commerce, the Georgia Partnership for Excellence in Education and Literacy For All. Wendell is a gubernatorial appointee and board chairman of the state of Georgia's Workforce Development Board. He's also served on the boards of the Georgia Chamber of Commerce and the Auburn University Engineering Alumni Council.
A native of Opelika, Alabama, Wendell earned a degree in mechanical engineering from Auburn University. Additionally, he is a graduate of Leadership Georgia, Leadership Atlanta and Leadership Savannah.
About Southern Company Gas
Southern Company Gas is a wholly owned subsidiary of Atlanta-based Southern Company (NYSE:SO), America's premier energy company. Southern Company Gas serves approximately 4.3 million natural gas customers through its regulated distribution companies in four states with more than 600,000 retail customers through its companies that market natural gas. Other businesses include investments in interstate pipelines and ownership and operation of natural gas storage facilities. For more information, visit southerncompanygas.com.
View original content to download multimedia:
SOURCE Southern Company Gas | https://www.wflx.com/prnewswire/2022/04/13/john-o-hudson-iii-retires-southern-company-gas-accepts-external-executive-position/ | 2022-04-14T03:45:35 | 0 | https://www.wflx.com/prnewswire/2022/04/13/john-o-hudson-iii-retires-southern-company-gas-accepts-external-executive-position/ |
BOSTON, April 13, 2022 /PRNewswire/ -- Below is the March 2022 Monthly Update for the Liberty All-Star Equity Fund. (NYSE: USA)
Liberty All-Star Equity Fund
Ticker: USA
Monthly Update, March, 2022
Investment Approach:
Fund Style: Large-Cap Core
Fund Strategy: Combines three value-style and two growth-style investment managers. Those selected demonstrate a consistent investment philosophy, decision making process, continuity of key people and above-average long-term results compared to managers with similar styles.
Investment Managers:
Value Managers:
Aristotle Capital Management, LLC
Fiduciary Management, Inc.
Pzena Investment Management, LLC
Growth Managers:
Sustainable Growth Advisers, LP
TCW Investment Management Company
New Holdings
Avery Dennison Corp.
Carlisle Cos., Inc.
CDW Corp.
Enphase Energy, Inc.
Holdings Liquidated
Cenovus Energy, Inc.
The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund's portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.
Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.
Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.
Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2022 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consists of a return of capital. These estimates may not match the final tax characterization (for the full year's distributions) contained in shareholder 1099-DIV forms after the end of the year.
All data is as of March 31, 2022 unless otherwise noted.
Liberty All-Star® Equity Fund
1-800-241-1850
www.all-starfunds.com
libinfo@alpsinc.com
View original content to download multimedia:
SOURCE Liberty All-Star® Equity Fund | https://www.wflx.com/prnewswire/2022/04/13/liberty-all-star-equity-fund-march-2022-monthly-update/ | 2022-04-14T03:45:42 | 0 | https://www.wflx.com/prnewswire/2022/04/13/liberty-all-star-equity-fund-march-2022-monthly-update/ |
BOSTON, April 13, 2022 /PRNewswire/ -- Below is the March 2022 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG)
Liberty All-Star Growth Fund, Inc.
Ticker: ASG
Monthly Update, March, 2022
Investment Approach:
Fund Style: All-Cap Growth
Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor.
New Holdings
Ecolab, Inc.
US Physical Therapy, Inc.
Holdings Liquidated
Apria, Inc.
Meta Platforms, Inc.
The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund's portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount.
Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results.
Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal.
Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2022 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates no portion of the distributions consists of a return of capital. These estimates may not match the final tax characterization (for the full year's distributions) contained in shareholder 1099-DIV forms after the end of the year.
All data is as of March 31, 2022 unless otherwise noted.
Liberty All-Star® Growth Fund, Inc.
1-800-241-1850
www.all-starfunds.com
libinfo@alpsinc.com
View original content to download multimedia:
SOURCE Liberty All-Star Growth Fund, Inc. | https://www.wflx.com/prnewswire/2022/04/13/liberty-all-star-growth-fund-inc-march-2022-monthly-update/ | 2022-04-14T03:45:49 | 1 | https://www.wflx.com/prnewswire/2022/04/13/liberty-all-star-growth-fund-inc-march-2022-monthly-update/ |
Focusing on removing the stigma associated with hearing health, fio™ is a product engineered with the consumer in mind.
FORTWORTH, Texas, April 13, 2022 /PRNewswire/ -- As part of their continued customer-focused approach Lucid Hearing launches one of the industry's most technologically advanced hearing aids. Developed by leveraging over 20 years of hearing health experience and a focus on the main consumer concern around discreet fit, fio, is Lucid Hearing's smallest in-canal, rechargeable hearing aid.
"Fio is focused on delivering the most comfortable fit and function for the active individual who is looking to maximize every moment of their lives. Hearing health is a right of every individual and our goal at Lucid Hearing is to simply help people hear better" said Jason Kidd, CEO Lucid Hearing "and part of that responsibility is to make products that are ready for use, discreet in nature and empower the end user to customize their hearing profile."
Compatible with LucidShape™, fio allows the user to develop custom hearing levels for all types of environments making wearing fio a way to bring the user back into the conversation.
For more information visit fiohears.com
About Lucid Hearing:
Lucid Hearing's mission is to advance hearing healthcare holistically across our family of brands that encompass hearing enhancement, enjoyment, protection, detection, and wellness. We believe every human should have access to better hearing, and we are proud to offer free online and in-store assessments at over 500 Lucid Hearing clinics nationwide.
View original content to download multimedia:
SOURCE Lucid Hearing | https://www.wflx.com/prnewswire/2022/04/13/lucid-hearing-launches-one-industrys-most-discreet-in-ear-hearing-devices-consumers/ | 2022-04-14T03:45:56 | 0 | https://www.wflx.com/prnewswire/2022/04/13/lucid-hearing-launches-one-industrys-most-discreet-in-ear-hearing-devices-consumers/ |
VANCOUVER, BC, April 13, 2022 /PRNewswire/ - Ritchie Bros. (NYSE: RBA) and (TSX: RBA) invites interested parties to participate in its First quarter 2022 earnings conference call, occurring on Tuesday, May 10, 2022, at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time / 4:00 p.m. BST. During the call, company executives will discuss Ritchie Bros.' earning results and answer questions from analysts and institutional investors. The Company's First quarter 2022 earnings results will be released after NYSE and TSX markets close the day prior, on May 9, 2022.
Analysts and institutional investors may participate via conference call, using the following dial-in information:
1-888-664-6392 (toll-free North America)
08006522435 (toll-free UK)
1-416-764-8659 (Toronto & overseas long-distance)
Please ask to participate in Ritchie Bros.' First quarter 2022 earnings call, and quote conference ID 15588553 if prompted.
Media and other interested parties may listen to the conference call via webcast, by selecting the First quarter 2022 earnings call webcast link at https://investor.ritchiebros.com.
Please note that there will be presentation slides accompanying the earnings call. The slides will be displayed live on the webcast, and will be available to download via the webcast player or at https://investor.ritchiebros.com/events-and-presentations the morning of the call.
A replay of the conference call can be accessed after 2:00 pm Eastern time / 11:00 am Pacific time / 7:00 pm BST until June 10, 2022, at 416-764-8677 or 1-888-390-0541 (using passcode 588553 #).
About Ritchie Bros.:
Established in 1958, Ritchie Bros. (NYSE and TSX: RBA) is a global asset management and disposition company, offering customers end-to-end solutions for buying and selling used heavy equipment, trucks and other assets. Operating in a number of sectors, including construction, transportation, agriculture, energy, mining, and forestry, the company's selling channels include: Ritchie Bros. Auctioneers, the world's largest industrial auctioneer offering live auction events with online bidding; IronPlanet, an online marketplace with weekly featured auctions and providing the exclusive IronClad Assurance® equipment condition certification; Marketplace-E, a controlled marketplace offering multiple price and timing options; Ritchie List, a self-serve listing service for North America; Mascus, a leading European online equipment listing service; Ritchie Bros. Private Treaty, offering privately negotiated sales; and sector-specific solutions GovPlanet, TruckPlanet, and Kruse Energy. The Company's suite of solutions also includes Ritchie Bros. Asset Solutions and Rouse Services LLC, which together provides a complete end-to-end asset management, data-driven intelligence and performance benchmarking system; SmartEquip, an innovative technology platform that supports customers' management of the equipment lifecycle and integrates parts procurement with both OEMs and dealers; plus equipment financing and leasing through Ritchie Bros. Financial Services. For more information about Ritchie Bros., visit RitchieBros.com.
View original content:
SOURCE Ritchie Bros. Auctioneers | https://www.wflx.com/prnewswire/2022/04/13/media-advisory-ritchie-bros-host-first-quarter-2022-results-earnings-conference-call-may-10-2022/ | 2022-04-14T03:46:02 | 1 | https://www.wflx.com/prnewswire/2022/04/13/media-advisory-ritchie-bros-host-first-quarter-2022-results-earnings-conference-call-may-10-2022/ |
RANDOR, Pa., April 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PLAYSTUDIOS, Inc. ("PLAYSTUDIOS") (NASDAQ: MYPS; MYPSW) f/k/a Acies Acquisition Corp. ("Acies") (NASDAQ: ACAC; ACACW). The action charges PLAYSTUDIOS with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. The lawsuit also includes claims relating to a merger transaction with Acies and asserts claims on behalf of investors who held Acies common stock as of May 25, 2021, were eligible to vote at Acies' June 17, 2021 special meeting, and who exchanged their shares of Acies stock for PLAYSTUDIOS stock in connection with the merger. As a result of PLAYSTUDIOS' materially misleading statements to the public, PLAYSTUDIOS' investors have suffered significant losses.
CLICK HERE TO SUBMIT YOUR PLAYSTUDIOS LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/playstudios-inc?utm_source=PR&utm_medium=link&utm_campaign=playstudios
TO VIEW OUR VIDEO, PLEASE CLICK HERE
LEAD PLAINTIFF DEADLINE: JUNE 6, 2022
CLASS PERIOD: JUNE 22, 2021 THROUGH MARCH 1, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. at (484) 270-1453 or via email at info@ktmc.com
THE CLASS INCLUDES: Investors who (1) purchased or acquired PLAYSTUDIOS securities between June 22, 2021 and March 1, 2022, including, but not limited to, those who purchased or acquired PLAYSTUDIOS securities pursuant to the offering of the private investment in public equity; (2) held Acies common stock as of May 25, 2021, and were eligible to vote at Acies' June 17, 2021 special meeting who exchanged their Acies stock for PLAYSTUDIOS stock; or (3) purchased or acquired PLAYSTUDIOS common stock pursuant or traceable to the Acies' Registration Statement and Proxy Statement issued in connection with the June 2021 merger.
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
PLAYSTUDIOS' ALLEGED MISCONDUCT
On February 1, 2021, Acies, a special purpose acquisition company, announced that it had reached a merger agreement with "Old Playstudios," a privately-held gaming company (the "Merger"). PLAYSTUDIOS' flagship game was Kingdom Boss. PLAYSTUDIOS told investors that "Kingdom Boss, which began development in 2020, will launch as expected in the second half of 2021."
On June 17, 2021, Acies held a General Meeting where Acies shareholders were asked to approve
the Merger. The Merger closed on June 21, 2021, and on June 22, 2021, PLAYSTUDIOS stock and warrants began publicly trading on NASDAQ.
The truth began to be revealed on August 11, 2021, when PLAYSTUDIOS released its financial results for the second quarter of 2021 wherein PLAYSTUDIOS revealed for the first time that the Kingdom Boss launch was being delayed until later in the year and that investors should expect decreased revenues and profits during the year as a result. These quarterly financial results were finalized on June 30, 2021, just nine days after the Merger closed. Thus, defendants knew or recklessly disregarded prior to the merger close (June 21, 2021) and prior to the merger vote by the Acies shareholders (June 17, 2021), that Kingdom Boss would not be ready to launch within just a matter of weeks. Following this news, PLAYSTUDIOS stock price fell $.66 to close at $5.09 per share on August 12, 2021, a decline of 13%.
Then, on February 24, 2022, during an earnings call for the fourth quarter ended December 31, 2021, PLAYSTUDIOS' CEO, much to investors' surprise, disclosed that Kingdom Boss would not be launched at all. Following this news, PLAYSTUDIOS stock price fell $.24 to close at $4.86 per share on February 25, 2022, a decline of 5%. Two days later, on February 26, 2022, PLAYSTUDIOS' CEO attributed the failure to meet the projections made for revenue and earnings to the failure to launch Kingdom Boss, and revealed that Kingdom Boss was not only delayed, but indefinitely "suspended."
WHAT CAN I DO?
Current PLAYSTUDIOS investors and/or former Acies shareholders may, no later than June 6, 2022 seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages PLAYSTUDIOS investors and/or former Acies shareholders who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View original content to download multimedia:
SOURCE Kessler Topaz Meltzer & Check, LLP | https://www.wflx.com/prnewswire/2022/04/13/myps-equity-alert-kessler-topaz-meltzer-amp-check-llp-announces-that-securities-fraud-class-action-lawsuit-filed-against-playstudios-inc/ | 2022-04-14T03:46:09 | 0 | https://www.wflx.com/prnewswire/2022/04/13/myps-equity-alert-kessler-topaz-meltzer-amp-check-llp-announces-that-securities-fraud-class-action-lawsuit-filed-against-playstudios-inc/ |
-- Exhibitors from 38 countries, one-fourth of attendees expected from outside the U.S. --
WASHINGTON, April 13, 2022 /PRNewswire/ -- NAB Show the world's largest annual conference for broadcast , entertainment and technology professionals, will host attendees from 154 countries and exhibiting companies from 38 nations at the 2022 NAB Show, held April 23 – 27 in Las Vegas, Nev.
Attendees from outside the U.S. make up nearly one-quarter of all pre-registered 2022 NAB Show attendees, which closely mirrors the 2019 NAB Show percentage.
"At a time when content can travel around the world in a blink of an eye, there is nothing like NAB Show to help the content community discover the tools, trainings and insights that will unleash the next global phenomenon," said Chris Brown, NAB executive vice president and managing director of Global Connections and Events. "We are excited to welcome back our friends and partners from all across the globe as our industry gets back to doing business in-person."
NAB Show participates in the U.S. Department of Commerce's Trade Event Partnership Program, which recruits international trade delegations to select U.S. trade shows and connects international buyers with U.S. suppliers.
Delegations attending NAB Show include Brazil, Columbia, Germany, India, Japan, Mexico, Nigeria, Panama, Peru, Turkey, Vietnam and more.
NAB Show's exhibit floor, located in the North Hall, Central Hall and the newly constructed West Hall of the Las Vegas Convention Center, will host 358 exhibitors from 42 countries outside of the United States, including United Kingdom, Canada, Germany, Belgium and France. The exhibition will also host the following pavilions:
- Bavarian Pavilion - Central Hall
- Brazilian Pavilion – North Hall
- French Pavilion – West Hall
- Great Britain & Northern Ireland Pavilion – North Hall
- Global Trade Show Row – West Hall
Additionally, several international organizations, including the Brazilian Society of Television Engineering (SET), will host meetings for their members at NAB Show. Demonstrations of global technologies currently deployed outside of the U.S. will also be conducted by broadcasters and other media and entertainment companies throughout the Show.
Register as press for the 2022 NAB Show.
About NAB Show
NAB Show, held April 23 – 27, 2022, in Las Vegas, is the premier event for content professionals in the media, entertainment and technology ecosystem. It is the ultimate marketplace for those seeking to create superior audio and video experiences. From creation to consumption, across multiple platforms, NAB Show is where global visionaries convene to bring content to life in new and exciting ways. For complete details, visit www.nabshow.com.
About NAB
The National Association of Broadcasters is the premier advocacy association for America's broadcasters. NAB advances radio and television interests in legislative, regulatory and public affairs. Through advocacy, education and innovation, NAB enables broadcasters to best serve their communities, strengthen their businesses and seize new opportunities in the digital age. Learn more at www.nab.org.
View original content to download multimedia:
SOURCE National Association of Broadcasters | https://www.wflx.com/prnewswire/2022/04/13/nab-show-ready-welcome-exhibitors-delegations-around-world/ | 2022-04-14T03:46:17 | 0 | https://www.wflx.com/prnewswire/2022/04/13/nab-show-ready-welcome-exhibitors-delegations-around-world/ |
Exclusive attributes will allow collectors to gain photographs and journals from voyage
TROMSØ, Norway, April 13, 2022 /PRNewswire/ -- On April 18th, 2022, a group of Swiss and American explorers will untie from Old Harbor in Tromsø to embark on a carbon-neutral two-week exploratory journey across the Barents Sea. Guided by legendary skipper Rasmus Jacobsen, the crew will sail the S/V Linden, Scandinavia's largest sailing vessel, to the Svalbard Archipelago, one of earth's most fragile and at-risk ecosystems. The wind-powered three-masted schooner will allow the group to move quietly, employing a "leave-no-trace" philosophy, entering a region controlled by no nation, where polar bears, bearded seals, and beluga whales rule.
Simultaneous with the group's departure will be the release of the world's first exclusive NFT auction of Expedition Tokens, designed by Rara Data, an Australia-based company that recently produced (and sold out) NFTs for several international brands. As the Linden moves northward, Rara will make available 5000 Expedition Tokens to the public, each with specific attributes and badges allowing collectors to gain access to physical artworks created along the journey – including film negatives and prints from Red Bull photographer Jordan Rosen, and longhand journal pages from New York Times and Patagonia climate change writer Brendan Jones. In accordance with the philosophy that the future of adventure travel looks a lot like the past, Rosen will be photographing on analog Kodak film, while Jones will use weatherproof journals to make a record of the voyage.
Though the exact route of the trip will depend on currents, weather and winds, the Linden will plan to anchor at "Bjørnøya," a pristine and solitary island at 74 degrees North, before continuing on to the coastline of Southern Spitsbergen. The explorers, including a world-class ski guide and an active duty JSCO Special Forces soldier, will deploy inflatables to approach glaciated fjords, wind-scoured mountains, and thawing permafrost. Along the way the group will also investigate abandoned whaling stations, seal rookeries, and the ruins of Soviet-era coal mines to create a record of how this thawing land – once a tropical home to dinosaurs – reacts in real-time to climate change.
The carbon footprint of the expedition will be offset by Aerial, an official partner for the expedition. Clothing is provided by high-end Colorado-based purveyor VOORMI, while Buck Knives will ensure crew members will each have a sharp blade handy.
The Svalbard expedition marks the first journey in a series of Expedition Token projects, as creators embark on human-powered journeys to bear witness to – and make a record of – at risk-ecosystems across the planet. The tokens associated with the journeys will continue to create utility and value for collectors as future projects unfold.
About Expedition Token
Expedition Token is a decentralized autonomous organization (DAO) that partners with elite expedition teams built out of frontline scientists, artists, and seasoned adventurers. https://expeditiontoken.com/
View original content:
SOURCE Expedition Token | https://www.wflx.com/prnewswire/2022/04/13/nft-expedition-tokens-wind-powered-arctic-journey-drop/ | 2022-04-14T03:46:24 | 0 | https://www.wflx.com/prnewswire/2022/04/13/nft-expedition-tokens-wind-powered-arctic-journey-drop/ |
JACKSONVILLE, Fla., April 13, 2022 /PRNewswire/ -- Nivel Parts & Manufacturing Co., LLC announced late Thursday afternoon that it has successfully acquired EPI Performance, a leading UTV clutch kit, drive belt, and driveline component supplier. The purchase combines Nivel's manufacturing, sourcing, and distribution capabilities with the reputable EPI brand. EPI Performance products are distributed worldwide by major powersports distributors and dealers.
Nivel aims to continue growing the business with a seamless transition of EPI's talent, vendor relationships, and distribution partnerships. Jeff Supinski, EPI's Operations Manager, said, "We are very excited to join the Nivel team; the opportunity is a great fit for EPI. Nivel's resources will position EPI to further accelerate our 30+ years of product innovation and brand strategy and will strengthen distribution relationships."
Nivel recognizes the growth in the UTV market and understands the importance of offering products and brands that are appealing to all UTV segments. Through the acquisition of EPI Performance, Nivel expands into the UTV clutch, drive belt, and driveline markets with a well-recognized brand built on providing an unparalleled customer experience and unique, high-quality products.
Nivel CEO, Brett Hankey, commented, "We are so excited to bring EPI Performance into Nivel's family of brands. EPI's innovation coupled with its promise to deliver well-tested, high-quality products has positioned them as a leading brand in the UTV aftermarket parts industry. We look forward to continuing to build on this success and delivering quality products to our UTV enthusiast customers."
About Nivel
Founded in 1968, Nivel is a global manufacturer, distributor, and seller of aftermarket parts and accessories for vehicles in the Personal Transportation Vehicle (PTV), Utility Terrain Vehicle (UTV), Heavy Duty, and Automotive sectors. It is a trusted business partner to thousands of dealers, distributors, and consumers in the US and international markets. Nivel owns the most valuable brands in the aftermarket niche vehicle parts and accessories categories:
MadJax, RedDot, GTW, Jake's, Reliance, Seizmik, Highlifter, and Falcon Ridge.
About EPI Performance
EPI Performance designs, develops, and manufactures high-performance CVT clutch calibration kits, drive belts, and other quality driveline replacement components for the UTV market. The EPI Performance brand has been a recognized leader for over 30 years in the ATV/UTV industry. EPI Performance has raised the bar in product innovation, design, and performance, earning preferred shelf space at dealerships worldwide.
Media Contact: media@nivel.com
View original content to download multimedia:
SOURCE Nivel Parts & Manufacturing Co. | https://www.wflx.com/prnewswire/2022/04/13/nivel-parts-amp-manufacturing-acquires-epi-performance/ | 2022-04-14T03:46:30 | 1 | https://www.wflx.com/prnewswire/2022/04/13/nivel-parts-amp-manufacturing-acquires-epi-performance/ |
MS. LAURYN HILL, MEGAN THEE STALLION, BRITTNEY SPENCER, D-NICE AND DARIN ATWATER & THE SOULFUL SYMPHONY TO PERFORM ALONGSIDE CELEBRITY CHEFS TOM COLICCHIO, MARCUS SAMUELSSON AND GAIL SIMMONS AND BALTIMORE STAR CHEFS SAON BRICE AND MARIO MOISE
CREATED BY 1/ST EXPERIENCE IN PARTNERSHIP WITH BALTIMORE NATIVE AND ENTERTAINMENT VISIONARY KEVIN LILES, PREAKNESS LIVE IS PART OF NEW BALTIMORE 1/ST CAMPAIGN
BALTIMORE, April 13, 2022 /PRNewswire/ -- 1/ST EXPERIENCE, curators of world-class entertainment and hometown hospitality for Preakness 147, announces a collaboration with Baltimore's own Kevin Liles, CEO and Chairman of 300 Entertainment and Elektra Music Group, to launch Preakness LIVE Culinary, Art & Music Festival as part of an expanded Preakness entertainment and cultural celebration set to take place on Black-Eyed Susan Day, Friday, May 20. The festival is just one part of 1/ST's new long-term campaign, Baltimore 1/ST, kicking off this year.
In consultation with Baltimore Mayor Brandon Scott and in collaboration with Baltimore notable, Kevin Liles, Preakness LIVE will be the first event to take place as part of Baltimore 1/ST, a holistic new campaign that heralds the Preakness' lifelong home Baltimore and represents a commitment from 1/ST, owner and operator of the Preakness, to support and build on the optimism and enthusiasm for the future of the city. Baltimore 1/ST will champion the race's connection to Baltimore by leveraging the Preakness platform to highlight and impact local culture year-round across the pillars of music, art, fashion, culinary, sports and community, featuring both international and local Baltimore talent.
"I am incredibly excited about this new collaboration being led by a true son of Baltimore. This will not only improve the Preakness experience, but also support and elevate Baltimore culture through art, sports, fashion, and food year-round," said Mayor Brandon M. Scott. "I look forward to the profound impact this new focus on Baltimore art and culture will have on our city's next generation of creative minds. I want to thank Kevin Liles, 300 Entertainment and Elektra Music Group, and 1/ST EXPERIENCE for their investment in our city and it's unique cultural fabric."
Taking place in the iconic Pimlico infield, Preakness LIVE will feature performances by GRAMMY Award winners Ms. Lauryn Hill and Megan Thee Stallion, NAACP Image Award winner D-Nice and Baltimore-bred talent including rising singer Brittney Spencer, Darin Atwater & The Soulful Symphony, plus a performance of "The Star-Spangled Banner" by WanMor and more. Local talent will also perform on the Charm City Stage throughout the evening. Preakness LIVE is produced in collaboration with Karlitz & Company.
"Baltimore is more than a city, just as Preakness is more than a race," said Kevin Liles, CEO and Chairman of 300 Entertainment and Elektra Music Group. "What we're building with Preakness LIVE is a movement, not a moment. As a native son of this great city and a life-long fan of Preakness, I'm so proud to help bring an event of this scale and scope home, creating a cultural milestone both for residents and visitors rediscovering Baltimore's charms."
Celebrity chefs Tom Colicchio, Marcus Samuelsson, Gail Simmons, and beloved Baltimore chefs Saon Brice of BLK Swan, and Mario Moise of Bar ONE will perform culinary showcases on the main stage. Chefs Colicchio, Samuelsson and Simmons will collaborate to develop unique offerings for guests in the Finish Line Suites, Turfside Terrace and the Home Stretch Pavilions. Preakness LIVE will also debut Restaurant Row made up of a diverse group of local eateries featuring regional culinary delights serving fans on both Black-Eyed Susan Day and Preakness Day.
Baltimore's vibrant art scene will be given a showcase in the Pimlico infield during Preakness weekend with unique installations throughout the art garden, curated by acclaimed Baltimore multidisciplinary artist and founder of "The Last Resort Artist Retreat" Derrick Adams. The art garden will display works from a multitude of local artists as well as entrants of the Preakness 147 Art of Racing campaign, among other exciting activations.
To further connect the Preakness weekend celebrations to Park Heights, Park Heights Renaissance will sponsor and lead the first annual George "Spider" Anderson Preakness Music and Arts Festival in recognition of the first African American jockey to win the Preakness Stakes in 1889. The day-long festival on May 21st will feature live music, arts & crafts, the days' races live streamed, top food trucks and will highlight community businesses and partners.
Park Heights Renaissance Executive Director Yolanda Jiggetts says, "We are committed to engaging the community in the history of Preakness. This will be a celebration of the Preakness in a way that's groundbreaking and we hope connects residents and local businesses like never before. 1/ST continues to show its commitment to strengthening its reach in the community through its growing relationship with Park Heights Renaissance."
During the third running of the George E. Mitchell Black-Eyed Susan Stakes, the recipient of the George E. Mitchell Park Heights Community Fellowship Grant, awarded by Park Heights Renaissance, will be recognized with a special presentation from the Winner's Circle. The iconic race was renamed in 2020 to highlight the extraordinary legacy of Mitchell himself and to create a platform for the recognition of those in the Park Heights community who share in Mitchell's vision and leadership towards revitalization of the Park Heights community.
"The Preakness 147 celebration, including everything we are doing on Black-Eyed Susan Day and on Preakness Day, will bring together entertainers, artists, lifestyle, hospitality and culinary leaders, and the community for weekend of events that will put Baltimore front and center," said Jimmy Vargas, CEO, 1/ST EXPERIENCE. "We are thrilled to be working with Mayor Scott, Kevin Liles, Yolanda Jiggetts and some of the city's top cultural shapeshifters to reaffirm and evolve the connection between the Preakness and the people of Baltimore."
Tickets for Preakness LIVE go on-sale April 13th and range from $49-$175. These and other Preakness weekend tickets can be purchased online by visiting www.preakness.com/tickets. As part of the ongoing partnership between 1/ST and Park Heights Renaissance, tickets for Preakness LIVE and for InfieldFest will be distributed to the Parks Heights community through Park Heights Renaissance.
For more information on Preakness 147, visit www.preakness.com or follow on social @PreaknessStakes #Preakness.
Photo Selects: Please click here
Press Contact:
Vanessa Menkes Communications
vanessa@vanessamenkes.com
The Brand Guild
Preakness@TheBrandGuild.com
ABOUT THE STRONACH GROUP AND 1/ST
The Stronach Group is a world-class technology, entertainment and real estate development company with Thoroughbred horse racing and pari-mutuel wagering at the core. The company's consumer facing brand 1/ST (pronounced "First") powers The Stronach Group's forward-thinking 1/ST RACING, 1/ST CONTENT, 1/ST TECHNOLOGY, 1/ST EXPERIENCE, and 1/ST PROPERTIES businesses, while advocating for and driving the 1/ST HORSE CARE mission. 1/ST represents The Stronach Group's continued movement toward redefining Thoroughbred horse racing and the ecosystem that drives it. 1/ST RACING drives the best-in-class horse racing operations at the company's premier racetracks and training centers including: Santa Anita Park, Golden Gate Fields and San Luis Rey Downs (California); Gulfstream Park – home of the Pegasus World Cup Championship Invitational Series, Gulfstream Park West and Palm Meadows Thoroughbred Training Center (Florida); the Maryland Jockey Club at Laurel Park, Pimlico Race Course - home of the legendary Preakness Stakes, Rosecroft Raceway and Bowie Training Center (Maryland). 1/ST CONTENT is the newly formed operating group for all of 1/ST's media and content companies including: Monarch Content Management, Elite, GWS and XBTV. 1/ST TECHNOLOGY is horse racing's largest racing and gaming technology company offering world-class products via its AmTote, Xpressbet, 1/ST BET, XB SELECT, XB NET, PariMAX and Betmix brands. 1/ST EXPERIENCE blends the worlds of sports, entertainment and hospitality through innovative content development, elevated national and local venue management and hospitality, strategic partnerships, sponsorships, and procurement development. 1/ST PROPERTIES is responsible for the development of the company's live, work and play communities surrounding its racing venues including: The Village at Gulfstream Park (Florida) and Paddock Pointe (Maryland). As the advocate for critical industry reforms and by making meaningful investments into aftercare programs for retired horses and jockeys, 1/ST HORSE CARE represents The Stronach Group's commitment to achieving the highest level of horse and rider care and safety standards in Thoroughbred horse racing on and off the track. For more information, please visit www.1st.com.
View original content to download multimedia:
SOURCE 1/ST | https://www.wflx.com/prnewswire/2022/04/13/preakness-147-announces-addition-preakness-live-culinary-art-amp-music-festival-celebrating-best-baltimore-black-eyed-susan-day-part-preakness-weekend-may-20-amp-may-21/ | 2022-04-14T03:46:37 | 0 | https://www.wflx.com/prnewswire/2022/04/13/preakness-147-announces-addition-preakness-live-culinary-art-amp-music-festival-celebrating-best-baltimore-black-eyed-susan-day-part-preakness-weekend-may-20-amp-may-21/ |
New year, new Precision Medical Products: the company will have a new leader at its helm, partnering with longtime founder and current CEO Jeremy Perkins. Stepping into Perkins' shoes will be well-respected industry veteran Steven Ingel, who will immediately become President & CEO of Precision Medical Products, Inc.
CARROLLTON, Texas, April 13, 2022 /PRNewswire/ -- Precision Medical Products today announced the appointment of Steven Ingel to President & CEO of Precision Medical Products, Inc. Ingel's official start date was April 4, 2022. At that time, he succeeded Precision Medical's current President and CEO, Jeremy Perkins, who will remain with the company and assume the role of Executive Chairman of the Board. In this new role, Mr. Perkins will identify strategies, business opportunities, and new technology architectures to grow Precision Medical Products. "Steve Ingel brings a wealth of medical device and digital health experience with a well-established proven track record of driving growth, margin expansion, and overall financial performance. His broad and deep industry experience combined with his respected leadership and team-building style make him the right fit to continue our important work at Precision Medical," said Jeremy Perkins.
Ingel is a seasoned leader with over 30+ years of experience in the healthcare sector. He most recently served as President of Footcare Solutions and National Accounts for Enovis, formerly DJO Global. Before that role, Steve held various executive and divisional leadership roles spanning multiple disciplines including Sales, Marketing, R & D, Operations, and Digital Health Solutions during his 28-year tenure at DJO Global. "I am honored to have the opportunity to lead Precision Medical and to begin working with its outstanding leadership team and talented organization of professionals," said Ingel. "There are tremendous opportunities ahead given the company's existing technologies, robust pipeline, and manufacturing platforms, and I'm looking forward to leading its next stage of growth. Together with Jeremy and the team, I am confident that we can continue to set the standards for excellence and drive innovation in the industry for our customers, patients, and employees."
Since becoming the market leader in mobile compression devices and completing the acquisition of Innovamed Health and VenaGroup earlier in 2021, the company has been hard at work building the corporate infrastructure and necessary strategic talent needed to continue to deliver double-digit growth and open new markets. Precision has demonstrated twelve years of consecutive year-over-year growth and significantly outpaced the market. This consistent success has positioned them to continually expand and innovate in a historically stagnant DVT prevention market. The addition of Ingel is a significant milestone for Precision and the healthcare industry, showing that innovation and patient-focused solutions continue to drive industry change.
About Precision Medical Products®
Founded in 2010, Precision Medical Products is a 12-year-old privately-owned growth stage company that provides recovery and prevention solutions to patients and healthcare organizations. Our products are intuitively designed to increase patient compliance, increase patient mobility, and increase staff and patient safety by eliminating tubes and cords. As the Nationwide leader in mobile DVT prevention therapy, Precision's goal is to improve the quality of patient care, decrease "never events," and reduce costs for patients and healthcare organizations across the US.
Join us on our mission to cut the cord and save countless lives.
View original content to download multimedia:
SOURCE Precision Medical Products Inc. | https://www.wflx.com/prnewswire/2022/04/13/precision-medical-products-inc-announces-steve-ingel-new-ceo/ | 2022-04-14T03:46:44 | 0 | https://www.wflx.com/prnewswire/2022/04/13/precision-medical-products-inc-announces-steve-ingel-new-ceo/ |
IRVING, Texas, April 13, 2022 /PRNewswire/ --Darling Ingredients Inc. (NYSE: DAR) today announced that it's health brand Rousselot®, the global leader of collagen-based solutions1, launched GMP grade GelMA. X-Pure® GelMA is the first gelatin methacryloyl, or GelMA, on the market to be produced under GMP conditions2.
The production of X-Pure GelMA under GMP conditions is a major step forward for companies that require GelMA for clinical use and in body medical applications. Up until now, research grade GelMA was the only available option. The GMP process ensures that Rousselot X-pure GelMAs are consistently produced and controlled according to strict quality standards, including consistent chemical modification and purification methods.
Because X-Pure GelMA has been designed for use throughout the entire product life cycle, from early-stage research through to clinical trials and marketed products, it supports a faster route to market by minimizing the risk of having to revalidate data. Batch-to-batch consistency and quality is guaranteed at any scale.
"We are proud to be the first in the market to offer GelMA produced under GMP," says Kathleen Jacobs (PhD), Regulatory Affairs Director at Rousselot Biomedical. "In less than two years, we developed a research grade as well as an X-Pure GelMA produced under suitable GMP. This marks our commitment to support customer needs. By creating reliable gelatin products with optimal properties and quality, we are helping customers to achieve success."
Research grade X-Pure GelMA was launched in June 2020 as a premium alternative to standard research grade GelMAs. It offers ultra-low impurity levels (including endotoxins, methacrylic acid and DNA), batch-to-batch consistency and tunable mechanical properties. It is ideal for a wide range of in vitro and in vivo research and development applications, particularly regenerative medicine applications such as tissue engineering, 3D bioprinting and 3D cell culture.
The product launch is being announced at the 6th edition of Rousselot's Innovation Days, which are taking place on 13th and 14th April 2022 in Ghent, Belgium. This major event for Rousselot takes place every two years, enabling our customers and partners to gain exclusive insights into the latest research in collagen-based innovations.
To find out more about Rousselot Biomedical and X-Pure GelMA, please visit our website: www.rousselot.com/biomedical
References:
1. Global Gelatin Market Insights Forecast to 2026 Calibre Research, 2020
2. IPEC PQG Good Manufacturing Guide for pharmaceutical excipients (2017)
About Darling
Darling Ingredients Inc. (NYSE: DAR) is a world leading producer of organic ingredients, generating a wide array of sustainable protein and fat products while being one of the largest producers of renewable clean energy. With operations on five continents, Darling collects waste streams from the agri-food industry, repurposing into specialty ingredients, such as hydrolyzed collagen, edible and feed-grade fats, animal proteins and meals, plasma, pet food ingredients, fuel feedstocks, and green bioenergy. Darling Ingredients named one of the 50 Sustainability and Climate Leaders in 2021, to learn more Darling Ingredients: The greenest Company on the planet - 50 Sustainability & Climate Leaders (50climateleaders.com). The Company sells its ingredients around the globe and works to strengthen our promise for a better tomorrow, creating product applications for health, nutrients and bioenergy while optimizing our services to the food chain. Darling is a 50% joint venture partner in Diamond Green Diesel (DGD), North America's largest renewable diesel manufacturer, which products reduce Greenhouse Gas (GHG) emissions by up to 85% compared to fossil fuels. For additional information, visit the Company's website at http://www.darlingii.com.
Rousselot® Biomedical
As the most recent strategic segment within Rousselot, we have drawn upon Rousselot's 130+ years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications. Offering unique advantages to assure performance, quality and safety from bench to clinic, Rousselot® X-Pure® and Rousselot® Quali-Pure™ provide consistent quality and are backed by strong scientific data and on-going research. Rousselot Biomedical is committed to support end-to-end partnerships to help "Advancing medical science". https://www.rousselot.com/biomedical
Rousselot
Caroline Brochard-Garnier
Director of Communications & PR, Rousselot
E: caroline.brochard-garnier@rousselot.com
Sciad Communications
Maria Patey / Sophie Protheroe
E: rousselot@sciad.com
T: +44 (0)20 3405 7892
Suann Guthrie
VP, Investor Relations, Sustainability & Communications
(469) 214-8202
View original content to download multimedia:
SOURCE Darling Ingredients Inc. | https://www.wflx.com/prnewswire/2022/04/13/rousselot-biomedical-darling-ingredients-brand-announces-worlds-first-gelma-produced-under-gmp/ | 2022-04-14T03:46:50 | 0 | https://www.wflx.com/prnewswire/2022/04/13/rousselot-biomedical-darling-ingredients-brand-announces-worlds-first-gelma-produced-under-gmp/ |
CHICAGO, April 13, 2022 /PRNewswire/ -- Ryerson Holding Corporation (NYSE: RYI), a leading value-added processor and distributor of industrial metals, announced today that it will host a conference call to discuss first quarter 2022 financial results for the period ended March 31, 2022, on Thursday, May 5th, at 10 a.m. Eastern Time. The live online broadcast will be available on the Company's investor relations website, ir.ryerson.com. Ryerson will report earnings after the market close on Wednesday, May 4th.
Ryerson Holding Corporation's First Quarter
2022 Earnings Call Details:
DATE: Thursday, May 5, 2022
TIME: 10:00 a.m. ET / 9:00 a.m. CT
DIAL-IN: 888-394-8218 (U.S. & Canada) / 646-828-8193 (International)
CONFERENCE ID: 5210309
An online replay of the call will be posted on the investor relations website, ir.ryerson.com, and remain available for 90 days.
Ryerson is a leading value-added processor and distributor of industrial metals, with operations in the United States, Canada, Mexico, and China. Founded in 1842, Ryerson has around 4,000 employees in approximately 100 locations. Visit Ryerson at www.ryerson.com.
View original content to download multimedia:
SOURCE Ryerson Holding Corporation | https://www.wflx.com/prnewswire/2022/04/13/ryerson-host-earnings-call-thursday-may-5th-discuss-first-quarter-2022-results/ | 2022-04-14T03:46:57 | 0 | https://www.wflx.com/prnewswire/2022/04/13/ryerson-host-earnings-call-thursday-may-5th-discuss-first-quarter-2022-results/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- S&P Global Inc. announced today that Daniel Yergin has been appointed Vice Chairman of the company following the completion of its merger with IHS Markit. He will serve as a member of the leadership team and report directly to S&P Global President and CEO Doug Peterson. Previously Vice Chairman of IHS Markit, Yergin's appointment became effective at the close of the merger.
"Daniel Yergin's strong track record as an award-winning author and highly respected authority on energy, international politics and economics make him a tremendous addition to our leadership team," Peterson said. "I am pleased to welcome him as Vice Chairman and look forward to his insights on key issues related to the global economy."
"I am honored to serve as Vice Chairman of S&P Global following the combination with IHS Markit to form what will be an extraordinary firm under Doug Peterson's leadership," Yergin said. "S&P Global already plays a unique and vital role across the global economy, and it is a privilege to join the leadership team as the company continues to evolve its role in providing essential data and analytics to the markets."
A renowned author and historian, Yergin's latest book is entitled The New Map: Energy, Climate and the Clash of Nations. His book The Prize: The Epic Quest for Oil Money and Power was awarded the Pulitzer Prize and became a number one New York Times best seller that has been translated into 20 languages. He is also the author of the bestseller The Quest: Energy, Security, and the Remaking of the Modern World and co-author of Commanding Heights: The Battle for the World Economy. Both The Prize and Commanding Heights were made into award-winning television documentaries for PBS and BBC, which Dr. Yergin co-produced, co-wrote and helped narrate.
Dr. Yergin is co-founder and chair of CERAWeek – presented by S&P Global – which is regarded as the world's preeminent energy conference. Dr. Yergin served on the U.S. Secretary of Energy Advisory Board under four U.S. Presidents. He is a director of the Council on Foreign Relations and a trustee of the Brookings Institution and serves on the Energy Advisory Council of the Dallas Federal Reserve.
Dr. Yergin is on the Advisory Boards of the Massachusetts Institute of Technology Energy Initiative and the Columbia University Center on Global Energy Policy. He is a member of the Energy Governors of the World Economic forum, the India Petroleum Ministry's Think Tank, and the U.S. National Petroleum Council.
Dr. Yergin holds a BA from Yale University, an MA from Trinity College, Cambridge University, and a Ph.D. from Cambridge University, where he was a Marshall Scholar. He has received honorary degrees from Dartmouth College, the Colorado School of Mines, the University of Houston, and the University of Missouri.
About S&P Global
S&P Global (NYSE: SPGI) provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make decisions with conviction. From helping our customers assess new investments to guiding them through ESG and energy transition across supply chains, we unlock new opportunities, solve challenges and accelerate progress for the world.
We are widely sought after by many of the world's leading organizations to provide credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help the world's leading organizations plan for tomorrow, today.
Contact:
Ola Fadahunsi
+1 332-210-9935
ola.fadahunsi@spglobal.com
Jeff Marn
+1 202-560-0776
jeff.marn@spglobal.com
View original content:
SOURCE S&P Global | https://www.wflx.com/prnewswire/2022/04/13/sampp-global-appoints-daniel-yergin-vice-chairman/ | 2022-04-14T03:47:04 | 0 | https://www.wflx.com/prnewswire/2022/04/13/sampp-global-appoints-daniel-yergin-vice-chairman/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS), in connection with the proposed acquisition of the Company by Halozyme Therapeutics, Inc. (NASDAQ: HALO) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $5.60 in cash for each share of Antares common stock owned. The transaction is valued at $960 million.
If you own Antares shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/atrs
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Weiss Law is investigating whether (i) Antares's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $5.60 per-share merger consideration adequately compensates Antares's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $6.50 median price target set by analysts, and at least one analyst set a price target for the Company of $8 per share, $2.40 above the per-share merger consideration.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com
View original content to download multimedia:
SOURCE Weiss Law | https://www.wflx.com/prnewswire/2022/04/13/shareholder-alert-weiss-law-investigates-antares-pharma-inc/ | 2022-04-14T03:47:11 | 1 | https://www.wflx.com/prnewswire/2022/04/13/shareholder-alert-weiss-law-investigates-antares-pharma-inc/ |
NEW YORK, April 13, 2022 /PRNewswire/ --
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Tivity Health, Inc. (NASDAQ: TVTY)
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tivity Health, Inc. (NASDAQ: TVTY), in connection with the proposed acquisition of TVTY by funds managed by Stone Point Capital. Under the terms of the merger agreement, TVTY shareholders will receive $32.50 in cash for each share of TVTY common stock owned. If you own TVTY shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/tvty
TEGNA Inc. (NYSE: TGNA)
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TEGNA Inc. (NYSE: TGNA), in connection with the proposed acquisition of TGNA by an affiliate of Standard General L.P. ("Standard General"). Under the terms of the merger agreement, TGNA shareholders will receive $24.00 in cash for each share of TGNA common stock that they hold. Additionally, TGNA shareholders will receive additional cash consideration in the form of a "ticking fee," the amount varying depending on the date of the closing of the transaction. If you own TGNA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/tgna
Meritor, Inc. (NYSE: MTOR)
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meritor, Inc. (NYSE: MTOR), in connection with the proposed acquisition of MTOR by Cummins Inc. Under the terms of the merger agreement, MTOR shareholders will receive $36.50 in cash for each share of MTOR common stock that they hold. If you own MTOR shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/mtor
Tenneco Inc. (NYSE: TEN)
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tenneco Inc. (NYSE: TEN), in connection with the proposed acquisition of TEN by funds managed by affiliates of Apollo. Under the terms of the acquisition agreement, TEN shareholders will receive $20.00 in cash for each share of TEN common stock that they hold. If you own TEN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/ten
View original content to download multimedia:
SOURCE Weiss Law | https://www.wflx.com/prnewswire/2022/04/13/shareholder-alert-weiss-law-reminds-tvty-tgna-mtor-ten-shareholders-about-its-ongoing-investigations/ | 2022-04-14T03:47:18 | 1 | https://www.wflx.com/prnewswire/2022/04/13/shareholder-alert-weiss-law-reminds-tvty-tgna-mtor-ten-shareholders-about-its-ongoing-investigations/ |
NEW YORK, April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sierra Oncology, Inc. (NASDAQ: SRRA)'s sale to GlaxoSmithKline plc for $55.00 per share in cash. If you are a Sierra Oncology shareholder, click here to learn more about your rights and options.
Antares Pharma, Inc. (NASDAQ: ATRS)'s sale to Halozyme Therapeutics, Inc. for $5.60 per share in cash. If you are an Antares Pharma shareholder, click here to learn more about your rights and options.
Origin Bancorp, Inc. (NASDAQ: OBNK)'s merger with BT Holdings, Inc. (BTH). Under the terms of the agreement, BTH shareholders will receive an aggregate of 6,828,390 shares of Origin's common stock in exchange for all outstanding shares of BTH common stock, subject to certain adjustments. If you are an Origin shareholder, click here to learn more about your rights and options.
Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
View original content to download multimedia:
SOURCE Halper Sadeh LLP | https://www.wflx.com/prnewswire/2022/04/13/shareholder-investigation-halper-sadeh-llp-investigates-srra-atrs-obnk/ | 2022-04-14T03:47:24 | 1 | https://www.wflx.com/prnewswire/2022/04/13/shareholder-investigation-halper-sadeh-llp-investigates-srra-atrs-obnk/ |
Mackey & Judd By skornorth | April 13, 2022 Anthony Edwards gives Minnesota Timberwolves their playoff moment! Share: Minnesota Timberwolves beat the LA Clippers and pie chart of praise for Anthony Edwards, D-Angelo Russel, Patrick Beverley … | https://www.skornorth.com/anthony-edwards-gives-minnesota-timberwolves-their-playoff-moment/ | 2022-04-14T03:47:31 | 0 | https://www.skornorth.com/anthony-edwards-gives-minnesota-timberwolves-their-playoff-moment/ |
TORONTO, April 13, 2022 /PRNewswire/ - Sun Life Financial Inc. (the "Company" or "Sun Life") (TSX: SLF) (NYSE: SLF) has been notified that Obatan LLC ("Obatan") has made another unsolicited "mini-tender offer" to purchase common shares of Sun Life at a price that is significantly lower than recent market prices for Sun Life shares on Canadian and U.S. stock exchanges.
Sun Life is not associated with Obatan and does not recommend or endorse acceptance of this unsolicited offer. Shareholders are not required to sell their shares to Obatan.
Sun Life cautions that Obatan's most recent offer has been made at a price that is significantly lower than recent market prices for Sun Life shares. This offer represents a discount of 35.7% below the closing price of Sun Life's common shares on the TSX and NYSE on April 7, 2022. Obatan has offered to purchase up to 50,000 common shares of Sun Life.
Securities administrators in Canada and the United States recommend that investors exercise caution with "mini-tender offers". Mini-tender offers are designed to avoid disclosure and procedural requirements applicable to most bids under Canadian and U.S. securities regulations. Canadian Securities Administrators and the U.S. Securities and Exchange Commission (SEC) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities.
The SEC has indicated that "bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price."
According to Obatan's offer documents, Sun Life shareholders who have already tendered their shares can withdraw their shares at any time before 5:00 p.m. (New York City time) on May 31, 2022 by following the procedures described in the offer documents. Shareholders are cautioned that the terms of the Obatan offer may be varied, and the cash consideration offered may be decreased. In such a case, shareholders who have already tendered to the offer may have limited notice of such change and limited time to withdraw their shares from the offer. There are also no assurances that Obatan will buy the shares delivered under the offer.
Obatan has also made other discounted offers to Sun Life's shareholders in the United Kingdom and Ireland. For more information on these offers, please visit: https://www.sloc.co.uk/en/latest-news/warning-on-obatan-llc-mini-tender-offer-/
Shareholders and policyholders should carefully review the Obatan offer documents, consult with their Sun Life advisor or investment advisor to discuss any offer they may receive and review all options they have for their investment in Sun Life shares. If you are in Canada and do not have a Sun Life advisor and are interested in finding one, please visit www.sunlife.ca/en/find-an-advisor/.
If you received your Sun Life shares as a result of demutualization of Sun Life or Clarica and would like to sell your shares, you may be eligible to do so through the Sun Life Share Selling Service. Under this service, shares are sold by TSX Trust Company on your behalf at market price, as opposed to the significantly discounted price offered by Obatan.
Sun Life has stock transfer agents providing shareholder services in Canada, the United States, the United Kingdom, Hong Kong and the Philippines. These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email sunlifeinquiries@tmx.com or call 1-877-224-1760 for more information.
If you were not aware that you own Sun Life shares, please contact sunlifeinquiries@tmx.com to verify your ownership and understand your options on dealing with your shares. You can also visit www.verifymyeligibility.com/SunLife, our online search tool to determine if you have unclaimed shares and dividends.
Sun Life requests that a copy of this news release be included in any distribution of materials relating to Obatan's mini-tender offer for Sun Life common shares.
Sun Life is a leading international financial services organization providing asset management, wealth, insurance, and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2021, Sun Life had total assets under management of $1.44 trillion. For more information please visit www.sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Note to editors: All figures in Canadian dollars
Media Relations Contact:
Krista Wilson
Director
Corporate Communications
T. 226-751-2391
krista.wilson@sunlife.com
Investor Relations Contact:
Yaniv Bitton
Vice-President, Head of Investor
Relations & Capital Markets
T. 416-979-6496
investor_relations@sunlife.com
View original content to download multimedia:
SOURCE Sun Life Financial Inc. | https://www.wflx.com/prnewswire/2022/04/13/sun-life-cautions-investors-regarding-obatan-llc-bid-shares/ | 2022-04-14T03:47:31 | 0 | https://www.wflx.com/prnewswire/2022/04/13/sun-life-cautions-investors-regarding-obatan-llc-bid-shares/ |
Minnesota Vikings draft and regular season predictions! Will the Vikings trade back and pick up future picks? Will they draft a …
Minnesota Vikings draft and regular season predictions! Will the Vikings trade back and pick up future picks? Will they draft a … | https://www.skornorth.com/minnesota-vikings-draft-and-regular-season-predictions/ | 2022-04-14T03:47:37 | 1 | https://www.skornorth.com/minnesota-vikings-draft-and-regular-season-predictions/ |